{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "e420ab67",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "from openai import OpenAI\n",
    "load_dotenv() \n",
    "\n",
    "# Load API key\n",
    "client = OpenAI(api_key=os.getenv(\"OPENAI_API_KEY\"))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "00744ae7",
   "metadata": {},
   "source": [
    "## LOAD DATA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "5a1a88fb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loaded 77 studies.\n"
     ]
    }
   ],
   "source": [
    "from langchain_core.documents import Document\n",
    "\n",
    "def load_studies(path):\n",
    "    docs = []\n",
    "    current = []\n",
    "    study_id = 0\n",
    "\n",
    "    with open(path, \"r\") as f:\n",
    "        for line in f:\n",
    "            line = line.rstrip(\"\\n\")\n",
    "\n",
    "            # If a new study starts\n",
    "            if line.startswith(\"Study:\"):\n",
    "                # Save the previous one if exists\n",
    "                if current:\n",
    "                    docs.append(\n",
    "                        Document(\n",
    "                            page_content=\"\\n\".join(current).strip(),\n",
    "                            metadata={\"source\": f\"study_{study_id}\"}\n",
    "                        )\n",
    "                    )\n",
    "                    study_id += 1\n",
    "                    current = []\n",
    "\n",
    "            current.append(line)\n",
    "\n",
    "        # Save last study when file ends\n",
    "        if current:\n",
    "            docs.append(\n",
    "                Document(\n",
    "                    page_content=\"\\n\".join(current).strip(),\n",
    "                    metadata={\"source\": f\"study_{study_id}\"}\n",
    "                )\n",
    "            )\n",
    "\n",
    "    print(f\"Loaded {len(docs)} studies.\")\n",
    "    return docs\n",
    "\n",
    "# Run it\n",
    "documents = load_studies(\"/Users/cj2837/Documents/Courses/Project/menopause_knowledge_graph_by_LLM/data/structured_for_llm.txt\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "13e2490b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(metadata={'source': 'study_0'}, page_content='Study: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis\\n\\nSummary: This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.\\n\\nResults: Outcome: Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density.Parameters: Mean Difference (Final Values) = 0.615 (p = 0.045, CI 0.013-1.216); Mean Difference (Final Values) = 1 (p = 0.001, CI 0.395-1.605). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.'),\n",
       " Document(metadata={'source': 'study_1'}, page_content='Study: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis\\n\\nSummary: This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.\\n\\nResults: Outcome: Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months.Parameters: Mean Difference (Final Values) = 1.257 (p = 0.001, CI 0.701-1.814); Mean Difference (Final Values) = 1.025 (p = 0.001, CI 0.471-1.578). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.'),\n",
       " Document(metadata={'source': 'study_2'}, page_content='Study: Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis\\n\\nSummary: This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.\\n\\nResults: Outcome: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24.Parameters: Mean Difference (Final Values) = 7 (p = 1e-04, CI 6.2-7.8). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_3'}, page_content='Study: A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia\\n\\nSummary: This 2 arm study will evaluate the efficacy and safety of oral Bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. Patients will be randomized to receive either Bonviva 150mg po monthly, or placebo monthly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.\\n\\nResults: Outcome: Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12.Parameters: Mean Difference (Net) = 4.1226 (p = 1e-04, CI 2.9613-5.2838). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_4'}, page_content='Study: Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women\\n\\nSummary: To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.\\n\\nResults: Outcome: Bone Biomarker Osteocalcin (OC) Percentage Change After 12 Months.Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Biomarker Undercarboxylated Osteocalcin (UCOC) Percentage Change After 12 Months.Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Biomarker Undercarboxylated Osteocalcin/Osteocalcin (UCOC/OC) Percentage Change After 12 Months.Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_5'}, page_content=\"Study: Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).\\n\\nSummary: The study has been designed to look at the transfer from using LNG IUS for contraception only, in reproductive age to using it for endometrial protection in menopausal age. The main area of interest in the study is the pattern of any vaginal bleeding that occurs.\\n\\nResults: Outcome: Assessment of QOL as Measured by Women's Health Questionnaire.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 1: Hot Flushes (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 2: Sweating Episodes (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 3: Vaginal Dryness (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 4: Sleep Problems (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Climacteric Symptom 5: Irritability (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 1: Headache (as Measured by a Visual Analogue Scale (VAS)).Parameters: NA = NA (p = 0.027, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 2: Depressive Mood (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 3: Acne or Greasy Skin (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 4: Nausea (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 6: Decreased Libido (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Progestogenic Symptom 8: Greasy Hair (as Measured by a VAS).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.\"),\n",
       " Document(metadata={'source': 'study_6'}, page_content='Study: A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)\\n\\nSummary: This study will determine the rapidity of suppression of the bone resorption marker sCTX in post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated. Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with vitamin D and calcium supplementation. The anticipated time on study treatment is approximately 7 months, and the target sample size is \\\\<100 individuals.\\n\\nResults: Outcome: Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen Concentration (sCTX) From Baseline to Day 3.Parameters: Difference in median = -64.2 (p = 1e-04, CI -80.28--46.21). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_7'}, page_content='Study: A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.\\n\\nSummary: This 2 arm crossover study will evaluate patient reported preference for either once monthly Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12 weeks; they will then cross over to receive the alternative treatment for a further 12 weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.\\n\\nResults: Outcome: Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_8'}, page_content='Study: Study of Transitioning From Alendronate to Denosumab\\n\\nSummary: The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.\\n\\nResults: Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density.Parameters: Mean Difference (Final Values) = 1.18 (p = 1e-04, CI 0.63-1.73). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I).Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Total Hip Bone Mineral Density.Parameters: Mean Difference (Final Values) = 0.85 (p = 1e-04, CI 0.44-1.25). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.'),\n",
       " Document(metadata={'source': 'study_9'}, page_content='Study: Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis\\n\\nSummary: This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate.\\n\\nEligible subjects will be randomised either ibandronate monthly regimen or risedronate weekly regimen.\\n\\nTreatment period consists of 3 month with ibandronate 150mg and additional 12 week with risedronate 35 mg or vice versa.\\n\\nAfter taking the first interventional medicine for 3 months or 12 weeks completely, a subject changes the treatment arm. There is no washout period.\\n\\nResults: Outcome: Percentage of Participants Choosing Ibandronate or Risedronate as Their Preferred Treatment Based on Convenience of Administration.Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants Who Prefer the Once-monthly Dosing of Ibandronate to the Once-weekly Dosing of Risedronate.Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_10'}, page_content='Study: Postmenopausal Women Estrogen and Progesterone Infusion\\n\\nSummary: The purpose of the study is to study the effects of aging, estrogen and progesterone on the brain. Specifically, we want to look at how the hypothalamus and pituitary (two small glands in the brain) respond to estrogen. The pituitary gland is controlled by the hypothalamus. The hypothalamus secretes GnRH (Gonadotropin-Releasing Hormone) that signals the pituitary to secrete the reproductive hormones, LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone). These hormones act on the ovaries and signal the ovaries to produce estrogen and progesterone. Estrogen in the bloodstream then acts on the brain to modulate this system with changes in LH and FSH. Early changes associated with low levels of estrogen are inhibitory (estrogen negative feedback) while higher levels of estrogen (such as those present when a follicle in the ovary is ready to ovulate) stimulate LH to cause ovulation (positive feedback). This study will determine: 1) hypothalamic and pituitary levels of glucose uptake (as a measure of brain metabolic activity) at baseline and in association with estrogen negative feedback on LH (24 hr) and estrogen positive feedback on LH (72 hr); and 2) the effect of aging on estrogen feedback on LH, assessing negative feedback (nadir \\\\~ 24 hr) and positive feedback (peak between 72 and 96 hr).\\n\\nResults: Outcome: 18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback.Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: 18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback.Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Effect of Aging on Estrogen Negative Feedback on LH.Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Effect of Aging on Estrogen Positive Feedback on LH.Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_11'}, page_content='Study: A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)\\n\\nSummary: The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis. In a placebo-controlled extension of the base study, participants continued to receive the same blinded study medication for a total of up to 5 years of blinded study medication combined between the base study and the extension. After participants received 5 years of blinded study medication, they received open-label odanacatib through the end of the first extension. Participants were then invited to enroll in a second extension study in which they received open-label odanacatib for an additional 5 years. Two imaging substudies (PN032-Base/Extension and PN035) were conducted for participants in the MK-0822-018 Study. Additional safety information was collected for participants who discontinued from the base study or the blinded first extension in an observational follow-up study, MK-0822-083 (EudraCT number: 2007-002693-66) .\\n\\nResults: Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm.Parameters: Difference in Least Squares Means = 1.1 (p = 0.001, CI 0.66-1.54); Difference in Least Squares Means = 1.36 (p = 0.001, CI 0.87-1.85); Difference in Least Squares Means = 1.96 (p = 0.001, CI 1.42-2.5); Difference in Least Squares Means = 2.18 (p = 0.001, CI 1.4-2.96); Difference in Least Squares Means = 2.33 (p = 0.001, CI 1.54-3.11). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Femoral Neck.Parameters: Difference in Least Squares Means = 1.47 (p = 0.001, CI 0.92-2.01); Difference in Least Squares Means = 2.21 (p = 0.001, CI 2.05-2.37); Difference in Least Squares Means = 4.39 (p = 0.001, CI 4.2-4.57); Difference in Least Squares Means = 6.5 (p = 0.001, CI 6.28-6.72); Difference in Least Squares Means = 8.29 (p = 0.001, CI 8.02-8.57); Difference in Least Squares Means = 10.05 (p = 0.001, CI 9.72-10.38). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Lumbar Spine.Parameters: Difference in Least Squares Means = 4.01 (p = 0.001, CI 3.87-4.15); Difference in Least Squares Means = 5.93 (p = 0.001, CI 5.75-6.11); Difference in Least Squares Means = 7.7 (p = 0.001, CI 7.48-7.91); Difference in Least Squares Means = 2.9 (p = 0.001, CI 2.4-3.39); Difference in Least Squares Means = 9.34 (p = 0.001, CI 9.08-9.61); Difference in Least Squares Means = 10.87 (p = 0.001, CI 10.55-11.19). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Total Hip.Parameters: Difference in Least Squares Means = 1.34 (p = 0.001, CI 0.94-1.74); Difference in Least Squares Means = 2.5 (p = 0.001, CI 2.38-2.62); Difference in Least Squares Means = 4.47 (p = 0.001, CI 4.31-4.62); Difference in Least Squares Means = 6.46 (p = 0.001, CI 6.26-6.65); Difference in Least Squares Means = 8.48 (p = 0.001, CI 8.24-8.73); Difference in Least Squares Means = 10.29 (p = 0.001, CI 9.99-10.59). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Percent Change From Baseline in BMD Measurements of the Trochanter.Parameters: Difference in Least Squares Means = 1.74 (p = 0.001, CI 1.06-2.42); Difference in Least Squares Means = 3.5 (p = 0.001, CI 3.31-3.7); Difference in Least Squares Means = 6.41 (p = 0.001, CI 6.16-6.65); Difference in Least Squares Means = 9.25 (p = 0.001, CI 8.95-9.54); Difference in Least Squares Means = 12.14 (p = 0.001, CI 11.76-12.51); Difference in Least Squares Means = 14.56 (p = 0.001, CI 14.11-15.01). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture.Parameters: Hazard Ratio (HR) = 0.48 (p = 0.001, CI 0.42-0.55). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.67 (p = 0.001, CI 0.6-0.75). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.52 (p = 0.001, CI 0.4-0.67). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.74 (p = 0.001, CI 0.66-0.83). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.33 (p = 0.001, CI 0.24-0.45). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First 3-Point MACE Confirmed by TIMI Adjudication.Parameters: Hazard Ratio (HR) = 1.17 (p = 0.029, CI 1.02-1.36). Non-inferiority type: OTHER. Outcome: Base Study + First Extension: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication.Parameters: Hazard Ratio (HR) = 1.37 (p = 0.005, CI 1.1-1.71). Non-inferiority type: OTHER. Outcome: Base Study: Number of Participants With Height Loss of > 1 cm.Parameters: Odds Ratio (OR) = 0.89 (p = 0.014, CI 0.81-0.98). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Distal-Third Forearm.Parameters: Difference in Least Squares Means = 1.11 (p = 0.001, CI 0.67-1.55); Difference in Least Squares Means = 1.35 (p = 0.001, CI 0.85-1.84); Difference in Least Squares Means = 1.93 (p = 0.001, CI 1.38-2.47); Difference in Least Squares Means = 2.2 (p = 0.001, CI 0.89-3.51); Difference in Least Squares Means = 3.5 (p = 0.001, CI 1.46-5.54). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck.Parameters: Difference in Least Squares Means = 1.49 (p = 0.001, CI 0.95-2.03); Difference in Least Squares Means = 2.21 (p = 0.001, CI 2.05-2.37); Difference in Least Squares Means = 4.38 (p = 0.001, CI 4.19-4.57); Difference in Least Squares Means = 6.46 (p = 0.001, CI 6.24-6.68); Difference in Least Squares Means = 8.42 (p = 0.001, CI 7.82-9.02); Difference in Least Squares Means = 8.53 (p = 0.001, CI 7.54-9.53). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Femoral Neck in Bisphosphonate-Intolerant Participants.Parameters: Difference in Least Squares Means = 9.08 (p = 0.001, CI 6.97-11.19); Difference in Least Squares Means = 2.21 (p = 0.001, CI 1.83-2.59); Difference in Least Squares Means = 4.33 (p = 0.001, CI 3.87-4.78); Difference in Least Squares Means = 6.09 (p = 0.001, CI 5.56-6.62). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine.Parameters: Difference in Least Squares Means = 2.96 (p = 0.001, CI 2.47-3.46); Difference in Least Squares Means = 4.07 (p = 0.001, CI 3.93-4.22); Difference in Least Squares Means = 6.05 (p = 0.001, CI 5.87-6.23); Difference in Least Squares Means = 7.84 (p = 0.001, CI 7.62-8.06); Difference in Least Squares Means = 9.72 (p = 0.001, CI 9.16-10.27); Difference in Least Squares Means = 11.23 (p = 0.001, CI 10.23-12.23). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Lumbar Spine in Bisphosphonate-Intolerant Participants.Parameters: Difference in Least Squares Means = 5.79 (p = 0.001, CI 5.37-6.2); Difference in Least Squares Means = 4.02 (p = 0.001, CI 3.67-4.37); Difference in Least Squares Means = 7.62 (p = 0.001, CI 7.11-8.13); Difference in Least Squares Means = 9.51 (p = 0.001, CI 7.96-11.06). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip.Parameters: Difference in Least Squares Means = 1.32 (p = 0.001, CI 0.9-1.75); Difference in Least Squares Means = 2.49 (p = 0.001, CI 2.37-2.61); Difference in Least Squares Means = 4.47 (p = 0.001, CI 4.31-4.62); Difference in Least Squares Means = 6.44 (p = 0.001, CI 6.25-6.64); Difference in Least Squares Means = 8.62 (p = 0.001, CI 8.11-9.12); Difference in Least Squares Means = 9.49 (p = 0.001, CI 8.7-10.29). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Total Hip in Bisphosphonate-Intolerant Participants.Parameters: Difference in Least Squares Means = 2.4 (p = 0.001, CI 2.11-2.68); Difference in Least Squares Means = 4.21 (p = 0.001, CI 3.84-4.57); Difference in Least Squares Means = 5.86 (p = 0.001, CI 5.41-6.3); Difference in Least Squares Means = 8.54 (p = 0.001, CI 7-10.09). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter.Parameters: Difference in Least Squares Means = 12.44 (p = 0.001, CI 11.66-13.22); Difference in Least Squares Means = 13.81 (p = 0.001, CI 12.58-15.04); Difference in Least Squares Means = 1.74 (p = 0.001, CI 1.03-2.46); Difference in Least Squares Means = 3.5 (p = 0.001, CI 3.31-3.7); Difference in Least Squares Means = 6.41 (p = 0.001, CI 6.17-6.65); Difference in Least Squares Means = 9.27 (p = 0.001, CI 8.98-9.57). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in BMD Measurements of the Trochanter in Bisphosphonate-Intolerant Participants.Parameters: Difference in Least Squares Means = 3.44 (p = 0.001, CI 2.98-3.9); Difference in Least Squares Means = 6.03 (p = 0.001, CI 5.47-6.59); Difference in Least Squares Means = 8.49 (p = 0.001, CI 7.81-9.16); Difference in Least Squares Means = 11.76 (p = 0.001, CI 9.15-14.36). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in Bone-Specific Alkaline Phosphatase (BSAP) After Log-Transformation.Parameters: Mean Difference (Final Values) = -14.13 (p = 0.001, CI -17--11.27); Mean Difference (Final Values) = -12.01 (p = 0.001, CI -15.22--8.79); Mean Difference (Final Values) = -9.29 (p = 0.001, CI -13.45--5.13); Mean Difference (Final Values) = -7.64 (p = 0.001, CI -11.87--3.41). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in N-Terminal Propeptide of Type 1 Collagen (P1NP) After Log-Transformation.Parameters: Mean Difference (Final Values) = -29.43 (p = 0.001, CI -33.47--25.39); Mean Difference (Final Values) = -25.94 (p = 0.001, CI -30.54--21.34); Mean Difference (Final Values) = -16.26 (p = 0.001, CI -21.41--11.12); Mean Difference (Final Values) = -12.11 (p = 0.001, CI -18.03--6.19). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in Serum C-Telopeptides of Type I Collagen (s-CTx) After Log-Transformation.Parameters: Difference in Least Squares Means = -58.99 (p = 0.001, CI -64.68--53.3); Difference in Least Squares Means = -60.01 (p = 0.001, CI -66.4--53.61); Difference in Least Squares Means = -46.7 (p = 0.001, CI -53.23--40.17). Non-inferiority type: OTHER. Outcome: Base Study: Percent Change From Baseline in Urinary N-Telopeptides of Type I Collagen/Creatinine (u-NTx/Cr) Ratio After Log-Transformation.Parameters: Difference in Least Squares Means = -51.7 (p = 0.001, CI -56.11--47.28); Difference in Least Squares Means = -53.59 (p = 0.001, CI -58.39--48.79); Difference in Least Squares Means = -56.68 (p = 0.001, CI -62.52--50.84); Difference in Least Squares Means = -59.14 (p = 0.001, CI -66.04--52.23); Difference in Least Squares Means = -44.54 (p = 0.001, CI -61.72--27.36). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral Fracture.Parameters: Hazard Ratio (HR) = 0.46 (p = 0.001, CI 0.4-0.53). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.53 (p = 0.001, CI 0.39-0.71). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.77 (p = 0.001, CI 0.68-0.87). Non-inferiority type: OTHER. Outcome: Base Study: Time From Baseline to First Osteoporotic Clinical Vertebral Fracture (Adjudicated).Parameters: Hazard Ratio (HR) = 0.28 (p = 0.001, CI 0.19-0.4). Non-inferiority type: OTHER. Outcome: Base Study: Time to First Fatal or Non-Fatal Stroke Confirmed by TIMI Adjudication.Parameters: Hazard Ratio (HR) = 1.32 (p = 0.034, CI 1.02-1.7). Non-inferiority type: OTHER. Outcome: Base Study: Yearly Rate of Height Loss.Parameters: Difference in Least Squares Means = 0.01 (p = 0.041, CI 0-0.03). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography.Parameters: Difference in Least Squares Means = 8.53 (p = 0.001, CI 5.79-11.28). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA.Parameters: Difference in Least Squares Means = 9.98 (p = 0.001, CI 6.91-13.06). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Lumbar Spine Using DXA.Parameters: Difference in Least Squares Means = 11.08 (p = 0.001, CI 8.41-13.74). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Total Hip Using DXA.Parameters: Difference in Least Squares Means = 10.41 (p = 0.001, CI 8.05-12.78). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in aBMD of the Trochanter Using DXA.Parameters: Difference in Least Squares Means = 14.94 (p = 0.001, CI 11.29-18.59). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed Tomography.Parameters: Difference in Least Squares Means = 26.45 (p = 0.001, CI 16.49-36.4). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in Areal BMD (aBMD) of the Lumbar Spine Using DXA.Parameters: Difference in Least Squares Means = 5.55 (p = 0.001, CI 4.06-7.05). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in BSAP After Log-Transformation.Parameters: Difference in Least Squares Means = -25.02 (p = 0.001, CI -35.92--14.12). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in Cortical vBMD of the Total Hip Using Quantitative Computed Tomography.Parameters: Difference in Least Squares Means = 2.76 (p = 0.001, CI 1.43-4.1). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in P1NP After Log-Transformation.Parameters: Difference in Least Squares Means = -26.7 (p = 0.001, CI -42.56--10.83). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed Tomography.Parameters: Difference in Least Squares Means = 8.92 (p = 0.001, CI 3.9-13.93). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Distal-Third Forearm Using DXA.Parameters: Difference in Least Squares Means = 1.67 (p = 0.016, CI 0.32-3.01). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Femoral Neck Using DXA.Parameters: Difference in Least Squares Means = 2.79 (p = 0.005, CI 0.86-4.72). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Total Hip Using DXA.Parameters: Difference in Least Squares Means = 3.63 (p = 0.001, CI 2.35-4.9). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in aBMD of the Trochanter Using DXA.Parameters: Difference in Least Squares Means = 5.65 (p = 0.001, CI 3.79-7.5). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in s-CTx After Log-Transformation.Parameters: Difference in Least Squares Means = -62.25 (p = 0.001, CI -79.99--44.5). Non-inferiority type: OTHER. Outcome: Imaging Substudy PN032-Base: Percent Change From Baseline in u-NTx/Cr Ratio After Log-Transformation.Parameters: Difference in Least Squares Means = -64.43 (p = 0.001, CI -87.8--41.07). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_12'}, page_content='Study: Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)\\n\\nSummary: To investigate efficacy and safety of 4 doses of esmirtazapine, compared to placebo, in the treatment of moderate to severe hot flushes (vasomotor symptoms) associated with the menopause. Co-primary efficacy endpoints are the frequency and severity of hot flushes after 4 and 12 weeks as compared to Baseline.\\n\\nResults: Outcome: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 12.Parameters: Difference between least squares means = -1.6 (p = 0.01, CI -2.7--0.5); Difference between least squares means = -1.5 (p = 0.01, CI -2.7--0.4); Difference between least squares means = -2 (p = 0.01, CI -3.1--0.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Frequency of Moderate/Severe Vasomotor Symptoms (Frequency Score A) at Week 4.Parameters: Difference between least squares means = -1.2 (p = 0.01, CI -2.2--0.2); Difference between least squares means = -1.7 (p = 0.01, CI -2.7--0.7); Difference between least squares means = -1.4 (p = 0.01, CI -2.4--0.4); Difference between least squares means = -1.9 (p = 0.01, CI -2.9--0.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 12.Parameters: Difference between least squares means = -0.07 (p = 0.02, CI -0.14--0.01). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 4.Parameters: Difference between least squares means = -0.07 (p = 0.01, CI -0.12--0.01); Difference between least squares means = -0.06 (p = 0.02, CI -0.11--0.01); Difference between least squares means = -0.07 (p = 0.01, CI -0.13--0.02); Difference between least squares means = -0.08 (p = 0.01, CI -0.14--0.03). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_13'}, page_content='Study: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis\\n\\nSummary: The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.\\n\\nResults: Outcome: Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 104 / Endpoint, ITT Population.Parameters: Relative Risk = 1.1 (p = 0.0066, CI 1.03-1.18). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Responders to Treatment (>0% Change From Baseline in Lumbar Spine BMD) at Week 104, ITT Population.Parameters: Relative Risk = 1.12 (p = 0.0014, CI 1.04-1.2); Relative Risk = 1.08 (p = 0.0476, CI 1-1.16). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.'),\n",
       " Document(metadata={'source': 'study_14'}, page_content='Study: A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.\\n\\nSummary: This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.\\n\\nResults: Outcome: Percent Change From Baseline in Bone Turnover Markers at Month 1, Month 6 and Month 12.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine BMD at Month 6.Parameters: Mean Difference (Final Values) = 2.22 (p = 0.001, CI 1.22-3.23). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12.Parameters: Mean Difference (Final Values) = 3.25 (p = 0.001, CI 2.09-4.41). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Total Hip BMD at Month 6 and Month 12.Parameters: Mean Difference (Final Values) = 1.81 (p = 0.001, CI 0.96-2.66). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_15'}, page_content='Study: A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide\\n\\nSummary: The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.\\n\\nResults: Outcome: Percent Change From Baseline in Areal BMD at the Femoral Neck at Month 18 and 24 Endpoint.Parameters: NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.049, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Areal BMD at the Lumbar Spine at Month 18 and 24 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Areal BMD at â…“ Distal Radius at Month 18 and 24 Endpoint.Parameters: NA = NA (p = 0.013, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 3, 6 and 24 Endpoint.Parameters: NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.016, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 3, 6 and 24 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Volumetric Bone Mineral Density (BMD) of Hip at Month 18 Endpoint.Parameters: NA = NA (p = 0.021, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Volumetric Bone Mineral Density (BMD) of Lumbar Spine at Month 18 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in the Estimate of Bone Strength of Hip at Month 18 Endpoint.Parameters: NA = NA (p = 0.045, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in the Estimate of Bone Strength of Lumbar Spine at Month 18 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_16'}, page_content='Study: Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)\\n\\nSummary: The most direct treatment of vasomotor symptions (hot flushes) may be by means of 5-HT2A receptor antagonist. Mirtazapine is a potent blocker of 5-HT2A receptors and was found to be effective in reducing the number and intensity of hot flushes in preliminary trials. Also several Selective Serotonin Reuptake Inhibitors (SSRIs) and other similar compounds have been investigated to manage hot flushes, confirming the role of the serotonergic system. In the present trial, the efficacy and safety of four different doses of esmirtazapine compared to placebo was investigated in women with moderate to severe vasomotor symptoms associated with the menopause. The primary study hypothesis was that esmirtazapine would show superior efficacy to placebo.\\n\\nResults: Outcome: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 12.Parameters: Mean Difference (Final Values) = -1.5 (p = 0.01, CI -2.6--0.5); Mean Difference (Final Values) = -2 (p = 0.01, CI -3--0.9); Mean Difference (Final Values) = -1.9 (p = 0.01, CI -2.9--0.9). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms (Frequency Score A) at Week 4.Parameters: Mean Difference (Final Values) = -1.4 (p = 0.01, CI -2.3--0.4); Mean Difference (Final Values) = -2.2 (p = 0.01, CI -3.1--1.2); Mean Difference (Final Values) = -1.9 (p = 0.01, CI -2.9--1); Mean Difference (Final Values) = -1.9 (p = 0.01, CI -2.9--1). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms (Severity Score A) at Week 4.Parameters: Mean Difference (Final Values) = -0.06 (p = 0.02, CI -0.12--0.01); Mean Difference (Final Values) = -0.07 (p = 0.01, CI -0.13--0.01); Mean Difference (Final Values) = -0.06 (p = 0.02, CI -0.12--0.01). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_17'}, page_content='Study: Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)\\n\\nSummary: The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.\\n\\nResults: Outcome: Mean Change in Frequency of Vasomotor Symptoms (VMS) From Baseline at Week 12.Parameters: Adjusted Mean Difference = 1.21 (p = 0.041, CI 0.05-2.37); Adjusted Mean Difference = -2.06 (p = 0.001, CI -3.2--0.92). Non-inferiority type: SUPERIORITY. Outcome: Mean Change in Severity of VMS From Baseline at Week 12.Parameters: Adjusted Mean Difference = 0.31 (p = 0.008, CI 0.08-0.54); Adjusted Mean Difference = -0.52 (p = 0.001, CI -0.75--0.3). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_18'}, page_content='Study: Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)\\n\\nSummary: The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10 mg, 25 mg, 50 mg or placebo is orally administered once weekly for 52 weeks to Japanese involutional osteoporosis participants. The study will also assess safety and tolerability of odanacatib (10, 25, and 50 mg) in these participants.\\n\\nThe study will enroll approximately 280 participants and randomly assign them to 3 different doses of odanacatib or placebo for 52 weeks, along with supplemental vitamin D3 and calcium carbonate. The primary efficacy hypothesis is that a dose-response relationship on the percent change from baseline in lumbar spine BMD (L1- L4) is seen when odanacatib 10, 25, 50 mg or placebo is orally administered once weekly for 52 weeks to involutional osteoporosis participants. The primary safety hypothesis is that odanacatib will be safe and well tolerated over 52 weeks to involutional osteoporosis participants.\\n\\nResults: Outcome: Percent Change From Baseline to Week 52 in Femoral Neck BMD.Parameters: Difference in LS Means = 3.08 (p = 0.001, CI 1.85-4.31); Difference in LS Means = 1.86 (p = 0.003, CI 0.64-3.08); Difference in LS Means = 2.23 (p = 0.001, CI 1.03-3.43). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Lumbar Spine Bone Mineral Density (BMD) at Lumbar Vertebrae 1 to 4 (L1-L4).Parameters: Difference in LS Means = 5.4 (p = 0.001, CI 4.16-6.64); Difference in LS Means = 5.12 (p = 0.001, CI 3.9-6.35); Difference in LS Means = 3.54 (p = 0.001, CI 2.33-4.75). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Serum Bone Specific Alkaline Phosphatase (s-BSAP) Level.Parameters: Difference in LS Means = -15.52 (p = 0.001, CI -25.11--5.93); Difference in LS Means = -12.55 (p = 0.009, CI -22.16--2.94). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Serum C-Telopeptides of Type 1 Collagen (s-CTx) Level.Parameters: Difference in LS Means = -60.42 (p = 0.001, CI -85.7--35.13); Difference in LS Means = -60.7 (p = 0.001, CI -85.91--35.49); Difference in LS Means = -38.73 (p = 0.001, CI -65.94--11.52). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Serum N-Terminal Propeptides of Type 1 Collagen (s-P1NP) Level.Parameters: Difference in LS Means = -28.86 (p = 0.001, CI -44.97--12.75); Difference in LS Means = -26.86 (p = 0.001, CI -43.3--10.42). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Total Hip BMD.Parameters: Difference in LS Means = 3.06 (p = 0.001, CI 2.14-3.98); Difference in LS Means = 2.2 (p = 0.001, CI 1.29-3.12); Difference in LS Means = 1.67 (p = 0.001, CI 0.77-2.57). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Trochanter BMD.Parameters: Difference in LS Means = 4.66 (p = 0.001, CI 3.18-6.14); Difference in LS Means = 3.84 (p = 0.001, CI 2.37-5.3); Difference in LS Means = 2.43 (p = 0.002, CI 0.99-3.88). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Urinary Deoxypyridinoline/Creatinine Ratio (u-DPD/Cre).Parameters: Difference in LS Means = -42.91 (p = 0.001, CI -65.55--20.27); Difference in LS Means = -37.45 (p = 0.001, CI -60.32--14.59); Difference in LS Means = -26.77 (p = 0.017, CI -50.37--3.16). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline to Week 52 in Urinary N-telopeptides/Creatinine (u-NTx/Cre) Ratio.Parameters: Difference in LS Means = -44.32 (p = 0.001, CI -60.42--28.21); Difference in LS Means = -35.75 (p = 0.001, CI -52.33--19.16); Difference in LS Means = -50.64 (p = 0.001, CI -66.43--34.84). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_19'}, page_content='Study: Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)\\n\\nSummary: To demonstrate the efficacy/safety of Fosamax Plus D\\n\\nResults: Outcome: Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of Treatment.Parameters: Odds Ratio (OR) = 0.02 (p = 1e-04, CI 0-0.08). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Less and Greater Than 20 ng/ml at 16 Weeks of Treatment.Parameters: Odds Ratio (OR) = 0.02 (p = 1e-04, CI 0.01-0.04). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Serum PTH (Parathyroid Hormone) Percentage Changes From Baseline to 16 Weeks of Treatment.Parameters: NA = NA (p = 0.0091, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.'),\n",
       " Document(metadata={'source': 'study_20'}, page_content='Study: Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis\\n\\nSummary: The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal osteoporosis. Subject participation will last approximately 14.5 months.\\n\\nResults: Outcome: Change From Baseline in Menopause-Specific Quality of Life (MENQOL) Score at Month 3: Sleep Sub-Study.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-Study.Parameters: Least Squares (LS) Mean Difference = 1.51 (p = 0.001, CI 0.822-2.201); LS Mean Difference = 1.87 (p = 0.001, CI 1.209-2.533). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 6: Osteoporosis Sub-Study.Parameters: LS Mean Difference = 0.8 (p = 0.017, CI 0.139-1.47); LS Mean Difference = 1.19 (p = 0.001, CI 0.556-1.83). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 6, 12: Osteoporosis Sub-Study.Parameters: LS Mean Difference = 1.32 (p = 0.001, CI 0.901-1.742); LS Mean Difference = 1.21 (p = 0.001, CI 0.756-1.671); LS Mean Difference = 1.56 (p = 0.001, CI 1.152-1.962); LS Mean Difference = 1.6 (p = 0.001, CI 1.164-2.044). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Turnover Markers (BTMs) at Month 6 and Month 12: Osteoporosis Sub-Study.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0074, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0016, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0024, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0012, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0029, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0046, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0043, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.0016, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Breast Tenderness.Parameters: NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Cumulative Amenorrhea: Main Study.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Participants With Uterine Bleeding.Parameters: NA = NA (p = 0.014, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_21'}, page_content='Study: A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women\\n\\nSummary: The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining (endometrium).\\n\\nResults: Outcome: Immunohistochemistry (IHC) Proliferative Effects Measurement.Parameters: Least Squares Mean = 0.49 (p = 0.001, CI 0.31-1); Least Squares Mean = 0.19 (p = 0.032, CI 0.02-1). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_22'}, page_content=\"Study: A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab\\n\\nSummary: To evaluate the combined effect of denosumab treatment and discontinuation on cortical thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography (HR-pQCT). Participants randomized to either denosumab or placebo in the 20050179 (NCT00293813) study who completed that study (ie, attended an end of study visit) can be included in this study. At least 12 months should have elapsed since the patient's 20050179 end of study visit.\\n\\nResults: Outcome: Actual Value of Procollagen Type 1 N-terminal Peptide.Parameters: Ratio of Denosumab to Placebo = 1.2 (p = 0.0079, CI 1-1.3). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Cortical BMD at the Distal Radius by HR-pQCT.Parameters: Mean Difference (Final Values) = 0.9 (p = 0.0228, CI 0.1-1.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Total BMD at the Distal Tibia by HR-pQCT.Parameters: Mean Difference (Final Values) = 2.6 (p = 0.0032, CI 0.9-4.3). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From the Parent Study Baseline in Trabecular BMD at the Distal Tibia by HR-pQCT.Parameters: Mean Difference (Final Values) = 3.9 (p = 0.0067, CI 1.1-6.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change of Distal 1/3 Radius BMD From the Parent Study Baseline by DXA.Parameters: Mean Difference (Final Values) = 2.1 (p = 0.0184, CI 0.4-3.8). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change of Total Radius BMD From the Parent Study Baseline by DXA.Parameters: Mean Difference (Final Values) = 2.1 (p = 0.0035, CI 0.7-3.5). Non-inferiority type: SUPERIORITY_OR_OTHER.\"),\n",
       " Document(metadata={'source': 'study_23'}, page_content='Study: MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women\\n\\nSummary: The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called LexaproÂ®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI increases serotonin, a brain substance that is believed to influence mood. Serotonin may also affect brain levels of estradiol, a hormone related to hot flashes. This research study will test whether escitalopram reduces menopausal hot flashes.\\n\\nResults: Outcome: Change in Daily Frequency of Hot Flashes Between Baseline and Week 8 as Assessed by Prospective Daily Diaries.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change in Daily Severity of Hot Flashes Between Baseline and Week 8 as Assessed by Prospective Daily Diaries.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Outcome: Change in Daily Hot Flash Bother Between Baseline and Week 8 as Recorded on Daily Diaries.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_24'}, page_content='Study: Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density\\n\\nSummary: The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density.\\n\\nResults: Outcome: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine.Parameters: LS Mean Difference from Placebo = 8.7 (p = 1e-04, CI 7.5-9.9); LS Mean Difference from placebo = 5.6 (p = 1e-04, CI 4.3-6.9); LS Mean Difference from Placebo = 7.4 (p = 1e-04, CI 6.1-8.7); LS Mean Difference from Placebo = 8.5 (p = 1e-04, CI 7.3-9.8). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_25'}, page_content='Study: Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women\\n\\nSummary: Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatment regimens for 3 months.\\n\\nResults: Outcome: Percent Change From Baseline CTX 150 mg IRBB Tablet Compared With 75 mg & 100 mg DRFB Tablet, Month 3, ITT Population.Parameters: LS Mean Difference = -10.787 (p = 0.0133, CI -17.917--3.657). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg & 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population.Parameters: LS Mean Difference = -12.197 (p = 0.0045, CI -19.208--5.185). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_26'}, page_content='Study: Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women\\n\\nSummary: The purpose of this study is to investigate how teriparatide or zoledronic acid affects the bone of postmenopausal osteoporotic women after 6 months of treatment as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis). After completing 12 months of treatment all participants are eligible to participate in an additional 12-month open label extension.\\n\\nResults: Outcome: Activation Frequency (Ac.f) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Activation Frequency (Ac.f) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Activation Frequency (Ac.f) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Active Formation Period (a.FP) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Adjusted Apposition Rate (Aj.AR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.016, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Adjusted Apposition Rate (Aj.AR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Adjusted Apposition Rate (Aj.AR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.003, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Average Length of Tetracycline Double Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Formation Rate (BFR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Formation Rate (BFR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Bone Formation Rate (BFR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 1, 3 and 6 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) at Month 12 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Osteocalcin (OC) at Month 1, 3, and 6 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Osteocalcin (OC) at Month 12 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 1, 3 and 6 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide (PINP) at Month 12 Endpoint.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineral Apposition Rate (MAR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.02, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineral Apposition Rate (MAR) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineral Apposition Rate (MAR) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.039, CI NA-NA); NA = NA (p = 0.025, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralization Lag Time (Mlt) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralization Lag Time (Mlt) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.049, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mineralizing Surface/Bone Surface(MS/BS) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.033, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Samples With Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Thickness (OTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Osteoid Thickness (OTh.) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.039, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS), (dLS/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Eroded Surface/Bone Surface (ES/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.025, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Eroded Surface/Bone Surface (ES/BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Eroded Surface/Bone Surface (ES/BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.012, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 24 Months.Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Formation Period (Tt.FP) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Formation Period (Tt.FP) in the Endocortical Compartment (EC) of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.022, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Wall Thickness (WTh.) in the Cancellous Compartment of Iliac Crest Bone Biopsies at 6 Months.Parameters: NA = NA (p = 0.014, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Wall Thickness (WTh.) in the Endocortical Compartment of Iliac Crest Bone Biopsies at 6 and 24 Months.Parameters: NA = NA (p = 0.027, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_27'}, page_content='Study: A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates\\n\\nSummary: This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.\\n\\nResults: Outcome: Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12.Parameters: Mean Difference (Net) = 1.2 (p = 1e-04, CI 0.7-1.7). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12.Parameters: Mean Difference (Net) = 2 (p = 1e-04, CI 1.5-2.5). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1.Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Total Hip Bone Mineral Density Percent Change From Baseline at Month 12.Parameters: Mean Difference (Net) = 1.4 (p = 1e-04, CI 1-1.8). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_28'}, page_content='Study: A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women\\n\\nSummary: The purpose of this study is to compare the effectiveness and tolerability of two medications, calcitonin nasal spray and a tablet containing calcitonin, in postmenopausal women with osteoporosis. Osteoporosis is the term used to describe a large group of diseases, which are characterized by loss of bone density, which makes the bones weaker. Osteoporosis often occurs in postmenopausal women.\\n\\nCalcitonin is a hormone found in the human body. Together with other substances, it regulates the concentration of calcium in the blood and inhibits the natural resorption of bone. Both medications in this study contain salmon calcitonin (sCT), because this form of calcitonin is more active than human calcitonin when used as a medicine.\\n\\nThe calcitonin Nasal Spray used in this study is registered and available to doctors in United States for the treatment of osteoporosis. The medication being tested in this study is an oral tablet form of salmon calcitonin.\\n\\nResults: Outcome: Change in Plasma C-terminal Telopeptide of Collagen 1 (CTx-1).Parameters: Mean Difference (Net) = -21.84 (p = 6e-04, CI NA-NA). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Change in Plasma CTx-1 From Baseline.Parameters: Mean Difference (Net) = -18.09 (p = 0.0012, CI NA-NA). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Axial Lumbar Spine.Parameters: Mean Difference (Net) = 0.77 (p = 0.002, CI 0.08-1.45). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.'),\n",
       " Document(metadata={'source': 'study_29'}, page_content='Study: Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients\\n\\nSummary: The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.\\n\\nResults: Outcome: Change From Baseline in Menopause Rating Scale (MRS) - Dryness of Vagina- S-equol Groups Combined.Parameters: NA = NA (p = 0.0381, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort) - S-equol Groups Combined.Parameters: NA = NA (p = 0.0097, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percentage Change From Baseline in Menopause Rating Scale (MRS) - Sum of 3 Symptoms (Irritability, Dry Vagina, Joint/Muscular Discomfort).Parameters: NA = NA (p = 0.0475, CI NA-NA); NA = NA (p = 0.0258, CI NA-NA); NA = NA (p = 0.0281, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_30'}, page_content='Study: MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)\\n\\nSummary: This study seeks to demonstrate that additional gain in bone mineral density (BMD) can be achieved by switching to MK-5442 from an oral bisphosphonate in participants who have been receiving oral bisphosphonate therapy for at least 3 years.\\n\\nResults: Outcome: Least Squares Mean Percent Change From Baseline To Month 12 in Lumbar Spine Areal Bone Mineral Density (BMD).Parameters: Difference in Least Squares Means = -1.96 (p = 0.012, CI -3.58--0.35); Difference in Least Squares Means = -1.81 (p = 0.019, CI -3.37--0.25); Difference in Least Squares Means = -1.82 (p = 0.019, CI -3.23--0.41). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Cortical Volumetric BMD of the Hip.Parameters: Difference in Least Squares Means = -1.48 (p = 0.01, CI -2.66--0.29). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Femoral Neck Areal BMD.Parameters: Difference in Least Squares Means = -2.04 (p = 0.002, CI -3.43--0.64); Difference in Least Squares Means = -1.29 (p = 0.035, CI -2.48--0.09); Difference in Least Squares Means = -1.76 (p = 0.009, CI -3.14--0.38). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Serum Bone-Specific Alkaline Phosphatase (s-BSAP).Parameters: Difference in Least Squares Means = 53.86 (p = 0.001, CI 39.31-68.6); Difference in Least Squares Means = 53.81 (p = 0.001, CI 41.37-66.38); Difference in Least Squares Means = 55.47 (p = 0.001, CI 41.19-69.94); Difference in Least Squares Means = 20.53 (p = 0.009, CI 5.96-35.03); Difference in Least Mean Squares = 20.47 (p = 0.009, CI 5.96-35.03); Difference in Least Squares Means = 22.13 (p = 0.009, CI 4.47-39.89). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx).Parameters: Difference in Least Squares Means = 48.29 (p = 0.034, CI 3.75-93.11); Difference in Least Squares Means = 61.27 (p = 0.019, CI 8.8-114.22); Difference in Least Squares Means = 85.28 (p = 0.002, CI 26.7-144.63); Difference in Least Squares Means = 187.31 (p = 0.001, CI 154.44-221.25); Difference in Least Squares Means = 200.29 (p = 0.001, CI 161.21-240.91); Difference in Least Squares Means = 224.3 (p = 0.001, CI 180.19-270.39). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Serum N-Terminal Propeptide (s-P1NP).Parameters: Difference in Least Squares Means = 133.03 (p = 0.001, CI 110.01-156.75); Difference in Least Squares Means = 133.03 (p = 0.001, CI 110.01-156.75); Difference in Least Squares Means = 131.53 (p = 0.001, CI 110.7-152.94); Difference in Least Squares Means = 169.8 (p = 0.001, CI 141.59-199.11); Difference in Least Squares Means = 58.57 (p = 0.001, CI 29.42-88.04); Difference in Least Squares Means = 57.07 (p = 0.001, CI 30.76-83.64); Difference in Least Squares Means = 95.34 (p = 0.001, CI 60.4-130.91). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Total Body Areal BMD.Parameters: Difference in Least Squares Means = -1.36 (p = 0.001, CI -2.18--0.54); Difference in Least Squares Means = -1.51 (p = 0.001, CI -2.46--0.55); Difference in Least Squares Means = -1.92 (p = 0.001, CI -2.93--0.91). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Total Hip Areal BMD.Parameters: Difference in Least Squares Means = -2.64 (p = 0.001, CI -3.9--1.38); Difference in Least Squares Means = -2.62 (p = 0.001, CI -3.83--1.4); Difference in Least Squares Means = -2.12 (p = 0.001, CI -3.22--1.02). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Trochanter Areal BMD.Parameters: Difference in Least Squares Means = -3.24 (p = 0.001, CI -4.91--1.57); Difference in Least Square Means = -3.18 (p = 0.001, CI -4.78--1.57); Difference in Least Squares Means = -3.2 (p = 0.001, CI -4.66--1.74). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Least Squares Mean Percent Change From Baseline to Month 12 in Urinary-N Telopeptides of Type 1 Collagen (u-NTx).Parameters: Difference in Least Squares Means = 86.33 (p = 0.001, CI 64.87-108.29); Difference in Least Squares Means = 82.14 (p = 0.001, CI 63-101.66); Difference in Least Squares Means = 107.26 (p = 0.001, CI 82.03-133.23); Difference in Least Squares Means = 43.8 (p = 0.003, CI 12.85-75.06). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_31'}, page_content='Study: Research Investigation of Soy and Estrogen\\n\\nSummary: The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.\\n\\nResults: Outcome: Change in STAI-6 Score.Parameters: NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_32'}, page_content='Study: A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)\\n\\nSummary: This study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes or hot flushes) in postmenopausal women. The primary study hypothesis is that one or more doses of MK-6913 will result in a significantly greater reduction from baseline, compared to placebo, in the number of moderate to very severe hot flashes after 4 weeks of treatment.\\n\\nResults: Outcome: Change From Baseline in Follicle-stimulating Hormone (FSH) Level at Week 4.Parameters: Difference in the LS means = -14.52 (p = 0.001, CI -21.73--7.32). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_33'}, page_content='Study: Impact of Hot Flashes on Sleep and Mood Disturbance\\n\\nSummary: We plan to enroll premenopausal women in a trial investigating the impact of hot flashes developed in response to an injection of a gonadotropin-releasing hormone agonist (GnRHa), leuprolide (brand name: Lupron), on sleep disruption and mood. This study is designed to mimic the menopause transition. We will collect data on sleep disruption and mood changes to assess their relationship to the development of hot flashes.\\n\\nResults: Outcome: Change in Montgomery-Asperg Depression Rating Scale (MADRS).Parameters: NA = NA (p = 0.01, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Wake After Sleep Onset (WASO).Parameters: NA = NA (p = 0.007, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_34'}, page_content='Study: Measuring Quality of Decisions About Treatment of Menopausal Symptoms\\n\\nSummary: The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of menopause. In particular, we will examine whether the decision aid increases knowledge about menopause/managing menopause symptoms and concordance between goals and treatment choices.\\n\\nResults: Outcome: Menopause Knowledge.Parameters: Mean Difference (Net) = 4.6 (p = 0.01, CI 1.02-7.96). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_35'}, page_content='Study: A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-NaÃ¯ve Women With Post-Menopausal Osteoporosis\\n\\nSummary: This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naÃ¯ve patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.\\n\\nResults: Outcome: Percent Change From Baseline in Lumbar Spine T-score at Month 12 and 24.Parameters: NA = NA (p = 5e-04, CI NA-NA); NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Hip Bone BMD at Month 12.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine BMD at Month 24.Parameters: NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12.Parameters: NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Total Hip T-score at Month 12 and 24.Parameters: NA = NA (p = 5e-04, CI NA-NA); NA = NA (p = 0.027, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_36'}, page_content='Study: Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women\\n\\nSummary: The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.\\n\\nResults: Outcome: Number of Participants With New Vertebral Fractures at 18 Months.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Number of Participants With Non-vertebral Fractures at 18 Months.Parameters: NA = NA (p = 0.0318, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Bone Mineral Density (BMD) of Femoral Neck From Baseline to Month 18.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 4e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 18 Months.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Bone Mineral Density (BMD) of Total Hip From Baseline to Month 18.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_37'}, page_content='Study: A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)\\n\\nSummary: This study will evaluate whether the once weekly administration of the combination tablet alendronate/vitamin D3 (FOSAMAX PLUS) will increase lumbar spine bone mineral density (BMD) more than the daily use of calcitriol.\\n\\nResults: Outcome: Base Study: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 6.Parameters: Estimated Difference = 1.95 (p = 0.001, CI 0.8-3.1). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Base Study: Percentage Change From Baseline in Serum C-Telopeptides of Type 1 Collagen (s-CTx) at Month 6.Parameters: LS mean difference = -52.03 (p = 0.001, CI -59.04--45.3). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Base Study: Percentage Change From Baseline in Serum Procollagen Type 1 N-Terminal Propeptide (s-P1NP) at Month 6.Parameters: LS mean difference = -42.37 (p = 0.001, CI -48.16--36.67). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage Change From Baseline in Lumbar Spine BMD at Month 12.Parameters: Estimated Difference = 2.92 (p = 0.001, CI 1.8-4.1). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage Change From Baseline in s-CTx at Month 12.Parameters: LS mean difference = -51.96 (p = 0.001, CI -58.77--45.39). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage Change From Baseline in s-P1NP at Month 12.Parameters: LS mean difference = -51.07 (p = 0.001, CI -57.29--44.99). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Extension Study: Percentage of Participants With Serum 25-Hydroxyvitamin (OH) D <20 ng/mL at Month 12.Parameters: Odds Ratio (OR) = 0.0279 (p = 0.001, CI 0.0074-0.1048). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.'),\n",
       " Document(metadata={'source': 'study_38'}, page_content='Study: Efficacy/Safety Study of Brisdelleâ„¢ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)\\n\\nSummary: The purpose of this study is to assess the safety \\\\& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.\\n\\nResults: Outcome: Clinical Meaningfulness Anchored to Patient Global Improvement (PGI-I) (%).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.Parameters: NA = NA (p = 0.0017, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12..Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 0.009, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_39'}, page_content='Study: Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)\\n\\nSummary: This observational cohort study is being conducted to further characterize selected adverse events of interest among a patient population with osteoporosis who are prescribed bazedoxifene, raloxifene, or a bisphosphonate in usual clinical care outside of a randomized clinical trial setting. The study will compare the rates of the selected clinical events among the three treatment groups.\\n\\nResults: Outcome: Cumulative Incidence of All Malignancies.Parameters: Hazard Ratio (HR) = 0.5 (p = 0.01, CI 0.3-0.7). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Biliary Events.Parameters: Hazard Ratio (HR) = 0.4 (p = 0.01, CI 0.3-0.7). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Cardiac Disorders.Parameters: Hazard Ratio (HR) = 0.6 (p = 0.01, CI 0.3-0.9). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Clinical Fractures.Parameters: Hazard Ratio (HR) = 0.4 (p = 0.01, CI 0.3-0.6); Hazard Ratio (HR) = 0.6 (p = 0.01, CI 0.4-0.9). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Hypertriglyceridemia.Parameters: Hazard Ratio (HR) = 1.9 (p = 0.01, CI 1.4-2.5). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Ischemic Stroke.Parameters: Hazard Ratio (HR) = 0.5 (p = 0.01, CI 0.3-0.7). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Renal Failure.Parameters: Hazard Ratio (HR) = 0.3 (p = 0.01, CI 0.1-0.5). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Selected Ocular Events.Parameters: Hazard Ratio (HR) = 0.8 (p = 0.03, CI 0.6-1). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Thyroid Disorders- Goitre.Parameters: Hazard Ratio (HR) = 0.3 (p = 0.01, CI 0.2-0.5). Non-inferiority type: SUPERIORITY. Outcome: Cumulative Incidence of Venous Thromboembolism (VTE).Parameters: Hazard Ratio (HR) = 0.4 (p = 0.01, CI 0.3-0.7). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_40'}, page_content='Study: MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms\\n\\nSummary: The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17-ÃŸ-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes. Included in this objective is the intention to compare venlafaxine XR to estradiol therapy, to provide evidence of the relative efficacy of venlafaxine to what is currently considered the most established but also a controversial therapy. 17-ÃŸ-estradiol is a type of estrogen. Venlafaxine XR is the extended release (XR) version of venlafaxine. Venlafaxine XR is an serotonin-norepinephrine reuptake inhibitor (SNRI). A placebo is a substance containing no medication.\\n\\nResults: Outcome: Bothersomeness of Hot Flashes -- Week 8.Parameters: NA = NA (p = 0.01, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Frequency of Hot Flashes (Daily Vasomotor Symptom [VMS] Frequency) -- Week 8.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Perceived Hot Flash Interference (Hot Flash Related Daily Interference Scale; HFRDIS) -- Week 8.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Severity of Hot Flashes -- Week 8.Parameters: NA = NA (p = 0.02, CI NA-NA); NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_41'}, page_content='Study: A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab\\n\\nSummary: The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.\\n\\nResults: Outcome: Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6.Parameters: Mean Difference (Final Values) = 3.21 (p = 1e-04, CI 2.06-4.36). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_42'}, page_content='Study: A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab\\n\\nSummary: The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.\\n\\nResults: Outcome: Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6.Parameters: Mean Difference (Final Values) = 3.05 (p = 1e-04, CI 1.91-4.19). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_43'}, page_content='Study: Therapy to Prevent Sexual Pain in Breast Cancer Survivors\\n\\nSummary: The purpose of this protocol is to determine whether pain with sexual intercourse can be reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a non-hormonal therapy (Lidocaine Liquid) vs. a placebo liquid in reducing pain.\\n\\nThe investigators hypothesize that the pain arises in the vulvar vestibule. The investigators predict that the localized use of lidocaine will be more efficacious than use of placebo liquid.\\n\\nResults: Outcome: Improvement of Quality of Sexual Life - Visit 1.Parameters: NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Location of Pain in Postmenopausal Dyspareunia.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Prevention of Entry Dyspareunia With Non-hormonal Therapy.Parameters: NA = NA (p = 0.0149, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_44'}, page_content='Study: Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis\\n\\nSummary: The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis\\n\\nResults: Outcome: Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24.Parameters: LS Mean Difference = 11.1 (p = 0.001, CI 10.8-11.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12.Parameters: LS Mean Difference = 12.7 (p = 0.001, CI 12.4-12.9). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12.Parameters: LS Mean Difference = 5.2 (p = 0.001, CI 4.9-5.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24.Parameters: LS Mean Difference = 4.9 (p = 0.001, CI 4.7-5.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12.Parameters: LS Mean Difference = 5.8 (p = 0.001, CI 5.6-6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24.Parameters: LS Mean Difference = 5.3 (p = 0.001, CI 5.1-5.5). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12.Parameters: Odds Ratio (OR) = 0.11 (p = 0.011, CI 0.01-0.87). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24.Parameters: Odds Ratio (OR) = 0.06 (p = 0.001, CI 0.01-0.44). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fracture Through Month 12.Parameters: Odds Ratio (OR) = 0.27 (p = 0.001, CI 0.15-0.47). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fracture Through Month 24.Parameters: Odds Ratio (OR) = 0.24 (p = 0.001, CI 0.15-0.39). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 12.Parameters: Hazard Ratio (HR) = 0.64 (p = 0.008, CI 0.46-0.89). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Osteoporotic Fracture Through Month 12.Parameters: Hazard Ratio (HR) = 0.6 (p = 0.012, CI 0.4-0.9). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Osteoporotic Fracture Through Month 24.Parameters: Hazard Ratio (HR) = 0.62 (p = 0.002, CI 0.46-0.84). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_45'}, page_content='Study: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis\\n\\nSummary: The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.\\n\\nResults: Outcome: Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12.Parameters: LS Mean Difference = 3.2 (p = 0.001, CI 2.9-3.54). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12.Parameters: LS Mean Difference = 8.7 (p = 0.001, CI 8.31-9.09). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 24.Parameters: LS Mean Difference = 8.1 (p = 0.001, CI 7.58-8.57). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12.Parameters: LS Mean Difference = 3.3 (p = 0.001, CI 3.03-3.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 36.Parameters: LS Mean Difference = 3.6 (p = 0.001, CI 3.18-3.97). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at at Month 24.Parameters: LS Mean Difference = 3.8 (p = 0.001, CI 3.4-4.14). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Lumbar Spine at Month 36.Parameters: LS Mean Difference = 7.4 (p = 0.001, CI 6.84-7.89). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24.Parameters: LS Mean Difference = 3.8 (p = 0.001, CI 3.42-4.1). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 36.Parameters: LS Mean Difference = 3.7 (p = 0.001, CI 3.29-4.02). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Any Fracture Through Month 12.Parameters: Hazard Ratio (HR) = 0.71 (p = 0.002, CI 0.57-0.88). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Any Fracture at the Primary Analysis.Parameters: Hazard Ratio (HR) = 0.65 (p = 0.001, CI 0.56-0.76). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24.Parameters: Odds Ratio (OR) = 0.51 (p = 0.008, CI 0.31-0.85). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fractures Through Month 12.Parameters: Odds Ratio (OR) = 0.63 (p = 0.008, CI 0.44-0.89). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With New Vertebral Fractures Through Month 24.Parameters: Odds Ratio (OR) = 0.48 (p = 0.001, CI 0.36-0.64). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 12.Parameters: Hazard Ratio (HR) = 0.72 (p = 0.027, CI 0.54-0.96). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture Through Month 24.Parameters: Hazard Ratio (HR) = 0.74 (p = 0.005, CI 0.59-0.91). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Fracture at the Primary Analysis.Parameters: Hazard Ratio (HR) = 0.73 (p = 0.001, CI 0.61-0.88). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Clinical Vertebral Fracture Through Month 24.Parameters: Hazard Ratio (HR) = 0.41 (p = 0.001, CI 0.24-0.71). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Hip Fracture at the Primary Analysis.Parameters: Hazard Ratio (HR) = 0.62 (p = 0.015, CI 0.42-0.92). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Major Nonvertebral Fracture at the Primary Analysis.Parameters: Hazard Ratio (HR) = 0.73 (p = 0.004, CI 0.59-0.9). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24.Parameters: Odds Ratio (OR) = 0.49 (p = 0.001, CI 0.37-0.64). Non-inferiority type: SUPERIORITY. Outcome: Percentage of Participants With a Nonvertebral Fracture at the Primary Analysis.Parameters: Hazard Ratio (HR) = 0.81 (p = 0.04, CI 0.66-0.99). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_46'}, page_content='Study: Homeopathic Treatment for Depression in Peri- and Postmenopausal Women\\n\\nSummary: The aim of this study was to determine whether individualized homeopathic treatment and fluoxetine are more efficient than placebo for moderate to severe depression in peri- and postmenopausal women.\\n\\nResults: Outcome: Change From Baseline in GreeneÂ´s Scale at 6 Weeks..Parameters: Mean Difference (Final Values) = 8.6 (p = 0.002, CI 2.72-14.52). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_47'}, page_content='Study: Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis\\n\\nSummary: To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.\\n\\nResults: Outcome: Percent Change From Baseline in BMD of Total Hip at 6 Months.Parameters: NA = NA (p = 0.0056, CI NA-NA); NA = NA (p = 0.0018, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at 6 Months.Parameters: NA = NA (p = 0.0066, CI NA-NA); NA = NA (p = 5e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.'),\n",
       " Document(metadata={'source': 'study_48'}, page_content='Study: VERtebral Fracture Treatment Comparisons in Osteoporotic Women\\n\\nSummary: The primary purpose of participation in this study is to answer whether teriparatide is superior to risedronate in reducing the occurrence of new vertebral fractures during 24 months of therapy.\\n\\nResults: Outcome: Proportion of Participants With New Moderate and/or Severe Vertebral Fractures.Parameters: Odds Ratio (OR) = 0.3812 (p = 0.001, CI 0.237-0.614); Risk Ratio (RR) = 0.4173 (p = 0.001, CI 0.27-0.646). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With New Multiple (2 or More) Vertebral Fractures.Parameters: Odds Ratio (OR) = 0.1593 (p = 0.007, CI 0.035-0.728); Risk Ratio (RR) = 0.1643 (p = 0.007, CI 0.036-0.744). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With New Vertebral Fractures.Parameters: Odds Ratio (OR) = 0.4071 (p = 9.4e-05, CI 0.256-0.647); Risk Ratio (RR) = 0.4431 (p = 9.4e-05, CI 0.29-0.677). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures.Parameters: Stratified Hazard Ratio (HR) = 0.4831 (p = 0.000869, CI 0.316-0.739). Non-inferiority type: SUPERIORITY. Outcome: Proportion of Participants With Pooled New and Worsening Vertebral Fractures.Parameters: Odds Ratio (OR) = 0.4187 (p = 7.5e-05, CI 0.269-0.652); Risk Ratio (RR) = 0.4561 (p = 7.5e-05, CI 0.305-0.682). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_49'}, page_content='Study: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis\\n\\nSummary: This study will compare the effectiveness of denosumab treatment every 6 months with once yearly zoledronic acid treatment on bone mineral density (BMD) at various skeletal sites.\\n\\nResults: Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 12 - Superiority Analysis.Parameters: Treatment Difference = 2.1 (p = 1e-04, CI 1.6-2.6). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY. Outcome: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority Analysis.Parameters: Treatment Difference = 2.1 (p = 1e-04, CI 1.6-2.6). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 12 - Non-inferiority Analysis.Parameters: Treatment Difference = 1.4 (p = 1e-04, CI 1-1.7). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE_LEGACY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 12 - Superiority Analysis.Parameters: Treatment Difference = 1.4 (p = 1e-04, CI 1-1.7). Non-inferiority type: SUPERIORITY_OR_OTHER_LEGACY.'),\n",
       " Document(metadata={'source': 'study_50'}, page_content='Study: Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor\\n\\nSummary: This is a study to determine how vaginal estrogen cream given for several weeks before pelvic reconstructive therapy will effect elastic fiber assembly in the muscularis layer of the vaginal wall. Postmenopausal women with at least Stage 2 pelvic organ prolapse will receive either estrogen vaginal cream or placebo cream 6-8 weeks prior to reconstructive surgery. At time of surgery, full thickness biopsies will be obtained from a standardized location at the top of vagina. The investigators will measure the thickness of the vaginal muscularis, elastic fiber number and morphology, and analyze if elastic fiber synthesis or degradation is affected by estrogen therapy. The results will provide important data to support a larger clinical trial to determine if preoperative and maintenance estrogen therapy alter long-term success rates of pelvic reconstructive surgery for pelvic organ prolapse.\\n\\nResults: Outcome: Vaginal Wall Composition: Epithelium (Per-Protocol).Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Vaginal Wall Degradative Activity, Muscularis, MMP-9.Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: hCOL1A1, Per-Protocol.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_51'}, page_content='Study: An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women\\n\\nSummary: The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were previously treated with bisphosphonate therapy.\\n\\nResults: Outcome: Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD).Parameters: Treatment difference = 3.2 (p = 1e-04, CI 2.7-3.8). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12.Parameters: Treatment difference = 4.6 (p = 1e-04, CI 3.9-5.3). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6.Parameters: Treatment difference = 3.4 (p = 1e-04, CI 2.8-4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12.Parameters: Treatment difference = 3.2 (p = 1e-04, CI 2.1-4.3). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6.Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.4-3.8). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Femoral Neck BMD at Month 12.Parameters: Treatment difference = 3.4 (p = 1e-04, CI 2.6-4.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Femoral Neck BMD at Month 6.Parameters: Treatment difference = 3.2 (p = 1e-04, CI 2.5-3.9). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12.Parameters: Treatment difference = 3.6 (p = 1e-04, CI 2.9-4.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6.Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.5-3.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 12.Parameters: Treatment difference = 4.4 (p = 1e-04, CI 3.4-5.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Lumbar Spine BMD at Month 6.Parameters: Treatment difference = 3.8 (p = 1e-04, CI 2.9-4.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 12.Parameters: Treatment difference = 3.4 (p = 1e-04, CI 2.8-4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip BMD at Month 6.Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.5-3.7). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12.Parameters: Treatment difference = 3.6 (p = 1e-04, CI 2.9-4.2). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6.Parameters: Treatment difference = 3.1 (p = 1e-04, CI 2.6-3.6). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_52'}, page_content='Study: A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms\\n\\nSummary: This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.\\n\\nResults: Outcome: Clinical Global Impression (CGI) - Week 12 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Clinical Global Impression (CGI) - Week 4 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.005, CI NA-NA); NA = NA (p = 0.007, CI NA-NA); NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Clinical Global Impression (CGI) - Week 8 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS).Parameters: Mean Difference (Final Values) = -16.58 (p = 0.001, CI -23.33--9.82); Mean Difference (Final Values) = -15.07 (p = 0.001, CI -21.72--8.42); Mean Difference (Final Values) = -10.79 (p = 0.002, CI -17.48--4.1); Mean Difference (Final Values) = -11.71 (p = 0.001, CI -18.31--5.11). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS).Parameters: Mean Difference (Final Values) = -12.81 (p = 0.001, CI -19.29--6.32); Mean Difference (Final Values) = -8.07 (p = 0.013, CI -14.46--1.68); Mean Difference (Final Values) = -10.4 (p = 0.001, CI -16.73--4.08). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.57 (p = 0.001, CI -0.77--0.38); Mean Difference (Final Values) = -0.39 (p = 0.001, CI -0.59--0.2); Mean Difference (Final Values) = -0.24 (p = 0.018, CI -0.43--0.04). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.13 (p = 0.031, CI -0.25--0.01); Mean Difference (Final Values) = -0.17 (p = 0.005, CI -0.28--0.05). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS).Parameters: Mean Difference (Final Values) = -21.01 (p = 0.001, CI -28.72--13.29); Mean Difference (Final Values) = -18.37 (p = 0.001, CI -25.96--10.78); Mean Difference (Final Values) = -13.03 (p = 0.001, CI -20.66--5.39); Mean Difference (Final Values) = -14.65 (p = 0.001, CI -22.19--7.12). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS).Parameters: Mean Difference (Final Values) = -21.83 (p = 0.001, CI -29.57--14.08); Mean Difference (Final Values) = -19.4 (p = 0.001, CI -27.02--11.77); Mean Difference (Final Values) = -13.98 (p = 0.001, CI -21.65--6.32); Mean Difference (Final Values) = -15.66 (p = 0.001, CI -23.23--8.1). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -20.61 (p = 0.001, CI -28.32--12.89); Mean Difference (Final Values) = -18.24 (p = 0.001, CI -25.84--10.65); Mean Difference (Final Values) = -12.62 (p = 0.001, CI -20.26--4.98); Mean Difference (Final Values) = -13.97 (p = 0.001, CI -21.51--6.43). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS).Parameters: Mean Difference (Final Values) = -10.38 (p = 0.003, CI -17.26--3.5); Mean Difference (Final Values) = -7.86 (p = 0.022, CI -14.58--1.15). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS).Parameters: Mean Difference (Final Values) = -15.32 (p = 0.001, CI -22.75--7.89); Mean Difference (Final Values) = -8.92 (p = 0.017, CI -16.24--1.6); Mean Difference (Final Values) = -11.32 (p = 0.002, CI -18.57--4.07). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS).Parameters: Mean Difference (Final Values) = -17.47 (p = 0.001, CI -24.65--10.28); Mean Difference (Final Values) = -10.26 (p = 0.005, CI -17.33--3.18); Mean Difference (Final Values) = -12.66 (p = 0.001, CI -19.68--5.65). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -20.32 (p = 0.001, CI -27.77--12.87); Mean Difference (Final Values) = -12.61 (p = 0.001, CI -19.95--5.28); Mean Difference (Final Values) = -8.33 (p = 0.027, CI -15.7--0.96); Mean Difference (Final Values) = -13.85 (p = 0.001, CI -21.13--6.58). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS).Parameters: Mean Difference (Final Values) = -21.45 (p = 0.001, CI -28.87--14.04); Mean Difference (Final Values) = -16.1 (p = 0.001, CI -23.39--8.8); Mean Difference (Final Values) = -12.01 (p = 0.001, CI -19.34--4.68); Mean Difference (Final Values) = -15.73 (p = 0.001, CI -22.97--8.49). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS).Parameters: Mean Difference (Final Values) = -20.52 (p = 0.001, CI -28.06--12.97); Mean Difference (Final Values) = -15.37 (p = 0.001, CI -22.8--7.95); Mean Difference (Final Values) = -11.49 (p = 0.003, CI -18.95--4.03); Mean Difference (Final Values) = -13.82 (p = 0.001, CI -21.19--6.46). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS).Parameters: Mean Difference (Final Values) = -20.34 (p = 0.001, CI -27.93--12.74); Mean Difference (Final Values) = -17.92 (p = 0.001, CI -25.39--10.45); Mean Difference (Final Values) = -12.97 (p = 0.001, CI -20.49--5.46); Mean Difference (Final Values) = -14.28 (p = 0.001, CI -21.7--6.87). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS).Parameters: Mean Difference (Final Values) = -16.8 (p = 0.001, CI -23.58--10.03); Mean Difference (Final Values) = -15.66 (p = 0.001, CI -22.32--8.99); Mean Difference (Final Values) = -11.2 (p = 0.001, CI -17.9--4.49); Mean Difference (Final Values) = -12.16 (p = 0.001, CI -18.78--5.55). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS).Parameters: Mean Difference (Final Values) = -18.11 (p = 0.001, CI -24.92--11.29); Mean Difference (Final Values) = -16.45 (p = 0.001, CI -23.17--9.74); Mean Difference (Final Values) = -12.41 (p = 0.001, CI -19.15--5.66); Mean Difference (Final Values) = -13.6 (p = 0.001, CI -20.26--6.93). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -10.79 (p = 0.002, CI -17.48--4.1); Mean Difference (Final Values) = -11.71 (p = 0.001, CI -18.31--5.11); Mean Difference (Final Values) = -16.58 (p = 0.001, CI -23.33--9.82); Mean Difference (Final Values) = -15.07 (p = 0.001, CI -21.72--8.42). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS).Parameters: Mean Difference (Final Values) = -8.56 (p = 0.007, CI -14.75--2.36); Mean Difference (Final Values) = -7.24 (p = 0.019, CI -13.28--1.19). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS).Parameters: Mean Difference (Final Values) = -12.81 (p = 0.001, CI -19.29--6.32); Mean Difference (Final Values) = -8.07 (p = 0.013, CI -14.46--1.68); Mean Difference (Final Values) = -10.4 (p = 0.001, CI -16.73--4.08). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS).Parameters: Mean Difference (Final Values) = -9.88 (p = 0.003, CI -16.34--3.41); Mean Difference (Final Values) = -12.05 (p = 0.001, CI -18.47--5.64); Mean Difference (Final Values) = -15.59 (p = 0.001, CI -22.16--9.02). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -17.87 (p = 0.001, CI -24.57--11.05); Mean Difference (Final Values) = -11.35 (p = 0.001, CI -18--4.7); Mean Difference (Final Values) = -7.82 (p = 0.022, CI -14.5--1.14); Mean Difference (Final Values) = -12.51 (p = 0.001, CI -19.11--5.91). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS).Parameters: Mean Difference (Final Values) = -17.75 (p = 0.001, CI -24.45--11.06); Mean Difference (Final Values) = -13.29 (p = 0.001, CI -19.88--6.7); Mean Difference (Final Values) = -10.22 (p = 0.003, CI -16.83--3.6); Mean Difference (Final Values) = -13.61 (p = 0.001, CI -20.15--7.07). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS).Parameters: Mean Difference (Final Values) = -16.63 (p = 0.001, CI -23.35--9.91); Mean Difference (Final Values) = -12.97 (p = 0.001, CI -19.58--6.36); Mean Difference (Final Values) = -9.63 (p = 0.005, CI -16.27--2.99); Mean Difference (Final Values) = -11.97 (p = 0.001, CI -18.53--5.41). Non-inferiority type: SUPERIORITY. Outcome: Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS).Parameters: Mean Difference (Final Values) = -17.12 (p = 0.001, CI -23.79--10.44); Mean Difference (Final Values) = -15.58 (p = 0.001, CI -22.15--9.01); Mean Difference (Final Values) = -11.05 (p = 0.001, CI -17.65--4.44); Mean Difference (Final Values) = -13.02 (p = 0.001, CI -19.54--6.5). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT).Parameters: Mean Difference (Final Values) = 7.56 (p = 0.01, CI 1.83-13.29); Mean Difference (Final Values) = 7.65 (p = 0.009, CI 1.94-13.36); Mean Difference (Final Values) = 7.89 (p = 0.007, CI 2.11-13.67). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = 8.58 (p = 0.019, CI 1.39-15.77); Mean Difference (Final Values) = 7.51 (p = 0.041, CI 0.3-14.71). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT).Parameters: Mean Difference (Final Values) = 7.1 (p = 0.007, CI 1.93-12.26); Mean Difference (Final Values) = 5.9 (p = 0.025, CI 0.75-11.04); Mean Difference (Final Values) = 8.38 (p = 0.002, CI 3.2-13.55). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS).Parameters: Mean Difference (Final Values) = 9.58 (p = 0.002, CI 3.43-15.74); Mean Difference (Final Values) = 8.94 (p = 0.005, CI 2.75-15.13). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = 6.16 (p = 0.043, CI 0.2-12.13). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT).Parameters: Mean Difference (Final Values) = -8.97 (p = 0.001, CI -13.76--4.19); Mean Difference (Final Values) = -9.6 (p = 0.001, CI -14.34--4.85); Mean Difference (Final Values) = -9.3 (p = 0.001, CI -14.03--4.56); Mean Difference (Final Values) = -7.72 (p = 0.002, CI -12.51--2.93). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -6.56 (p = 0.04, CI -12.8--0.31); Mean Difference (Final Values) = -10.02 (p = 0.001, CI -15.99--4.04); Mean Difference (Final Values) = -9.96 (p = 0.002, CI -16.11--3.81); Mean Difference (Final Values) = -6.85 (p = 0.029, CI -12.99--0.7). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT).Parameters: Mean Difference (Final Values) = -8.38 (p = 0.001, CI -12.72--4.04); Mean Difference (Final Values) = -7.52 (p = 0.001, CI -11.83--3.2); Mean Difference (Final Values) = -7.32 (p = 0.001, CI -11.63--3.02); Mean Difference (Final Values) = -5.6 (p = 0.011, CI -9.93--1.27). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -7.54 (p = 0.008, CI -13.14--1.93); Mean Difference (Final Values) = -6.72 (p = 0.016, CI -12.18--1.26); Mean Difference (Final Values) = -8.69 (p = 0.002, CI -14.28--3.1); Mean Difference (Final Values) = -6.18 (p = 0.028, CI -11.68--0.68). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -6.48 (p = 0.02, CI -11.92--1.04); Mean Difference (Final Values) = -5.85 (p = 0.033, CI -11.22--0.48). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT).Parameters: Mean Difference (Final Values) = -7.34 (p = 0.001, CI -11.55--3.13); Mean Difference (Final Values) = -5.6 (p = 0.009, CI -9.8--1.4); Mean Difference (Final Values) = -5.13 (p = 0.016, CI -9.31--0.95). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT).Parameters: Mean Difference (Final Values) = -6.01 (p = 0.001, CI -9.71--2.32); Mean Difference (Final Values) = -7.22 (p = 0.001, CI -10.89--3.55); Mean Difference (Final Values) = -6.92 (p = 0.001, CI -10.58--3.27); Mean Difference (Final Values) = -6.42 (p = 0.001, CI -10.12--2.72). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -6.49 (p = 0.006, CI -11.14--1.85); Mean Difference (Final Values) = -7.39 (p = 0.003, CI -12.17--2.61); Mean Difference (Final Values) = -6.69 (p = 0.006, CI -11.46--1.92). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT).Parameters: Mean Difference (Final Values) = -5.69 (p = 0.001, CI -9.05--2.33); Mean Difference (Final Values) = -5.58 (p = 0.001, CI -8.93--2.24); Mean Difference (Final Values) = -5.12 (p = 0.003, CI -8.45--1.79); Mean Difference (Final Values) = -5.11 (p = 0.003, CI -8.46--1.76). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -5.32 (p = 0.013, CI -9.52--1.13); Mean Difference (Final Values) = -5.76 (p = 0.006, CI -9.85--1.68); Mean Difference (Final Values) = -5.59 (p = 0.009, CI -9.77--1.4); Mean Difference (Final Values) = -5.68 (p = 0.007, CI -9.79--1.57). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT).Parameters: Mean Difference (Final Values) = -4.92 (p = 0.003, CI -8.18--1.65); Mean Difference (Final Values) = -3.79 (p = 0.023, CI -7.05--0.53); Mean Difference (Final Values) = -3.28 (p = 0.047, CI -6.52--0.04); Mean Difference (Final Values) = -3.41 (p = 0.039, CI -6.65--0.17). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -5.1 (p = 0.015, CI -9.19--1). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT).Parameters: Mean Difference (Final Values) = -6.28 (p = 0.001, CI -9.91--2.65); Mean Difference (Final Values) = -7.58 (p = 0.001, CI -11.18--3.98); Mean Difference (Final Values) = -7.43 (p = 0.001, CI -11.02--3.84); Mean Difference (Final Values) = -6.54 (p = 0.001, CI -10.17--2.91). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -7.36 (p = 0.002, CI -11.91--2.81); Mean Difference (Final Values) = -7.92 (p = 0.001, CI -12.6--3.23); Mean Difference (Final Values) = -6.78 (p = 0.005, CI -11.46--2.1). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -5.41 (p = 0.011, CI -9.57--1.25); Mean Difference (Final Values) = -5.54 (p = 0.008, CI -9.6--1.48); Mean Difference (Final Values) = -5.74 (p = 0.007, CI -9.9--1.59); Mean Difference (Final Values) = -5.32 (p = 0.011, CI -9.4--1.24). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT).Parameters: Mean Difference (Final Values) = -4.6 (p = 0.004, CI -7.75--1.44); Mean Difference (Final Values) = -3.49 (p = 0.03, CI -6.64--0.34); Mean Difference (Final Values) = -3.15 (p = 0.049, CI -6.29--0.02). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -4.21 (p = 0.039, CI -8.21--0.21); Mean Difference (Final Values) = -4.37 (p = 0.03, CI -8.32--0.42). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT).Parameters: Mean Difference (Final Values) = -5.34 (p = 0.008, CI -9.28--1.4); Mean Difference (Final Values) = -4.94 (p = 0.014, CI -8.87--1.01). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -6.01 (p = 0.019, CI -11.04--0.97); Mean Difference (Final Values) = -5.75 (p = 0.03, CI -10.94--0.57). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS).Parameters: Mean Difference (Final Values) = -6.33 (p = 0.047, CI -12.56--0.09). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT).Parameters: Mean Difference (Final Values) = 0.11 (p = 0.045, CI 0-0.21). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT).Parameters: Mean Difference (Final Values) = -5.44 (p = 0.001, CI -8.74--2.14); Mean Difference (Final Values) = -5.53 (p = 0.001, CI -8.81--2.25); Mean Difference (Final Values) = -5.12 (p = 0.002, CI -8.39--1.85); Mean Difference (Final Values) = -4.64 (p = 0.006, CI -7.93--1.35). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT).Parameters: Mean Difference (Final Values) = -6.54 (p = 0.001, CI -10.18--2.9); Mean Difference (Final Values) = -7.61 (p = 0.001, CI -11.23--4); Mean Difference (Final Values) = -7.44 (p = 0.001, CI -11.04--3.84); Mean Difference (Final Values) = -6.76 (p = 0.001, CI -10.41--3.1). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -7.48 (p = 0.001, CI -12.04--2.92); Mean Difference (Final Values) = -7.96 (p = 0.001, CI -12.67--3.25); Mean Difference (Final Values) = -6.78 (p = 0.005, CI -11.5--2.06). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT).Parameters: Mean Difference (Final Values) = -5.39 (p = 0.002, CI -8.73--2.05); Mean Difference (Final Values) = -5.39 (p = 0.002, CI -8.72--2.06); Mean Difference (Final Values) = -4.88 (p = 0.004, CI -8.19--1.58); Mean Difference (Final Values) = -4.42 (p = 0.009, CI -7.75--1.09). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -5.48 (p = 0.011, CI -9.68--1.28); Mean Difference (Final Values) = -5.25 (p = 0.012, CI -9.36--1.14); Mean Difference (Final Values) = -5.58 (p = 0.009, CI -9.75--1.41); Mean Difference (Final Values) = -4.99 (p = 0.018, CI -9.11--0.87). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT).Parameters: Mean Difference (Final Values) = -4.88 (p = 0.003, CI -8.08--1.69); Mean Difference (Final Values) = -3.61 (p = 0.027, CI -6.8--0.42); Mean Difference (Final Values) = -3.44 (p = 0.034, CI -6.61--0.26). Non-inferiority type: SUPERIORITY. Outcome: Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -4.39 (p = 0.033, CI -8.44--0.35); Mean Difference (Final Values) = -4.6 (p = 0.024, CI -8.58--0.61). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT).Parameters: Mean Difference (Final Values) = -0.62 (p = 0.001, CI -0.89--0.36); Mean Difference (Final Values) = -0.62 (p = 0.001, CI -0.88--0.36); Mean Difference (Final Values) = -0.47 (p = 0.001, CI -0.73--0.21); Mean Difference (Final Values) = -0.37 (p = 0.006, CI -0.63--0.1). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.43 (p = 0.012, CI -0.76--0.1); Mean Difference (Final Values) = -0.73 (p = 0.001, CI -1.05--0.41); Mean Difference (Final Values) = -0.49 (p = 0.004, CI -0.81--0.16). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT).Parameters: Mean Difference (Final Values) = -0.61 (p = 0.001, CI -0.85--0.38); Mean Difference (Final Values) = -0.45 (p = 0.001, CI -0.69--0.22); Mean Difference (Final Values) = -0.36 (p = 0.003, CI -0.59--0.12); Mean Difference (Final Values) = -0.26 (p = 0.03, CI -0.5--0.03). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.55 (p = 0.001, CI -0.84--0.25); Mean Difference (Final Values) = -0.42 (p = 0.004, CI -0.71--0.13); Mean Difference (Final Values) = -0.44 (p = 0.003, CI -0.73--0.14). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT).Parameters: Mean Difference (Final Values) = -0.62 (p = 0.001, CI -0.85--0.4); Mean Difference (Final Values) = -0.49 (p = 0.001, CI -0.71--0.26); Mean Difference (Final Values) = -0.52 (p = 0.001, CI -0.75--0.3); Mean Difference (Final Values) = -0.42 (p = 0.001, CI -0.64--0.2). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.58 (p = 0.001, CI -0.87--0.29); Mean Difference (Final Values) = -0.34 (p = 0.016, CI -0.62--0.06); Mean Difference (Final Values) = -0.48 (p = 0.001, CI -0.76--0.2); Mean Difference (Final Values) = -0.32 (p = 0.023, CI -0.6--0.05). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT).Parameters: Mean Difference (Final Values) = -0.3 (p = 0.026, CI -0.57--0.04). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.43 (p = 0.01, CI -0.75--0.1). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT).Parameters: Mean Difference (Final Values) = -0.28 (p = 0.014, CI -0.51--0.06). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.33 (p = 0.018, CI -0.61--0.06). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.54 (p = 0.002, CI -0.88--0.2). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT).Parameters: Mean Difference (Final Values) = -0.31 (p = 0.023, CI -0.59--0.04); Mean Difference (Final Values) = -0.28 (p = 0.045, CI -0.55--0.01). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.35 (p = 0.04, CI -0.68--0.02). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT).Parameters: Mean Difference (Final Values) = -0.44 (p = 0.029, CI -0.84--0.05); Mean Difference (Final Values) = -0.45 (p = 0.026, CI -0.84--0.05). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.49 (p = 0.044, CI -0.97--0.01). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.41 (p = 0.049, CI -0.83-0). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT).Parameters: Mean Difference (Final Values) = -1.65 (p = 0.001, CI -2.06--1.25); Mean Difference (Final Values) = -1.47 (p = 0.001, CI -1.87--1.07); Mean Difference (Final Values) = -1.3 (p = 0.001, CI -1.7--0.9); Mean Difference (Final Values) = -1.08 (p = 0.001, CI -1.48--0.67). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -1.2 (p = 0.001, CI -1.75--0.66); Mean Difference (Final Values) = -1.46 (p = 0.001, CI -1.98--0.94); Mean Difference (Final Values) = -1.23 (p = 0.001, CI -1.76--0.69); Mean Difference (Final Values) = -0.72 (p = 0.008, CI -1.26--0.19). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT).Parameters: Mean Difference (Final Values) = -1.73 (p = 0.001, CI -2.12--1.34); Mean Difference (Final Values) = -1.29 (p = 0.001, CI -1.68--0.91); Mean Difference (Final Values) = -1.2 (p = 0.001, CI -1.58--0.81); Mean Difference (Final Values) = -0.96 (p = 0.001, CI -1.34--0.57). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -1.4 (p = 0.001, CI -1.91--0.89); Mean Difference (Final Values) = -1.32 (p = 0.001, CI -1.81--0.82); Mean Difference (Final Values) = -1.12 (p = 0.001, CI -1.63--0.62); Mean Difference (Final Values) = -0.69 (p = 0.007, CI -1.19--0.19). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT).Parameters: Mean Difference (Final Values) = -1.92 (p = 0.001, CI -2.29--1.55); Mean Difference (Final Values) = -1.44 (p = 0.001, CI -1.81--1.07); Mean Difference (Final Values) = -1.44 (p = 0.001, CI -1.81--1.07); Mean Difference (Final Values) = -1.25 (p = 0.001, CI -1.62--0.88). Non-inferiority type: SUPERIORITY. Outcome: Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -1.65 (p = 0.001, CI -2.13--1.17); Mean Difference (Final Values) = -1.31 (p = 0.001, CI -1.79--0.84); Mean Difference (Final Values) = -1.17 (p = 0.001, CI -1.64--0.69); Mean Difference (Final Values) = -1.04 (p = 0.001, CI -1.51--0.58). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.049, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13.Parameters: NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13.Parameters: NA = NA (p = 0.013, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.03, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.023, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.044, CI NA-NA); NA = NA (p = 0.011, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.045, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects With Cumulative Amenorrhea From the 13th Cycle.Parameters: NA = NA (p = 0.023, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0.009, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0.035, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.04, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0, CI NA-NA); NA = NA (p = 0.032, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Number of Subjects Without Bleeding for Consecutive Cycles.Parameters: NA = NA (p = 0.006, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.017, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS).Parameters: NA = NA (p = 0.036, CI NA-NA); NA = NA (p = 0.015, CI NA-NA); NA = NA (p = 0.011, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.011, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.003, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.048, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.02, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.013, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS).Parameters: NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA); NA = NA (p = 0.018, CI NA-NA); NA = NA (p = 0.021, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.015, CI NA-NA); NA = NA (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS).Parameters: NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.013, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS).Parameters: NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.015, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA); NA = NA (p = 0.017, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.025, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.007, CI NA-NA); NA = NA (p = 0.008, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.019, CI NA-NA); NA = NA (p = 0.026, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.018, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.003, CI NA-NA); NA = NA (p = 0.017, CI NA-NA); NA = NA (p = 0.025, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.037, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.016, CI NA-NA); NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.009, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.002, CI NA-NA); NA = NA (p = 0.015, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.52 (p = 0.001, CI -0.71--0.33); Mean Difference (Final Values) = -0.26 (p = 0.007, CI -0.44--0.07); Mean Difference (Final Values) = -0.2 (p = 0.038, CI -0.39--0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.53 (p = 0.001, CI -0.72--0.34); Mean Difference (Final Values) = -0.35 (p = 0.001, CI -0.54--0.16); Mean Difference (Final Values) = -0.22 (p = 0.027, CI -0.41--0.02). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.57 (p = 0.001, CI -0.77--0.37); Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.57--0.18); Mean Difference (Final Values) = -0.21 (p = 0.039, CI -0.4--0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.11 (p = 0.03, CI -0.2--0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.13 (p = 0.027, CI -0.24--0.01); Mean Difference (Final Values) = -0.15 (p = 0.011, CI -0.26--0.03). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.23 (p = 0.001, CI -0.36--0.09). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.36 (p = 0.001, CI -0.53--0.2); Mean Difference (Final Values) = -0.19 (p = 0.018, CI -0.35--0.03). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.54--0.2); Mean Difference (Final Values) = -0.23 (p = 0.006, CI -0.4--0.07); Mean Difference (Final Values) = -0.2 (p = 0.014, CI -0.37--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.38 (p = 0.001, CI -0.55--0.21); Mean Difference (Final Values) = -0.21 (p = 0.016, CI -0.37--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.48 (p = 0.001, CI -0.66--0.3); Mean Difference (Final Values) = -0.27 (p = 0.003, CI -0.45--0.1); Mean Difference (Final Values) = -0.21 (p = 0.022, CI -0.39--0.03); Mean Difference (Final Values) = -0.25 (p = 0.006, CI -0.43--0.07). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.52 (p = 0.001, CI -0.71--0.33); Mean Difference (Final Values) = -0.28 (p = 0.003, CI -0.46--0.09); Mean Difference (Final Values) = -0.23 (p = 0.016, CI -0.41--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.53 (p = 0.001, CI -0.72--0.34); Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.56--0.19); Mean Difference (Final Values) = -0.25 (p = 0.011, CI -0.44--0.06). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.57 (p = 0.001, CI -0.77--0.38); Mean Difference (Final Values) = -0.39 (p = 0.001, CI -0.59--0.2); Mean Difference (Final Values) = -0.24 (p = 0.018, CI -0.43--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.11 (p = 0.039, CI -0.21--0.01); Mean Difference (Final Values) = -0.11 (p = 0.03, CI -0.21--0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.13 (p = 0.031, CI -0.25--0.01); Mean Difference (Final Values) = -0.17 (p = 0.005, CI -0.28--0.05). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.23 (p = 0.001, CI -0.37--0.09); Mean Difference (Final Values) = -0.15 (p = 0.034, CI -0.28--0.01). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.36 (p = 0.001, CI -0.53--0.2); Mean Difference (Final Values) = -0.18 (p = 0.03, CI -0.34--0.02); Mean Difference (Final Values) = -0.19 (p = 0.022, CI -0.35--0.03). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.37 (p = 0.001, CI -0.54--0.2); Mean Difference (Final Values) = -0.25 (p = 0.002, CI -0.42--0.09); Mean Difference (Final Values) = -0.18 (p = 0.031, CI -0.34--0.02); Mean Difference (Final Values) = -0.2 (p = 0.016, CI -0.36--0.04). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.38 (p = 0.001, CI -0.55--0.21); Mean Difference (Final Values) = -0.23 (p = 0.008, CI -0.4--0.06). Non-inferiority type: SUPERIORITY. Outcome: Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS).Parameters: Mean Difference (Final Values) = -0.48 (p = 0.001, CI -0.66--0.3); Mean Difference (Final Values) = -0.29 (p = 0.001, CI -0.47--0.12); Mean Difference (Final Values) = -0.24 (p = 0.009, CI -0.42--0.06); Mean Difference (Final Values) = -0.24 (p = 0.007, CI -0.42--0.07). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 1 (Safety Pop.).Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 2 (Safety Pop.).Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 3 (Safety Pop.).Parameters: NA = NA (p = 0.008, CI NA-NA); NA = NA (p = 0.036, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Bleeding - Trimester 4 (Safety Pop.).Parameters: NA = NA (p = 0.023, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 1 (Safety Pop.).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.004, CI NA-NA); NA = NA (p = 0.012, CI NA-NA); NA = NA (p = 0.032, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 2 (Safety Pop.).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.022, CI NA-NA); NA = NA (p = 0.004, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 3 (Safety Pop.).Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.006, CI NA-NA); NA = NA (p = 0.025, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Subject Incidence With Spotting - Trimester 4 (Safety Pop.).Parameters: NA = NA (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_53'}, page_content='Study: Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis\\n\\nSummary: The purpose of this study is to determine if treatment with romosozumab increases bone mineral density in Japanese women with postmenopausal osteoporosis.\\n\\nResults: Outcome: Area Under the Curve Through Month 12 of P1NP.Parameters: Treatment Difference = 84.1 (p = 2e-04, CI 40.1-128); Treatment Difference = 153.8 (p = 1e-04, CI 109.2-198.4). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline at 6 Months in Bone Mineral Density at the Lumbar Spine.Parameters: Treatment Difference = 9 (p = 1e-04, CI 8-NA); Treatment Difference = 5.3 (p = 1e-04, CI 4.4-NA); Treatment Difference = 11.9 (p = 1e-04, CI 10.6-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline at 6 Months in Bone Mineral Density at the Total Hip.Parameters: Treatment Difference = 1.7 (p = 2e-04, CI 0.9-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.7-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Femoral Neck.Parameters: Treatment Difference = 1.6 (p = 0.0067, CI 0.5-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.6-NA); Treatment Difference = 3.5 (p = 1e-04, CI 2.3-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Lumbar Spine.Parameters: Treatment Difference = 7.5 (p = 1e-04, CI 6.5-NA); Treatment Difference = 12.4 (p = 1e-04, CI 11.1-NA); Treatment Difference = 16 (p = 1e-04, CI 14.6-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 12 Months in Bone Mineral Density at the Total Hip.Parameters: Treatment Difference = 1.5 (p = 0.0012, CI 0.7-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.8-NA); Treatment Difference = 4.1 (p = 1e-04, CI 3.3-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to 6 Months in Bone Mineral Density at the Femoral Neck.Parameters: Treatment Difference = 1.3 (p = 0.0151, CI 0.3-NA); Treatment Difference = 2.6 (p = 1e-04, CI 1.5-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_54'}, page_content='Study: Denosumab China Phase III Study\\n\\nSummary: This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.\\n\\nResults: Outcome: Percent Change From Baseline in BMD at the Femoral Neck at Month 12.Parameters: Mean Difference (Net) = 2.62 (p = 1e-04, CI 1.96-3.27). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Femoral Neck at Month 6.Parameters: Mean Difference (Net) = 1.59 (p = 1e-04, CI 0.98-2.2). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Lumbar Spine at Month 6.Parameters: Mean Difference (Net) = 3.21 (p = 1e-04, CI 2.45-3.96). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Total Hip at Month 12.Parameters: Mean Difference (Net) = 3.31 (p = 1e-04, CI 2.74-3.88). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Total Hip at Month 6.Parameters: Mean Difference (Net) = 2.26 (p = 1e-04, CI 1.72-2.8). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Trochanter at Month 12.Parameters: Mean Difference (Net) = 4.72 (p = 1e-04, CI 3.71-5.72). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in BMD at the Trochanter at Month 6.Parameters: Mean Difference (Net) = 3.36 (p = 1e-04, CI 2.39-4.32). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12.Parameters: Mean Difference (Net) = 4.42 (p = 1e-04, CI 3.67-5.18). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline to Month 6 and Month 12.Parameters: Hodges Lehmann Estimate of Difference = -56.92 (p = 1e-04, CI -61.38--52.65); Hodges Lehmann Estimate of Difference = -52.56 (p = 1e-04, CI -59.38--46.17). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline to Month 6 and Month 12.Parameters: Hodges Lehmann Estimate of Difference = -56.94 (p = 1e-04, CI -61.6--52.7); Hodges Lehmann Estimate of Difference = -51.21 (p = 1e-04, CI -56.26--45.91). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_55'}, page_content='Study: A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis\\n\\nSummary: This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.\\n\\nResults: Outcome: Percent Change From Baseline in Lumbar Spine BMD.Parameters: Difference from CP2 = -0.07 (p = 0.001, CI -0.72-0.57); Difference from CP2 = -0.07 (p = 0.001, CI -0.72-0.57). Non-inferiority type: NON_INFERIORITY_OR_EQUIVALENCE.'),\n",
       " Document(metadata={'source': 'study_56'}, page_content='Study: Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women\\n\\nSummary: This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.\\n\\nResults: Outcome: Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia).Parameters: NA = NA (p = 0.0149, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Co-Primary Efficacy Endpoint - Vaginal pH.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score.Parameters: NA = NA (p = 0.0492, CI NA-NA); NA = NA (p = 0.0019, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal.Parameters: NA = NA (p = 0.0085, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication.Parameters: NA = NA (p = 0.0013, CI NA-NA); NA = NA (p = 3e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain.Parameters: NA = NA (p = 0.0099, CI NA-NA); NA = NA (p = 0.015, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction.Parameters: NA = NA (p = 0.0073, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation).Parameters: NA = NA (p = 0.0055, CI NA-NA); NA = NA (p = 0.0263, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation).Parameters: NA = NA (p = 0.0356, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia).Parameters: NA = NA (p = 0.026, CI NA-NA); NA = NA (p = 0.0019, CI NA-NA); NA = NA (p = 0.0105, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia).Parameters: NA = NA (p = 0.0069, CI NA-NA); NA = NA (p = 9e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia).Parameters: NA = NA (p = 3e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness).Parameters: NA = NA (p = 0.0014, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness).Parameters: NA = NA (p = 0.0019, CI NA-NA); NA = NA (p = 0.0082, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness).Parameters: NA = NA (p = 0.0094, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 5e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness).Parameters: NA = NA (p = 0.0128, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 8e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color).Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity).Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness).Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions).Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions).Parameters: NA = NA (p = 4e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Parabasal Cells.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal Superficial Cells.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints - Vaginal pH.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Secondary Efficacy Endpoints- Vaginal Superficial Cells.Parameters: NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA); NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_57'}, page_content='Study: Perimenopausal Effects of Estradiol on Reward Responsiveness\\n\\nSummary: Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.\\n\\nResults: Outcome: Change in Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria Scores.Parameters: NA = NA (p = 2e-04, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Putamen Signal Intensity in Response to Reward During the MID fMRI Task Following Estradiol Treatment..Parameters: NA = NA (p = 0.015, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_58'}, page_content='Study: TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy\\n\\nSummary: The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 Î¼g in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and variability of vulvovaginal atrophy endpoints. In addition, the systemic exposure to estradiol from single and multiple doses of TX-12-004-HR was to be investigated.\\n\\nResults: Outcome: Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity).Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions).Parameters: NA = NA (p = 0.0401, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells).Parameters: NA = NA (p = 0.0017, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells).Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells).Parameters: NA = NA (p = 2e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Analysis of Change From Baseline to Day 15 in Vaginal pH.Parameters: NA = NA (p = 2e-04, CI NA-NA). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_59'}, page_content='Study: The Vaginal Health Trial\\n\\nSummary: This is a new application from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) Clinical Trials network. Here we propose to conduct a large multicenter trial comparing two common treatments, a vaginal hormone tablet and an over-the-counter gel, with placebo to evaluate their effects on bothersome vaginal symptoms and sexual function, and to create a biorepository of specimens for future translational, mechanistic research on the etiology of vaginal symptoms.\\n\\nResults: Outcome: Patient Benefit Evaluation.Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Vaginal Maturation Index.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: pH.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_60'}, page_content='Study: A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis\\n\\nSummary: This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.\\n\\nResults: Outcome: Percentage of Participants Who Were \"Very Confident\" or \"Confident\" to Items on the Boniva Confidence Scale (BCS) at Month 6.Parameters: Difference in percentage of participants = 16.9 (p = 0.002, CI 6.1-27.7); Difference in percentage of participants = 14.9 (p = 0.009, CI 4-25.8); Difference in percentage of participants = 16.9 (p = 0.001, CI 6.3-27.5); Difference in percentage of participants = 14.9 (p = 0.01, CI 3.9-25.9). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_61'}, page_content='Study: Neuropeptide Treatment for Hot Flushes During the Menopause\\n\\nSummary: Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product\\n\\nResults: Outcome: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period.Parameters: Mean Difference (Net) = 29.66 (p = 1e-04, CI 17.39-42.87). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_62'}, page_content='Study: Preventing Osteoporosis Using Denosumab\\n\\nSummary: The purpose of this research study is to find out if denosumab (ProliaÂ®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities.\\n\\nResults: Outcome: Bone Density of the Spine.Parameters: Mean Difference (Final Values) = 3.99 (p = 0.014, CI NA-NA); Mean Difference (Final Values) = 5.16 (p = 0.002, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Bone Density of the Total Hip.Parameters: Mean Difference (Final Values) = 4.8 (p = 0.007, CI NA-NA); Mean Difference (Final Values) = 2.7 (p = 0.018, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: CTX.Parameters: Mean Difference (Final Values) = -0.16 (p = 0.001, CI NA-NA); Mean Difference (Final Values) = -0.09 (p = 0.005, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: P1NP.Parameters: Mean Difference (Final Values) = -26.2 (p = 0.001, CI NA-NA); Mean Difference (Final Values) = -8.2 (p = 0.038, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_63'}, page_content='Study: A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis\\n\\nSummary: The primary objective is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.\\n\\nResults: Outcome: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Femoral Neck.Parameters: LS Mean Difference = 2.2 (p = 0.004, CI 0.7-3.6). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine.Parameters: LS Mean Difference = 9.6 (p = 0.001, CI 7.6-11.5). Non-inferiority type: SUPERIORITY. Outcome: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Total Hip.Parameters: LS Mean Difference = 2.6 (p = 0.001, CI 1.4-3.7). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_64'}, page_content='Study: A Food Effect Study of TAK-385 Final Formulation\\n\\nSummary: The purpose of this study is to evaluate food effects on the pharmacokinetics of a single oral dose of TAK-385 in Japanese premenopausal healthy adult women.\\n\\nResults: Outcome: AUC(0-120): Area Under the Plasma Concentration-time Curve From Time 0 to 120 Hours Postdose for TAK-385.Parameters: Least Square Mean Ratio (%) = 52.56 (p = 0.001, CI 40.78-67.74). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-385.Parameters: Least Square Mean Ratio (%) = 52.56 (p = 0.001, CI 40.78-67.74). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: AUCâˆž: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385.Parameters: Least Square Mean Ratio (%) = 53.2 (p = 0.001, CI 41.39-68.37). Non-inferiority type: SUPERIORITY_OR_OTHER. Outcome: Cmax: Maximum Observed Plasma Concentration for TAK-385.Parameters: Least Square Mean Ratio (%) = 45.43 (p = 0.012, CI 27.86-74.07). Non-inferiority type: SUPERIORITY_OR_OTHER.'),\n",
       " Document(metadata={'source': 'study_65'}, page_content='Study: Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms\\n\\nSummary: This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.\\n\\nResults: Outcome: Change From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8).Parameters: LS means difference = -25 (p = 0.0248, CI -43.1--6.8); LS means difference = -43.9 (p = 1e-04, CI -62.1--25.8); LS means difference = -42.9 (p = 4e-04, CI -61.9--23.8). Non-inferiority type: OTHER. Outcome: Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary..Parameters: LS means difference = -10.18 (p = 0.0012, CI -15.2--5.15); LS means difference = -12.28 (p = 4e-04, CI -17.73--6.83); LS means difference = -7.79 (p = 0.0253, CI -13.47--2.11). Non-inferiority type: OTHER. Outcome: Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary.Parameters: LS means difference = -0.31 (p = 0.0199, CI -0.52--0.09); LS means difference = -0.63 (p = 4e-04, CI -0.92--0.35). Non-inferiority type: OTHER. Outcome: Change From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary.Parameters: LS means difference = -1.8 (p = 0.0022, CI -2.74--0.86); LS means difference = -2.2 (p = 5e-04, CI -3.21--1.2); LS means difference = -1.38 (p = 0.0309, CI -2.43--0.34). Non-inferiority type: OTHER. Outcome: Change in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary..Parameters: LS means difference = -5 (p = 1e-04, CI -7--3); LS means difference = -3.4 (p = 0.008, CI -5.5--1.3); LS means difference = -5.5 (p = 7e-04, CI -8.1--2.9). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_66'}, page_content='Study: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women\\n\\nSummary: The physiological relevance of brown adipose tissue (BAT) in humans is largely unknown. The investigators have shown that suppressing ovarian function in premenopausal women reduces resting energy expenditure (REE), and this is prevented by adding back estradiol (E2). The investigators preliminary data suggest that this may be due, in part, to reduced brown adipose tissue (BAT) activity. The overarching hypothesis is that BAT activity in humans is modulated by E2. To determine if natural declines in endogenous E2 contribute to changes in BAT activity, we will compare BAT activity in pre-and post-menopausal women. The investigators will also explore whether suppression of ovarian hormones in pre-menopausal women impairs BAT activity. BAT activity will be quantified using dynamic positron emission topography/computed tomography (PET/CT) imaging combined with 11C-acetate tracers. We will assess the thermogenic response of BAT by measuring cold-induced changes in REE, shivering, and skin and core temperature.\\n\\nResults: Outcome: Brown Adipose Tissue Activity -Warm Exposure.Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_67'}, page_content='Study: Menopausal Sleep Fragmentation and Body Fat Gain\\n\\nSummary: This study aims to investigate the impact of menopause-related sleep fragmentation on metabolic biomarkers of body fat gain. The investigators hypothesize that experimental sleep fragmentation will result in an adverse leptin response as a metabolic biomarker for body fat gain.\\n\\nResults: Outcome: Normalized Satiety Scores.Parameters: NA = NA (p = 0.048, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Normalized Serum Leptin Levels.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_68'}, page_content='Study: A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)\\n\\nSummary: This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.\\n\\nResults: Outcome: Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8, 12, and 15.Parameters: LSMean difference = -1.9 (p = 0.0405, CI -3.7--0.08); LSMean difference = -2.4 (p = 0.0115, CI -4.18--0.53); LSMean difference = -2.2 (p = 0.0178, CI -4.03--0.38); LSMean difference = -1 (p = 0.0037, CI -1.73--0.34); LSMean difference = -1.6 (p = 1e-04, CI -2.3--0.92); LSMean difference = -1.5 (p = 1e-04, CI -2.21--0.81); LSMean difference = -0.9 (p = 0.0088, CI -1.6--0.23); LSMean difference = -1.2 (p = 5e-04, CI -1.93--0.54); LSMean difference = -0.4 (p = 0.0416, CI -0.69--0.01); LSMean difference = -0.4 (p = 0.0353, CI -0.71--0.03); LSMean difference = -0.5 (p = 0.004, CI -0.84--0.16); LSMean difference = -0.3 (p = 0.0495, CI -0.69-0); LSMean difference = -3.6 (p = 0.0225, CI -6.6--0.5); LSMean differencce = -4.3 (p = 0.0058, CI -7.38--1.26); LSMean difference = -3.4 (p = 0.0301, CI -6.48--0.33); LSMean difference = -4.2 (p = 0.0069, CI -7.27--1.17); LSMean difference = -1.1 (p = 0.0025, CI -1.83--0.4); LSMean difference = -1.5 (p = 1e-04, CI -2.2--0.74); LSMean difference = -1.6 (p = 1e-04, CI -2.33--0.86); LSMean difference = -1 (p = 0.009, CI -1.67--0.24); LSMean difference = -1.1 (p = 0.0024, CI -1.84--0.4); LSMean difference = -0.4 (p = 0.0276, CI -0.76--0.04); LSMean difference = -0.4 (p = 0.0304, CI -0.75--0.04); LSMean difference = -3.3 (p = 0.0419, CI -6.53--0.12); LSMean difference = -1 (p = 0.0046, CI -1.69--0.31); LSMean difference = -1.5 (p = 1e-04, CI -2.19--0.8); LSMean difference = -1.5 (p = 1e-04, CI -2.19--0.78); LSMean difference = -0.8 (p = 0.0333, CI -1.45--0.06); LSMean difference = -0.7 (p = 0.0423, CI -1.39--0.02); LSMean difference = -0.8 (p = 0.0208, CI -1.49--0.12); LSMean difference = -0.6 (p = 0.0021, CI -0.98--0.22); LSMean difference = -0.4 (p = 0.0408, CI -0.79--0.02). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) at Weeks 4, 8, 12, and 15.Parameters: LSMean difference = -1.1 (p = 0.0179, CI -1.95--0.18); LSMean difference = -1.4 (p = 0.0027, CI -2.25--0.47); LSMean difference = -1.6 (p = 4e-04, CI -2.5--0.73); LSMean difference = -1.5 (p = 9e-04, CI -2.43--0.64); LSMean difference = -1.2 (p = 0.0105, CI -2.03--0.27); LSMean difference = -1.3 (p = 0.0048, CI -2.16--0.39); LSMean difference = -1.4 (p = 0.0028, CI -2.33--0.49); LSMean difference = -1.5 (p = 0.0018, CI -2.4--0.55); LSMean difference = -0.9 (p = 0.0463, CI -1.82--0.02); LSMean difference = -1.4 (p = 0.0027, CI -2.26--0.48); -1.3 = -1.3 (p = 0.0043, CI -2.2--0.41); LSMean difference = -1 (p = 0.0265, CI -1.84--0.11). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in Menopause-Specific Quality of Life (MENQoL) at Weeks 4, 8, 12, and 15.Parameters: LSMean difference = -1.2 (p = 0.0045, CI -2.03--0.38); LSMean difference = -1.6 (p = 2e-04, CI -2.43--0.77); LSMean difference = -1.9 (p = 1e-04, CI -2.7--1.02); LSMean difference = -1 (p = 0.0187, CI -1.83--0.17); LSMean difference = -0.7 (p = 0.0056, CI -1.15--0.2); LSMean difference = -0.5 (p = 0.0265, CI -1.02--0.06); LSMean differencce = -1 (p = 0.0084, CI -1.78--0.26); LSMean difference = -0.5 (p = 0.0437, CI -0.97--0.01); LSMean difference = -0.8 (p = 0.0211, CI -1.51--0.12); LSMean difference = -1.1 (p = 0.0017, CI -1.82--0.42); LSMean difference = -0.7 (p = 0.0035, CI -1.16--0.23); LSMean difference = -0.5 (p = 0.0266, CI -0.99--0.06); LSMean difference = -0.6 (p = 0.0124, CI -1.06--0.13); LSMean difference = -1.3 (p = 0.0013, CI -2.16--0.53); LSMean difference = -1.7 (p = 1e-04, CI -2.53--0.87); LSMean difference = -2 (p = 1e-04, CI -2.83--1.16); LSMean difference = -1 (p = 0.0211, CI -1.78--0.15); LSMean difference = -1.3 (p = 0.0021, CI -2.1--0.47); LSMean difference = -0.5 (p = 0.0424, CI -0.99--0.02); LSMean difference = -0.7 (p = 0.041, CI -1.4--0.03); LSMean difference = -0.5 (p = 0.0257, CI -0.99--0.06); LSMean difference = -0.5 (p = 0.0293, CI -0.99--0.05); LSMean difference = -0.9 (p = 0.0287, CI -1.69--0.09); LSMean difference = -1.2 (p = 0.0028, CI -2.05--0.43); LSMean difference = -1.5 (p = 4e-04, CI -2.32--0.67); LSMean difference = -2 (p = 1e-04, CI -2.87--1.22); LSMean difference = -1 (p = 0.0178, CI -1.79--0.17); LSMean differnce = -1.2 (p = 0.0025, CI -2.06--0.44); LSMean difference = -0.9 (p = 0.03, CI -1.66--0.09); LSMean difference = -0.5 (p = 0.031, CI -0.98--0.05). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Hot Flash Score of Mild, Moderate, and Severe VMS to Each Study Week.Parameters: LSMean difference = -6.9 (p = 4e-04, CI -10.78--3.09); LSMean difference = -6.9 (p = 5e-04, CI -10.69--3.05); LSMean difference = -4.1 (p = 0.038, CI -8.01--0.23); LSMean difference = -7.6 (p = 2e-04, CI -11.46--3.64); LSMean differencce = -8.1 (p = 1e-04, CI -11.96--4.17); LSMean difference = -4.8 (p = 0.0142, CI -8.62--0.97); LSMean difference = -7.9 (p = 1e-04, CI -11.73--4.05); LSMean difference = -9.2 (p = 1e-04, CI -13.17--5.25); LSMean difference = -4.6 (p = 0.0245, CI -8.52--0.59); LSMean difference = -5.9 (p = 0.0031, CI -9.83--2.01); LSMean difference = -5.6 (p = 0.0046, CI -9.53--1.75); LSMean difference = -5.6 (p = 0.0064, CI -9.61--1.59); LSMean difference = -9.1 (p = 1e-04, CI -12.98--5.31); LSMean difference = -10.5 (p = 1e-04, CI -14.39--6.61); LSMean difference = -5.5 (p = 0.0075, CI -9.46--1.47); LSMean difference = -8.4 (p = 1e-04, CI -12.44--4.42); LSMean difference = -8.2 (p = 1e-04, CI -12.15--4.16); LSMean difference = -10.2 (p = 1e-04, CI -14.3--6.16); LSMean difference = -8.7 (p = 1e-04, CI -12.72--4.65); LSMean difference = -8.8 (p = 1e-04, CI -12.78--4.75); LSMean difference = -10.2 (p = 1e-04, CI -14.27--6.09); LSMean difference = -6.4 (p = 0.0021, CI -10.54--2.36); LSMean difference = -7.7 (p = 2e-04, CI -11.71--3.66); LSMean difference = -7 (p = 7e-04, CI -10.96--2.95); LSMean difference = -6.4 (p = 0.0021, CI -10.46--2.34); LSMean difference = -8.3 (p = 1e-04, CI -12.25--4.25); LSMean difference = -7.6 (p = 2e-04, CI -11.58--3.62); LSMean difference = -4.8 (p = 0.0123, CI -8.6--1.05); LSMean difference = -7.8 (p = 1e-04, CI -11.63--4.07); LSMean difference = -8 (p = 1e-04, CI -11.8--4.23); LSMean difference = -9.9 (p = 1e-04, CI -13.73--6.03); LSMean difference = -7.8 (p = 1e-04, CI -11.57--4.06); LSMean difference = -9.1 (p = 1e-04, CI -12.89--5.27); LSMean difference = -5.4 (p = 0.0057, CI -9.18--1.58); LSMean difference = -6.7 (p = 6e-04, CI -10.4--2.9); LSMean difference = -6.5 (p = 6e-04, CI -10.27--2.81); LSMean difference = -6.3 (p = 0.0013, CI -10.13--2.47); LSMean difference = -7.2 (p = 2e-04, CI -10.97--3.41); LSMean difference = -6.7 (p = 6e-04, CI -10.41--2.89); LSMean difference = -4.8 (p = 0.0119, CI -8.54--1.07); LSMean difference = -6.8 (p = 4e-04, CI -10.58--3.09); LSMean difference = -4.5 (p = 0.021, CI -8.27--0.68); LSMean difference = -7.2 (p = 2e-04, CI -10.98--3.38); LSMean difference = -7.3 (p = 2e-04, CI -11.12--3.49); LSMean difference = -9.1 (p = 1e-04, CI -12.99--5.25); LSMean difference = -5.6 (p = 0.0047, CI -9.45--1.73); LSMean difference = -6.5 (p = 9e-04, CI -10.29--2.67); LSMean difference = -6.5 (p = 8e-04, CI -10.28--2.71); LSMean difference = -7.5 (p = 2e-04, CI -11.36--3.58); LSMean difference = -4.4 (p = 0.0255, CI -8.3--0.55); LSMean difference = -5.8 (p = 0.0031, CI -9.63--1.98); LSMean difference = -5.9 (p = 0.0023, CI -9.76--2.13); LSMean difference = -6.5 (p = 9e-04, CI -10.36--2.71); LSMean difference = -5.7 (p = 0.0037, CI -9.45--1.85); LSMean difference = -4 (p = 0.0316, CI -7.59--0.35); LSMean difference = -5.4 (p = 0.0036, CI -9.02--1.78); LSMean difference = -6.6 (p = 4e-04, CI -10.23--2.94); LSMean difference = -6 (p = 0.0017, CI -9.77--2.29); LSMean difference = -4.7 (p = 0.0119, CI -8.37--1.05); LSMean difference = -6 (p = 0.0015, CI -9.61--2.29); LSMean difference = -7.7 (p = 1e-04, CI -11.38--3.99); LSMean difference = -7.6 (p = 1e-04, CI -11.33--3.87); LSMean difference = -5.3 (p = 0.0051, CI -9.07--1.62); LSMean difference = -6.6 (p = 4e-04, CI -10.33--2.96); LSMean difference = -7.2 (p = 1e-04, CI -10.93--3.54); LSMean difference = -5.6 (p = 0.0025, CI -9.28--1.99); LSMean difference = -5.1 (p = 0.0063, CI -8.67--1.44); LSMean difference = -4.8 (p = 0.0117, CI -8.58--1.08); LSMean difference = -5.4 (p = 0.0047, CI -9.17--1.67); LSMean difference = -7 (p = 3e-04, CI -10.8--3.23); LSMean difference = -7.7 (p = 1e-04, CI -11.51--3.86); LSMean difference = -5.2 (p = 0.0083, CI -8.97--1.34); LSMean difference = -6 (p = 0.0014, CI -9.64--2.34); LSMean difference = -5.1 (p = 0.0054, CI -8.67--1.51); LSMean difference = -6.1 (p = 8e-04, CI -9.71--2.55); LSMean difference = -7.6 (p = 1e-04, CI -11.2--3.97); LSMean difference = -8.2 (p = 1e-04, CI -11.88--4.59); LSMean difference = -5.6 (p = 0.0026, CI -9.27--1.99); LSMean difference = -6.8 (p = 3e-04, CI -10.35--3.16); LSMean difference = -5.6 (p = 0.0111, CI -9.89--1.28); LSMean difference = -4.6 (p = 0.0349, CI -8.94--0.33); LSMean difference = -6.3 (p = 0.0011, CI -10.1--2.56); LSMean difference = -6.3 (p = 6e-04, CI -9.88--2.75); LSMean difference = -5.3 (p = 0.0126, CI -9.48--1.15); LSMean difference = -5.3 (p = 0.0198, CI -9.67--0.84); LSMean difference = -4.6 (p = 0.0417, CI -9.05--0.18). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Hot Flash Score of Moderate and Severe VMS to Each Study Week.Parameters: LSMean difference = -4.8 (p = 0.0177, CI -8.8--0.84); LSMean difference = -6.5 (p = 0.0012, CI -10.45--2.6); LSMean difference = -6.6 (p = 0.0072, CI -9.26--2.64); LSMean difference = -5.9 (p = 0.0044, CI -9.86--1.84); LSMean difference = -9.2 (p = 1e-04, CI -13.27--5.21); LSMean difference = -8.6 (p = 1e-04, CI -12.57--4.55); LSMean difference = -10.2 (p = 1e-04, CI -14.29--6.11); LSMean difference = -5.2 (p = 0.0089, CI -9.01--1.3); LSMean difference = -8.4 (p = 1e-04, CI -12.22--4.48); LSMean difference = -9.2 (p = 1e-04, CI -13.06--5.34); LSMean difference = -10.7 (p = 1e-04, CI -14.58--6.75); LSMean difference = -7 (p = 9e-04, CI -11.04--2.87); LSMean difference = -8.4 (p = 1e-04, CI -12.44--4.39); LSMean difference = -6.6 (p = 0.0012, CI -10.65--2.64); LSMean difference = -5.7 (p = 0.0053, CI -9.72--1.71); LSMean difference = -7.2 (p = 3e-04, CI -11.04--3.3); LSMean difference = -6.7 (p = 7e-04, CI -10.53--2.84); LSMean difference = -4.5 (p = 0.0231, CI -8.43--0.63); LSMean difference = -8.8 (p = 1e-04, CI -12.77--4.73); LSMean difference = -7.8 (p = 1e-04, CI -11.84--3.84); LSMean difference = -10 (p = 1e-04, CI -14.12--5.96); LSMean difference = -8 (p = 1e-04, CI -11.94--4.09); LSMean differencce = -8 (p = 1e-04, CI -11.87--4.05); LSMean difference = -9.2 (p = 1e-04, CI -13.21--5.26); LSMean difference = -6.9 (p = 0.001, CI -10.92--2.78); LSMean difference = -8.5 (p = 1e-04, CI -12.49--4.46); LSMean difference = -7.1 (p = 5e-04, CI -11.12--3.13); LSMean difference = -5.4 (p = 0.0057, CI -9.15--1.58); LSMean difference = -8.4 (p = 1e-04, CI -12.15--4.56); LSMean difference = -7.9 (p = 1e-04, CI -11.68--4.08); LSMean difference = -9.8 (p = 1e-04, CI -13.66--5.93); LSMean difference = -6.7 (p = 7e-04, CI -10.54--2.85); LSMean difference = -7.7 (p = 1e-04, CI -11.55--3.95); LSMean difference = -6.4 (p = 0.001, CI -10.16--2.6); LSMean difference = -5.2 (p = 0.0064, CI -8.99--1.48); LSMean difference = -7.2 (p = 2e-04, CI -10.94--3.42); LSMean difference = -3.7 (p = 0.0018, CI -9.9-0.14); LSMean difference = -6.2 (p = 0.0017, CI -9.98--2.34); LSMean difference = -7.2 (p = 3e-04, CI -11.09--3.32); LSMean difference = -6.1 (p = 0.002, CI -9.88--2.23); LSMean difference = -7.5 (p = 1e-04, CI -11.29--3.75); LSMean difference = -8.9 (p = 1e-04, CI -12.69--5.03); LSMean difference = -5.8 (p = 0.003, CI -9.62--1.99); LSMean difference = -7.1 (p = 2e-04, CI -10.92--3.37); LSMean difference = -5.2 (p = 0.0076, CI -8.98--1.39); LSMean difference = -4.4 (p = 0.0182, CI -8.01--0.75); LSMean difference = -5.8 (p = 0.0019, CI -9.42--2.16); LSMean difference = -6.4 (p = 7e-04, CI -10.02--2.71); LSMean difference = -6.2 (p = 0.0013, CI -9.91--2.42); LSMean difference = -4.8 (p = 0.0137, CI -8.61--0.99); LSMean difference = -7.4 (p = 2e-04, CI -11.24--3.6); LSMean difference = -7 (p = 4e-04, CI -10.79--3.13); LSMean difference = -8.9 (p = 1e-04, CI -12.74--4.97); LSMean difference = -5.9 (p = 0.0028, CI -9.82--2.07); LSMean difference = -6.8 (p = 6e-04, CI -10.6--2.94); LSMean difference = -6 (p = 0.002, CI -9.82--2.21); LSMean difference = -6.8 (p = 4e-04, CI -10.62--3.05); LSMean difference = -7.1 (p = 2e-04, CI -10.76--3.35); LSMean difference = -4.2 (p = 0.0263, CI -7.89--0.5); LSMean difference = -6 (p = 0.0015, CI -9.61--2.29); LSMean difference = -4.7 (p = 0.0113, CI -8.32--1.07); LSMean difference = -5.3 (p = 0.0059, CI -9.04--1.54); LSMean difference = -6 (p = 0.0018, CI -9.76--2.25); LSMean difference = -7.6 (p = 1e-04, CI -11.39--3.73); LSMean difference = -5.6 (p = 0.0044, CI -9.4--1.75); LSMean difference = -6.6 (p = 6e-04, CI -10.4--2.84); LSMean difference = -5.8 (p = 0.0025, CI -9.57--2.07); LSMean difference = -5.8 (p = 0.0022, CI -9.56--2.11); LSMean difference = -6.9 (p = 3e-04, CI -10.56--3.19); LSMean difference = -5.8 (p = 0.002, CI -9.44--2.13); LSMean difference = -5.6 (p = 0.0023, CI -9.18--2.01); LSMean difference = -5.2 (p = 0.0059, CI -8.81--1.49); LSMean difference = -6.4 (p = 7e-04, CI -10.06--2.74); LSMean difference = -7.5 (p = 1e-04, CI -11.18--3.79); LSMean difference = -7.5 (p = 1e-04, CI -11.18--3.72); LSMean difference = -6.5 (p = 4e-04, CI -10.06--2.89); LSMean difference = -7.4 (p = 1e-04, CI -11.05--3.81); LSMean difference = -8.1 (p = 1e-04, CI -11.8--4.49); LSMean difference = -6.1 (p = 0.0011, CI -9.77--2.47); LSMean difference = -6.9 (p = 2e-04, CI -10.54--3.32); LSMean differencce = -4.8 (p = 0.0308, CI -9.17--0.45); LSMean difference = -6.1 (p = 8e-04, CI -9.71--2.56); LSMean difference = -6 (p = 0.0054, CI -10.26--1.8); LSMean difference = -6.2 (p = 0.0072, CI -10.71--1.7); LSMean difference = -4.9 (p = 0.0338, CI -9.46--0.38); LSMean difference = -6.7 (p = 0.0029, CI -11.02--2.29); LSMean difference = -5 (p = 0.0239, CI -9.42--0.67). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Frequency of Mild, Moderate, and Severe VMS to Each Study Week.Parameters: LSMean difference = -2.7 (p = 0.0014, CI -4.3--1.04); LSMean differencce = -3.2 (p = 1e-04, CI -4.82--1.58); LSMean difference = -3.6 (p = 1e-04, CI -5.3--2); LSMean difference = -2.7 (p = 9e-04, CI -4.22--1.1); LSMean difference = -3.5 (p = 1e-05, CI -5.06--1.94); LSMean difference = -4 (p = 1e-05, CI -5.63--2.47); LSMean difference = -1.8 (p = 0.0343, CI -3.38--0.13); LSMean difference = -2.3 (p = 0.0049, CI -3.95--0.71); LSMean difference = -1.8 (p = 0.0285, CI -3.5--0.2); LSMean difference = -2.4 (p = 0.0032, CI -3.92--0.8); LSMean difference = -2.7 (p = 6e-04, CI -4.29--1.19); LSMean difference = -3 (p = 4e-04, CI -4.69--1.37); LSMean difference = -3.5 (p = 1e-04, CI -5.14--1.84); LSMean difference = -4 (p = 1e-04, CI -5.65--2.28); LSMean difference = -2.1 (p = 0.0169, CI -3.74--0.37); LSMean difference = -4.1 (p = 1e-04, CI -5.73--2.37); LSMean difference = -2 (p = 0.0225, CI -3.64--0.28); LSMean difference = -2.8 (p = 8e-04, CI -4.49--1.19); LSMean difference = -3.1 (p = 3e-04, CI -4.7--1.42); LSMean difference = -2.4 (p = 0.0049, CI -4.04--0.73); LSMean difference = -2.8 (p = 8e-04, CI -4.48--1.18); LSMean difference = -1.7 (p = 0.0428, CI -3.36--0.06); LSMean difference = -3 (p = 4e-04, CI -4.65--1.34); LSMean difference = -2.6 (p = 0.0012, CI -4.15--1.03); LSMean difference = -3 (p = 2e-04, CI -4.54--1.42); LSMean difference = -3.2 (p = 1e-05, CI -4.88--1.58); LSMean difference = -2.2 (p = 0.0063, CI -3.75--0.62); LSMean difference = -2.7 (p = 7e-04, CI -4.25--1.14); LSMean difference = -3.9 (p = 1e-04, CI -5.44--2.28); LSMean difference = -2 (p = 0.0134, CI -3.58--0.42); LSMean difference = -2.2 (p = 0.0057, CI -3.76--0.65); LSMean difference = -2.5 (p = 0.0016, CI -4.06--0.96); LSMean difference = -2.3 (p = 0.0035, CI -3.9--0.77); LSMean difference = -3.1 (p = 1e-04, CI -4.66--1.52); LSMean difference = -3.7 (p = 1e-04, CI -5.28--2.1); LSMean difference = -2.5 (p = 0.0018, CI -4.14--0.95); LSMean difference = -2.9 (p = 4e-04, CI -4.54--1.34); LSMean difference = -3.8 (p = 1e-04, CI -5.4--2.15); LSMean difference = -1.9 (p = 0.0231, CI -3.5--0.26); LSMean difference = -2.3 (p = 0.0056, CI -3.86--0.67); LSMean difference = -2.8 (p = 7e-04, CI -4.35--1.17); LSMean difference = -2 (p = 0.0129, CI -3.65--0.43); LSMean difference = -1.7 (p = 0.0315, CI -3.33--0.16); LSMean difference = -2 (p = 0.0173, CI -3.57--0.35); LSMean difference = -2.4 (p = 0.0038, CI -3.97--0.77); LSMean difference = -2.6 (p = 0.0018, CI -4.19--0.97); LSMean difference = -3.1 (p = 3e-04, CI -4.7--1.42); LSMean difference = -1.7 (p = 0.0308, CI -3.2--0.16); LSMean difference = -2.5 (p = 0.0013, CI -4.07--1); LSMean difference = -2.9 (p = 3e-04, CI -4.47--1.36); LSMean difference = -1.9 (p = 0.0152, CI -3.44--0.37); LSMean difference = -2.1 (p = 0.0075, CI -3.61--0.56); LSMean difference = -2.7 (p = 9e-04, CI -4.3--1.12); LSMean difference = -3.1 (p = 2e-04, CI -4.68--1.46); LSMean difference = -1.6 (p = 0.0456, CI -3.25--0.03); LSMean difference = -2.2 (p = 0.0073, CI -3.76--0.59); LSMean difference = -2.4 (p = 0.0026, CI -4.01--0.86); LSMean difference = -1.9 (p = 0.0182, CI -3.39--0.32); LSMean difference = -2.4 (p = 0.0021, CI -3.88--0.87); LSMean difference = -2.4 (p = 0.0021, CI -3.88--0.87); LSMean difference = -2.5 (p = 0.0013, CI -3.96--0.97); LSMean difference = -3 (p = 2e-04, CI -4.55--1.44); LSMean difference = -3 (p = 2e-04, CI -4.53--1.4); LSMean difference = -1.7 (p = 0.0387, CI -3.22--0.09); LSMean difference = -2.3 (p = 0.0031, CI -3.89--0.8); LSMean difference = -2.3 (p = 0.0029, CI -3.88--0.81); LSMean difference = -2 (p = 0.0102, CI -3.46--0.47); LSMean difference = -2.9 (p = 2e-04, CI -4.38--1.36); LSMean difference = -3.2 (p = 1e-04, CI -4.72--1.67); LSMean difference = -1.8 (p = 0.0231, CI -3.3--0.25). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Frequency of Moderate and Severe VMS to Each Study Week.Parameters: LSMean difference = -1.7 (p = 0.0297, CI -3.23--0.17); LSMean difference = -3.1 (p = 1e-04, CI -4.66--1.58); LSMean difference = -3.6 (p = 1e-05, CI -5.1--2.02); LSMean difference = -2.6 (p = 0.001, CI -4.13--1.05); LSMean difference = -2.6 (p = 0.0011, CI -4.1--1.04); LSMean difference = -1.6 (p = 0.0405, CI -3.2--0.07); LSMean difference = -3.1 (p = 1e-04, CI -4.7--1.55); LSMean differencce = -3.1 (p = 1e-04, CI -4.66--1.52); LSMean difference = -4.2 (p = 1e-04, CI -5.78--2.66); LSMean difference = -2.6 (p = 0.0021, CI -4.17--0.93); LSMean difference = -3.7 (p = 1e-04, CI -5.26--2.07); LSMean difference = -3.1 (p = 1e-04, CI -4.71--1.52); LSMean difference = -2.5 (p = 0.002, CI -4.11--0.93); LSMean difference = -1.8 (p = 0.021, CI -3.27--0.27); LSMean difference = -1.7 (p = 0.0325, CI -3.34--0.15); LSMean difference = -2.4 (p = 0.0035, CI -3.92--0.78); LSMean difference = -2.1 (p = 0.0102, CI -3.61--0.49); LSMean difference = -2.1 (p = 0.0098, CI -3.69--0.51); LSMean difference = -3.1 (p = 1e-04, CI -4.59--1.58); LSMean difference = -2.88 (p = 3e-04, CI -4.34--1.33); LSMean difference = -3.8 (p = 1e-04, CI -5.29--2.23); LSMean difference = -2.4 (p = 0.0023, CI -3.91--0.86); LSMean difference = -3.6 (p = 1e-04, CI -5.18--1.98); LSMean difference = -3.3 (p = 1e-04, CI -4.89--1.7); LSMean difference = -4 (p = 1e-04, CI -5.61--2.37); LSMean difference = -2.7 (p = 4e-04, CI -4.25--1.24); LSMean difference = -2.2 (p = 0.0036, CI -3.73--0.74); LSMean difference = -1.8 (p = 0.0195, CI -3.33--0.29); LSMean difference = -2.7 (p = 6e-04, CI -4.21--1.17); LSMean difference = -2.8 (p = 4e-04, CI -4.32--1.27); LSMean difference = -3.5 (p = 1e-04, CI -5.01--1.92); LSMean difference = -2.2 (p = 0.0061, CI -3.71--0.62); LSMean difference = -2.7 (p = 6e-04, CI -4.19--1.14); LSMean difference = -2.3 (p = 0.003, CI -3.81--0.78); LSMean difference = -1.6 (p = 0.0383, CI -3.17--0.09); LSMean difference = -2.8 (p = 4e-04, CI -4.33--1.24); LSMean difference = -2.6 (p = 0.0011, CI -4.14--1.04); LSMean difference = -3.5 (p = 1e-04, CI -5.07--1.93); LSMean difference = -2.2 (p = 0.0055, CI -3.8--0.66); LSMean difference = -2.2 (p = 0.0054, CI -3.76--0.66); LSMean difference = -1.9 (p = 0.0167, CI -3.43--0.34); LSMean difference = -2.5 (p = 0.0014, CI -4.09--0.99); LSMean difference = -2.3 (p = 0.004, CI -3.8--0.73); LSMean difference = -2.1 (p = 0.0065, CI -3.54--0.58); LSMean difference = -2.3 (p = 0.0025, CI -3.8--0.82); LSMean difference = -2.2 (p = 0.0057, CI -3.74--0.64); LSMean difference = -2.2 (p = 0.0054, CI -3.76--0.66); LSMean difference = -2.7 (p = 5e-04, CI -4.22--1.2); LSMean difference = -2.8 (p = 6e-04, CI -4.38--1.22); LSMean difference = -2.2 (p = 0.0039, CI -3.69--0.71); LSMean difference = -1.7 (p = 0.0245, CI -3.18--0.22); LSMean difference = -1.8 (p = 0.0187, CI -3.36--0.31); LSMean difference = -1.6 (p = 0.0412, CI -3.21--0.07); LSMean difference = -2.1 (p = 0.006, CI -3.68--0.62); LSMean difference = -2.5 (p = 0.0014, CI -4.06--0.98); LSMean difference = -2.9 (p = 3e-04, CI -4.49--1.37); LSMean difference = -2 (p = 0.0205, CI -3.63--0.31); LSMean difference = -2.1 (p = 0.01, CI -3.61--0.49); LSMean difference = -2.4 (p = 0.0019, CI -3.98--0.91); LSMean difference = -2.2 (p = 0.0049, CI -3.73--0.67); LSMean difference = -2.4 (p = 0.0064, CI -4.12--0.68); LSMean difference = -1.8 (p = 0.0186, CI -3.25--0.3); LSMean difference = -2.3 (p = 0.0024, CI -3.77--0.82); LSMean difference = -2.8 (p = 3e-04, CI -4.28--1.3); LSMean difference = -2.8 (p = 3e-04, CI -4.3--1.29); LSMean difference = -2.1 (p = 0.0058, CI -3.63--0.62); LSMean difference = -2.6 (p = 8e-04, CI -4.04--1.7); LSMean difference = -2.1 (p = 0.005, CI -3.59--0.64); LSMean difference = -2.1 (p = 0.0202, CI -3.86--0.33). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Severity of Mild, Moderate, and Severe VMS to Each Study Week.Parameters: LSMean difference = -0.5 (p = 1e-04, CI -0.71--0.24); LSMean difference = -0.6 (p = 0.0014, CI -0.91--0.22); LSMean difference = -0.7 (p = 1e-04, CI -1.02--0.34); LSMean difference = -0.5 (p = 0.0046, CI -0.85--0.16); LSMean difference = -0.6 (p = 3e-04, CI -0.99--0.29); LSMean difference = -0.8 (p = 1e-04, CI -1.14--0.45); LSMean difference = -1.1 (p = 1e-04, CI -1.14--0.7); LSMean difference = -0.4 (p = 0.0209, CI -0.77--0.06); LSMean difference = -0.3 (p = 0.0104, CI -0.53--0.07); LSMean difference = -0.3 (p = 0.006, CI -0.56--0.09); LSMean difference = -0.7 (p = 1e-04, CI -1.07--0.38); LSMean difference = -0.5 (p = 0.005, CI -0.89--0.16); LSMean difference = -0.8 (p = 1e-04, CI -1.18--0.45); LSMean difference = -1 (p = 1e-04, CI -1.4--0.65); LSMean difference = -0.5 (p = 0.0063, CI -0.9--0.15); LSMean difference = -0.8 (p = 1e-04, CI -1.13--0.38); LSMean difference = -0.6 (p = 0.002, CI -1--0.23); LSMean difference = -0.6 (p = 0.0011, CI -0.93--0.24); LSMean difference = -0.4 (p = 0.0378, CI -0.75--0.02); LSMean difference = -0.5 (p = 0.0053, CI -0.89--0.16); LSMean difference = -0.5 (p = 0.004, CI -0.92--0.18); LSMean difference = -1 (p = 1e-04, CI -1.33--0.58); LSMean difference = -1.1 (p = 1e-04, CI -1.47--0.71); LSMean difference = -0.9 (p = 1e-04, CI -1.29--0.51); LSMean difference = -1.1 (p = 1e-04, CI -1.48--0.69); LSMean difference = -0.4 (p = 0.0308, CI -0.82--0.04); LSMean difference = -0.5 (p = 0.0105, CI -0.89--0.12); LSMean difference = -0.6 (p = 0.001, CI -1.03--0.26); LSMean difference = -0.4 (p = 0.0424, CI -0.83--0.01); LSMean difference = -0.4 (p = 0.0315, CI -0.84--0.04); LSMean difference = -0.8 (p = 2e-04, CI -1.18--0.38); LSMean difference = -0.8 (p = 1e-04, CI -1.26--0.43); LSMean difference = -0.6 (p = 0.0065, CI -0.96--0.16); LSMean difference = -0.5 (p = 0.0134, CI -0.91--0.11); LSMean difference = -0.4 (p = 0.03, CI -0.84--0.04); LSMean difference = -0.8 (p = 1e-04, CI -1.2--0.4); LSMean difference = -1 (p = 1e-04, CI -1.38--0.56); LSMean difference = -0.4 (p = 0.0321, CI -0.84--0.04); LSMean difference = -0.8 (p = 1e-04, CI -1.22--0.41); LSMean difference = -0.8 (p = 1e-04, CI -1.26--0.43); LSMean difference = -0.4 (p = 0.036, CI -0.85--0.03); LSMean difference = -0.6 (p = 0.0025, CI -1.01--0.22); LSMean difference = -0.4 (p = 0.0441, CI -0.81--0.01); LSMean difference = -0.4 (p = 0.0422, CI -0.82--0.01); LSMean difference = -0.9 (p = 1e-04, CI -1.27--0.45); LSMean difference = -1 (p = 1e-04, CI -1.44--0.62); LSMean difference = -0.5 (p = 0.0144, CI -0.91--0.1); LSMean difference = -0.7 (p = 6e-04, CI -1.15--0.32); LSMean difference = -0.8 (p = 2e-04, CI -1.23--0.39); LSMean difference = -0.5 (p = 0.022, CI -0.89--0.07); LSMean difference = -0.4 (p = 0.038, CI -0.84--0.02); LSMean difference = -0.3 (p = 0.0067, CI -0.6--0.1); LSMean difference = -0.7 (p = 0.0013, CI -1.06--0.26); LSMean difference = -0.4 (p = 0.0041, CI -0.62--0.12); LSMean difference = -0.3 (p = 0.0208, CI -0.57--0.05); LSMean difference = -0.4 (p = 0.0022, CI -0.67--0.15); LSMean difference = -0.3 (p = 0.0479, CI -0.53-0); LSMean differencce = -0.3 (p = 0.0262, CI -0.52--0.03); LSMean difference = -0.4 (p = 0.0047, CI -0.63--0.12); LSMean difference = -0.5 (p = 2e-04, CI -0.75--0.23); LSMean difference = -0.3 (p = 0.0369, CI -0.52--0.02); LSMean difference = -0.3 (p = 0.0126, CI -0.6--0.07); LSMean difference = -0.6 (p = 1e-04, CI -0.85--0.38); LSMean difference = -0.3 (p = 0.0121, CI -0.53--0.07); LSMean difference = -0.3 (p = 0.0086, CI -0.54--0.08); LSMean difference = -0.4 (p = 0.0138, CI -0.66--0.08); LSMean difference = -0.5 (p = 0.0014, CI -0.78--0.19); LSMean differencce = -0.7 (p = 1e-04, CI -1.02--0.43); LSMean difference = -0.9 (p = 1e-04, CI -1.19--0.59); LSMean difference = -0.4 (p = 0.0051, CI -0.72--0.13); LSMean difference = -0.5 (p = 6e-04, CI -0.81--0.22); LSMean difference = -0.5 (p = 0.0058, CI -0.83--0.14); LSMean difference = -0.6 (p = 4e-04, CI -0.97--0.28); LSMean difference = -0.8 (p = 1e-04, CI -1.14--0.46); LSMean difference = -0.9 (p = 1e-04, CI -1.27--0.57). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in The Mean Severity of Moderate and Severe VMS to Each Study Week.Parameters: LSMean difference = -0.3 (p = 0.0098, CI -0.6--0.08); LSMean difference = -0.3 (p = 0.0188, CI -0.57--0.05); LSMean difference = -0.4 (p = 0.0067, CI -0.61--0.1); LSMean difference = -0.4 (p = 0.0335, CI -0.68--0.03); LSMean difference = -0.6 (p = 7e-04, CI -0.91--0.25); LSMean differencce = -0.8 (p = 1e-04, CI -1.14--0.48); LSMean difference = -0.4 (p = 0.0048, CI -0.63--0.11); LSMean difference = -0.5 (p = 1e-04, CI -0.8--0.28); LSMean difference = -0.7 (p = 1e-04, CI -1--0.47); LSMean difference = -1.1 (p = 1e-04, CI -1.41--0.74); LSMean difference = -0.4 (p = 0.0085, CI -0.77--0.11); LSMean difference = -0.6 (p = 2e-04, CI -0.95--0.3); LSMean difference = -0.6 (p = 0.0024, CI -0.97--0.21); LSMean difference = -0.8 (p = 1e-04, CI -1.17--0.41); LSMean difference = -0.6 (p = 0.0046, CI -0.98--0.18); LSMean difference = -0.5 (p = 0.0102, CI -0.87--0.12); LSMean difference = -0.8 (p = 1e-04, CI -1.15--0.39); LSMean difference = -0.9 (p = 1e-04, CI -1.29--0.54); LSMean difference = -1.1 (p = 1e-04, CI -1.46--0.68); LSMean difference = -0.9 (p = 1e-04, CI -1.28--0.47); LSMean difference = -1.1 (p = 1e-04, CI -1.51--0.69); LSMean difference = -0.6 (p = 0.006, CI -0.96--0.16); LSMean difference = -0.5 (p = 0.016, CI -0.91--0.09); LSMean difference = -0.7 (p = 3e-04, CI -1.15--0.34); LSMean difference = -0.4 (p = 0.0374, CI -0.83--0.03); LSMean difference = -0.6 (p = 0.0042, CI -1--0.19); LSMean difference = -1 (p = 1e-04, CI -1.38--0.56); LSMean difference = -1.1 (p = 1e-04, CI -1.54--0.71); LSMean difference = -0.7 (p = 0.0011, CI -1.11--0.28); LSMean difference = -0.9 (p = 1e-04, CI -1.36--0.53); LSMean difference = -1.1 (p = 1e-04, CI -1.57--0.72); LSMean difference = -0.4 (p = 0.0476, CI -0.85-0); LSMean difference = -0.5 (p = 0.022, CI -0.9--0.07); LSMean difference = -0.7 (p = 0.0019, CI -1.07--0.24); LSMean difference = -0.5 (p = 0.0284, CI -0.91--0.05); LSMean difference = -0.5 (p = 0.0371, CI -0.88--0.03); LSMean difference = -0.5 (p = 0.0121, CI -0.97--0.12); LSMean difference = -0.5 (p = 0.0281, CI -0.89--0.05); LSMean difference = -0.8 (p = 2e-04, CI -1.26--0.39); LSMean difference = -0.9 (p = 1e-04, CI -1.36--0.48); LSMean difference = -0.4 (p = 0.0442, CI -0.87--0.01); LSMean difference = -0.4 (p = 0.0436, CI -0.86--0.01); LSMean difference = -0.9 (p = 1e-04, CI -1.34--0.49); LSMean difference = -1 (p = 1e-04, CI -1.47--0.6); LSMean difference = -0.6 (p = 0.0071, CI -1.02--0.16); LSMean difference = -0.5 (p = 0.0336, CI -0.89--0.04); LSMean difference = -0.9 (p = 1e-04, CI -1.32--0.46); LSMean difference = -0.5 (p = 0.0251, CI -0.91--0.06); LSMean difference = -0.7 (p = 0.0027, CI -1.08--0.23); LSMean difference = -0.9 (p = 1e-04, CI -1.34--0.47); LSMean difference = -0.5 (p = 0.0304, CI -0.9--0.04); LSMean difference = -0.9 (p = 1e-04, CI -1.33--0.43); LSMean difference = -1.1 (p = 1e-04, CI -1.49--0.61); LSMean difference = -0.5 (p = 0.0076, CI -0.83--0.13); LSMean difference = -0.5 (p = 0.0124, CI -0.97--0.12); LSMean difference = -0.7 (p = 0.0014, CI -1.12--0.27); LSMean difference = -0.3 (p = 0.0479, CI -0.68-0); LSMean difference = -0.4 (p = 0.0103, CI -0.79--0.11); LSMean difference = -0.5 (p = 0.007, CI -0.84--0.13); LSMean difference = -0.4 (p = 0.0095, CI -0.79--0.11); LSMean difference = -0.6 (p = 0.0021, CI -0.91--0.21); LSMean difference = -0.5 (p = 0.0084, CI -0.82--0.12); LSMean difference = -0.4 (p = 0.0277, CI -0.75--0.04). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4.Parameters: LSMean difference = -1.9 (p = 0.024, CI -3.56--0.25); LSMean difference = -3 (p = 4e-04, CI -4.68--1.38); LSMean difference = -2.8 (p = 0.001, CI -4.44--1.14); LSMean difference = -3.5 (p = 1e-04, CI -5.2--1.89); LSMean difference = -2.3 (p = 0.0058, CI -4--0.68); LSMean difference = -3 (p = 3e-04, CI -4.65--1.41); LSMean difference = -2.4 (p = 0.0042, CI -4.06-0.76). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12.Parameters: LSMean difference = -1.8 (p = 0.0154, CI -3.3--0.35); LSMean difference = -2.1 (p = 0.0043, CI -3.6--0.67); LSMean difference = -2.3 (p = 0.0023, CI -3.76--0.83); LSMean difference = -2.6 (p = 5e-04, CI -4.09--1.16); LSMean difference = -2.1 (p = 0.0064, CI -3.52--0.58); -2.6 = -2.6 (p = 5e-04, CI -4.04--1.15); LSMean difference = -2.1 (p = 0.0063, CI -3.52--0.59). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12.Parameters: LSMean difference = -0.6 (p = 0.0028, CI -1.07--0.22); LSMean difference = -0.5 (p = 0.016, CI -0.92--0.1); LSMean difference = -0.6 (p = 0.008, CI -0.98--0.15). Non-inferiority type: SUPERIORITY. Outcome: Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4.Parameters: LSMean difference = -0.4 (p = 0.0322, CI -0.81--0.04); LSMean difference = -0.5 (p = 0.0215, CI -0.84--0.07); LSMean difference = -0.6 (p = 0.0017, CI -1.01--0.24); LSMean difference = -0.8 (p = 1e-04, CI -1.21--0.44); LSMean difference = -1 (p = 1e-04, CI -1.37--0.59); LSMean difference = -0.6 (p = 0.0017, CI -0.99--0.23); LSMean differencce = -0.7 (p = 4e-04, CI -1.08--0.31). Non-inferiority type: SUPERIORITY. Outcome: Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores at Weeks 4, 8, 12 and 15.Parameters: LSMean difference = 9.6 (p = 0.0316, CI 0.85-18.36); 0.1 = 15.4 (p = 0.0074, CI 4.19-26.67). Non-inferiority type: SUPERIORITY. Outcome: Mean Percent Reduction of Mild, Moderate, And Severe Vasomotor Symptoms From Baseline to Each Study Week.Parameters: LSMean difference = 24.5 (p = 6e-04, CI 10.62-38.37); LSMean differencce = 33.7 (p = 1e-04, CI 19.87-47.52); LSMean difference = 38 (p = 1e-04, CI 23.93-52.04); LSMean difference = 14.5 (p = 0.0441, CI 0.38-28.53); LSMean difference = 19.4 (p = 0.0061, CI 5.58-33.28); LSMean difference = 14.6 (p = 0.0388, CI 0.76-28.49); LSMean difference = 25.7 (p = 3e-04, CI 11.96-39.53); LSMean difference = 20.2 (p = 0.0078, CI 5.36-35.07); LSMean difference = 28.3 (p = 2e-04, CI 13.36-43.22); LSMean difference = 36.9 (p = 1e-04, CI 22.07-51.77); LSMean difference = 40.5 (p = 1e-04, CI 25.41-55.67); LSMean difference = 23.1 (p = 0.0012, CI 9.17-37.02); LSMean difference = 37.3 (p = 1e-04, CI 23.41-51.22); LSMean difference = 41 (p = 1e-04, CI 26.88-55.05); LSMean difference = 25.6 (p = 3e-04, CI 11.65-39.47); LSMean difference = 19.7 (p = 0.0108, CI 4.59-34.88); LSMean difference = 25 (p = 0.0011, CI 10.09-39.84); LSMean difference = 30.9 (p = 1e-04, CI 16.03-45.67); LSMean difference = 20.5 (p = 0.0063, CI 5.84-35.23); LSMean difference = 30.2 (p = 1e-04, CI 16.39-44.06); LSMean difference = 15.9 (p = 0.024, CI 2.11-29.71); LSMean difference = 25.1 (p = 4e-04, CI 11.24-39.05); LSMean difference = 28.7 (p = 2e-04, CI 13.98-43.46); LSMean difference = 33.3 (p = 1e-04, CI 18.66-48); LSMean difference = 41.5 (p = 1e-04, CI 26.52-56.41); LSMean difference = 19.7 (p = 0.0098, CI 4.78-34.66); LSMean difference = 14.6 (p = 0.0282, CI 1.56-27.6); LSMean difference = 19.9 (p = 0.0029, CI 6.85-32.92); LSMean difference = 29.7 (p = 1e-04, CI 16.58-42.73); LSMean difference = 29.9 (p = 1e-04, CI 15.26-44.61); LSMean difference = 33.1 (p = 1e-04, CI 18.5-47.73); LSMean difference = 15.4 (p = 0.0303, CI 1.48-29.4); LSMean difference = 24.8 (p = 6e-04, CI 10.77-38.74); LSMean difference = 35.7 (p = 1e-04, CI 22.42-48.99); LSMean difference = 14.6 (p = 0.0304, CI 1.4-27.9); LSMean difference = 20.4 (p = 0.0022, CI 7.38-33.5); LSMean difference = 26.5 (p = 1e-04, CI 13.56-39.5); LSMean difference = 30.8 (p = 1e-04, CI 16.77-44.75); LSMean difference = 38.8 (p = 1e-04, CI 24.55-53); LSMean difference = 19.1 (p = 0.0086, CI 4.88-33.23); LSMean difference = 22.3 (p = 0.0018, CI 8.33-36.24); LSMean difference = 14.4 (p = 0.0362, CI 0.93-27.95); LSMean difference = 22.9 (p = 9e-04, CI 9.41-36.47); LSMean difference = 28.9 (p = 1e-04, CI 15.27-42.46); LSMean difference = 36.8 (p = 1e-04, CI 22.99-50.57); LSMean difference = 15.6 (p = 0.0265, CI 1.83-29.34); LSMean difference = 21.2 (p = 0.0023, CI 7.6-34.71); LSMean difference = 25.2 (p = 3e-04, CI 11.77-38.71); LSMean difference = 30.6 (p = 1e-04, CI 16.93-44.31); LSMean difference = 27.1 (p = 1e-04, CI 13.64-40.59); LSMean difference = 18.1 (p = 0.0082, CI 4.72-31.5); LSMean difference = 18.3 (p = 0.0077, CI 4.87-31.76); LSMean difference = 23.6 (p = 6e-04, CI 10.29-37.01); LSMean difference = 14.3 (p = 0.0367, CI 0.89-27.62); LSMean difference = 21.2 (p = 0.0017, CI 7.99-34.34); LSMean difference = 14.6 (p = 0.025, CI 1.84-27.27); LSMean difference = 24.4 (p = 2e-04, CI 11.54-37.17); LSMean difference = 29.6 (p = 1e-04, CI 16.6-42.57); LSMean difference = 24.4 (p = 3e-04, CI 11.29-37.44); LSMean difference = 14.5 (p = 0.0255, CI 1.78-27.15); LSMean difference = 15.3 (p = 0.0186, CI 2.57-27.94); LSMean difference = 26.5 (p = 1e-04, CI 13.71-39.36); LSMean difference = 29.9 (p = 1e-04, CI 16.94-42.81); LSMean difference = 13.9 (p = 0.0347, CI 1.01-26.85); LSMean difference = 18.4 (p = 0.0049, CI 5.62-31.2); LSMean difference = 20.7 (p = 0.0015, CI 8-33.37); LSMean difference = 15.8 (p = 0.0184, CI 2.68-28.89); LSMean difference = 25.8 (p = 2e-04, CI 12.51-39); LSMean difference = 31.6 (p = 1e-04, CI 18.17-44.93); LSMean difference = 21.9 (p = 8e-04, CI 9.16-34.65); LSMean difference = 23.4 (p = 3e-04, CI 10.75-36.04); LSMean difference = 14.8 (p = 0.0221, CI 2.13-27.43); LSMean difference = 17 (p = 0.0087, CI 4.32-29.62); LSMean difference = 26.4 (p = 1e-04, CI 13.65-39.23); LSMean difference = 31 (p = 1e-04, CI 18.13-43.94); LSMean difference = 14.8 (p = 0.0244, CI 1.92-27.7); LSMean difference = 21.9 (p = 8e-04, CI 9.21-34.62); LSMean difference = 23.2 (p = 3e-04, CI 10.63-35.83). Non-inferiority type: SUPERIORITY. Outcome: Mean Percent Reduction of Moderate And Severe Vasomotor Symptoms From Baseline to Each Study Week.Parameters: LSMean difference = 27.8 (p = 2e-04, CI 13.45-42.22); LSMean difference = 29.5 (p = 1e-04, CI 15.21-43.82); LSMean difference = 19.9 (p = 0.0049, CI 6.1-33.76); LSMean difference = 19.1 (p = 0.009, CI 4.82-33.46); LSMean difference = 27 (p = 3e-04, CI 12.61-41.39); LSMean difference = 39.5 (p = 1e-04, CI 25.14-53.9); LSMean difference = 28.6 (p = 1e-04, CI 14.64-42.46); LSMean differencce = 33.8 (p = 1e-04, CI 19.96-47.69); LSMean difference = 39.5 (p = 1e-04, CI 25.4-53.58); LSMean difference = 17.6 (p = 0.0146, CI 3.5-31.7); LSMean difference = 44.8 (p = 1e-04, CI 30.27-59.39); LSMean difference = 24.1 (p = 7e-04, CI 10.21-38); LSMean difference = 23.9 (p = 8e-04, CI 10.05-37.7); LSMean difference = 23.2 (p = 0.002, CI 8.56-37.9); LSMean difference = 34.4 (p = 1e-04, CI 19.6-49.11); LSMean difference = 35.6 (p = 1e-04, CI 20.96-50.32); LSMean difference = 43 (p = 1e-04, CI 28.03-57.93); LSMean difference = 25.4 (p = 9e-04, CI 10.48-40.37); LSMean difference = 31.2 (p = 1e-04, CI 16.49-45.9); LSMean difference = 28.9 (p = 1e-04, CI 14.24-43.52); LSMean difference = 23.1 (p = 0.0021, CI 8.46-37.66); LSMean difference = 32.1 (p = 1e-04, CI 17.42-46.71); LSMean difference = 31.3 (p = 1e-04, CI 16.75-45.94); LSMean difference = 29.4 (p = 1e-04, CI 14.91-43.97); LSMean difference = 20.2 (p = 0.0045, CI 6.31-34.06); LSMean difference = 31.3 (p = 1e-04, CI 16.73-45.91); LSMean difference = 30.6 (p = 1e-04, CI 16.68-44.49); LSMean difference = 41.8 (p = 1e-04, CI 26.95-56.68); LSMean difference = 25.6 (p = 8e-04, CI 10.77-40.43); LSMean difference = 25.9 (p = 2e-04, CI 12.42-39.29); LSMean difference = 29.1 (p = 1e-04, CI 15.14-42.98); LSMean difference = 40.1 (p = 1e-04, CI 25.96-54.26); LSMean difference = 24.4 (p = 7e-04, CI 10.28-38.42); LSMean difference = 25.8 (p = 2e-04, CI 12.29-39.33); LSMean difference = 36.3 (p = 1e-04, CI 22.58-49.98); LSMean difference = 20.6 (p = 0.0031, CI 7-34.29); LSMean difference = 22.9 (p = 9e-04, CI 9.43-36.38); LSMean difference = 26.7 (p = 2e-04, CI 1.78-40.55); LSMean difference = 23.4 (p = 0.001, CI 9.55-37.22); LSMean difference = 19.1 (p = 0.004, CI 6.13-32.11); LSMean difference = 23.8 (p = 4e-04, CI 10.8-36.83); LSMean difference = 27.2 (p = 1e-04, CI 14.1-40.24); LSMean difference = 35.6 (p = 1e-04, CI 22.34-48.88); LSMean difference = 20 (p = 0.0032, CI 6.76-33.19); LSMean difference = 24.1 (p = 3e-04, CI 11.02-37.13); LSMean difference = 22.8 (p = 9e-04, CI 9.42-36.19); LSMean difference = 13.8 (p = 0.0408, CI 0.58-26.97); LSMean difference = 20 (p = 0.0031, CI 6.77-33.21); LSMean difference = 23.1 (p = 5e-04, CI 10.17-36.08); LSMean difference = 19.6 (p = 0.004, CI 6.3-32.87); LSMean difference = 17.6 (p = 0.0102, CI 4.2-31.04); LSMean difference = 24.4 (p = 3e-04, CI 11.2-37.6); LSMean difference = 32.1 (p = 1e-04, CI 18.77-45.42); LSMean difference = 19.1 (p = 0.005, CI 5.79-32.38); LSMean difference = 23.1 (p = 6e-04, CI 9.95-36.22); LSMean difference = 22.8 (p = 6e-04, CI 9.79-35.85); LSMean difference = 18.5 (p = 0.0036, CI 6.11-30.98); LSMean difference = 22.1 (p = 0.0012, CI 8.8-35.4); LSMean difference = 29.9 (p = 1e-04, CI 16.39-43.42); LSMean difference = 14.9 (p = 0.0303, CI 1.42-28.32); LSMean difference = 20.2 (p = 0.0015, CI 7.77-32.65); LSMean difference = 25 (p = 1e-04, CI 12.41-37.57); LSMean difference = 29.8 (p = 1e-04, CI 17.12-42.49); LSMean difference = 19.6 (p = 0.0026, CI 6.9-32.21); LSMean difference = 23.4 (p = 3e-04, CI 10.92-35.94); LSMean difference = 21.7 (p = 6e-04, CI 9.34-34.14); LSMean difference = 19.3 (p = 0.0026, CI 6.78-31.83); LSMean difference = 20.8 (p = 0.0012, CI 8.29-33.33); LSMean difference = 25.1 (p = 1e-04, CI 12.48-37.82); LSMean difference = 31.9 (p = 1e-04, CI 19.11-44.67); LSMean difference = 20.1 (p = 0.0021, CI 7.32-32.81); LSMean difference = 22.7 (p = 4e-04, CI 10.1-35.29); LSMean difference = 21.9 (p = 6e-04, CI 9.42-34.38); LSMean difference = 17 (p = 0.0304, CI 1.62-32.4); LSMean difference = 16.3 (p = 0.0444, CI 0.41-32.29); LSMean difference = 19.5 (p = 0.0038, CI 6.34-32.73); LSMean difference = 16 (p = 0.0137, CI 3.29-28.68); LSMean difference = 18.1 (p = 0.0052, CI 5.44-30.82); LSMean difference = 22.6 (p = 6e-04, CI 9.81-35.39); LSMean difference = 29.4 (p = 1e-04, CI 16.41-42.32); LSMean difference = 13.7 (p = 0.0378, CI 0.78-26.63); LSMean difference = 20.1 (p = 0.002, CI 7.31-32.85); LSMean difference = 17.4 (p = 0.0071, CI 4.77-30.09); LSMean difference = 20.7 (p = 0.002, CI 7.61-33.71); LSMean difference = 18.7 (p = 0.005, CI 5.68-31.79). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 3.57 (p = 0.0084, CI 1.39-9.2); Odds Ratio (OR) = 5.71 (p = 7e-04, CI 2.09-15.62); Odds Ratio (OR) = 5.11 (p = 0.0015, CI 1.87-14); Odds Ratio (OR) = 4.57 (p = 0.0021, CI 1.73-12.05); Odds Ratio (OR) = 3.06 (p = 0.0171, CI 1.22-7.68); Odds Ratio (OR) = 4.49 (p = 0.0112, CI 1.41-14.32); Odds Ratio (OR) = 3.08 (p = 0.0461, CI 1.02-9.31); Odds Ratio (OR) = 3.05 (p = 0.0419, CI 1.04-8.92); Odds Ratio (OR) = 3.79 (p = 0.0245, CI 1.19-12.11); Odds Ratio (OR) = 5.62 (p = 0.0129, CI 1.44-21.93); Odds Ratio (OR) = 4.48 (p = 0.0167, CI 1.31-15.33); Odds Ratio (OR) = 7.34 (p = 0.0136, CI 1.51-35.75); Odds Ratio (OR) = 5.86 (p = 0.0118, CI 1.48-23.21); Odds Ratio (OR) = 5.29 (p = 0.0163, CI 1.36-20.62); Odds Ratio (OR) = 10.15 (p = 0.0337, CI 1.2-86.09); Odds Ratio (OR) = 5.88 (p = 0.0376, CI 1.11-31.25); Odds Ratio (OR) = 10.08 (p = 0.0343, CI 1.19-85.64); Odds Ratio (OR) = 10.5 (p = 0.0316, CI 1.23-89.63); Odds Ratio (OR) = 6.15 (p = 0.0313, CI 1.18-32.09); Odds Ratio (OR) = 12.49 (p = 0.0208, CI 1.47-106.3); Odds Ratio (OR) = 4.73 (p = 0.0389, CI 1.08-20.65); Odds Ratio (OR) = 13.71 (p = 0.0235, CI 1.42-132); Odds Ratio (OR) = 1.88 (p = 0.0366, CI 0.52-6.85). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 7.32 (p = 0.0149, CI 1.48-36.28); Odds Ratio (OR) = 4.37 (p = 0.0377, CI 1.09-17.59); Odds Ratio (OR) = 3.32 (p = 0.0454, CI 1.03-10.77); Odds Ratio (OR) = 3.77 (p = 0.039, CI 1.07-13.26); Odds Ratio (OR) = 13.41 (p = 0.0157, CI 1.63-110.3); Odds Ratio (OR) = 5.42 (p = 0.0171, CI 1.35-21.75); Odds Ratio (OR) = 4.71 (p = 0.0262, CI 1.2-18.49); Odds Ratio (OR) = 5.92 (p = 0.0385, CI 1.1-31.94); Odds Ratio (OR) = 10.85 (p = 0.0299, CI 1.26-93.28); Odds Ratio (OR) = 2.6 (p = 0.0429, CI 1.03-6.55); Odds Ratio (OR) = 2.81 (p = 0.0296, CI 1.11-7.12); Odds Ratio (OR) = 4.48 (p = 0.0032, CI 1.65-12.13); Odds Ratio (OR) = 7.11 (p = 6e-04, CI 2.31-21.9); Odds Ratio (OR) = 3.54 (p = 0.0096, CI 1.36-9.2); Odds Ratio (OR) = 2.52 (p = 0.0462, CI 1.02-6.27); Odds Ratio (OR) = 3.32 (p = 0.0392, CI 1.06-10.4); Odds Ratio (OR) = 5.7 (p = 0.0135, CI 1.43-22.71); Odds Ratio (OR) = 4.47 (p = 0.0163, CI 1.32-15.17); Odds Ratio (OR) = 7.65 (p = 0.0155, CI 1.47-39.72); Odds Ratio (OR) = 8.32 (p = 0.0126, CI 1.58-43.9); Odds Ratio (OR) = 8.6 (p = 0.0495, CI 1-73.7); Odds Ratio (OR) = 7.67 (p = 0.0199, CI 1.38-42.67); Odds Ratio (OR) = 5.28 (p = 0.0472, CI 1.02-27.34). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 4.69 (p = 0.0013, CI 1.83-12.04); Odds Ratio (OR) = 7.01 (p = 1e-04, CI 2.65-18.54); Odds Ratio (OR) = 4.96 (p = 0.001, CI 1.91-12.89); Odds Ratio (OR) = 5.77 (p = 3e-04, CI 2.23-14.93); Odds Ratio (OR) = 4.15 (p = 0.0025, CI 1.65-10.45); Odds Ratio (OR) = 2.82 (p = 0.0279, CI 1.12-7.12); Odds Ratio (OR) = 3.36 (p = 0.0114, CI 1.31-8.61); Odds Ratio (OR) = 7.55 (p = 1e-04, CI 2.66-21.45); Odds Ratio (OR) = 6.41 (p = 5e-04, CI 2.25-18.26); Odds Ratio (OR) = 4.83 (p = 0.0015, CI 1.83-12.77); Odds Ratio (OR) = 3.28 (p = 0.012, CI 1.3-8.28); Odds Ratio (OR) = 5.44 (p = 0.0023, CI 1.83-16.18); Odds Ratio (OR) = 7.33 (p = 0.0015, CI 2.15-25.02); Odds Ratio (OR) = 3.61 (p = 0.012, CI 1.33-9.81); Odds Ratio (OR) = 3.85 (p = 0.0153, CI 1.29-11.45); Odds Ratio (OR) = 7.52 (p = 0.0034, CI 1.95-28.98); Odds Ratio (OR) = 3.03 (p = 0.0327, CI 1.1-8.4); Odds Ratio (OR) = 3.92 (p = 0.0265, CI 1.17-13.11); Odds Ratio (OR) = 4.77 (p = 0.0174, CI 1.32-17.32); Odds Ratio (OR) = 8.95 (p = 0.0075, CI 1.8-44.61); Odds Ratio (OR) = 3.28 (p = 0.0431, CI 1.04-10.38); Odds Ratio (OR) = 3.39 (p = 0.04, CI 1.06-10.84); Odds Ratio (OR) = 8.22 (p = 0.0097, CI 1.67-40.55); Odds Ratio (OR) = 8.63 (p = 0.0031, CI 2.07-35.96); Odds Ratio (OR) = 10.16 (p = 0.0043, CI 2.07-49.9); Odds Ratio (OR) = 6.86 (p = 0.0199, CI 1.36-34.74); Odds Ratio (OR) = 8.93 (p = 0.009, CI 1.73-46.19); Odds Ratio (OR) = 17.22 (p = 0.0089, CI 2.04-145.2); Odds Ratio (OR) = 11.72 (p = 0.024, CI 1.38-99.35); Odds Ratio (OR) = 5.28 (p = 0.0475, CI 1.02-27.4); Odds Ratio (OR) = 9.32 (p = 0.0412, CI 1.09-79.44); Odds Ratio (OR) = 12.96 (p = 0.0187, CI 1.53-109.5); Odds Ratio (OR) = 4.18 (p = 0.0458, CI 1.03-17); Odds Ratio (OR) = 12.03 (p = 0.023, CI 1.41-102.7); Odds Ratio (OR) = 3.06 (p = 0.01268, CI 0.73-12.86); Odds Ratio (OR) = 6.13 (p = 0.0317, CI 1.17-32.11). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 4.88 (p = 0.001, CI 1.89-12.57); Odds Ratio (OR) = 5.24 (p = 6e-04, CI 2.03-13.51); Odds Ratio (OR) = 9.07 (p = 1e-04, CI 3.23-25.45); Odds Ratio (OR) = 7.05 (p = 1e-04, CI 2.65-18.71); Odds Ratio (OR) = 3.51 (p = 0.007, CI 1.41-8.76); Odds Ratio (OR) = 3.15 (p = 0.0193, CI 1.2-8.23); Odds Ratio (OR) = 3.34 (p = 0.0148, CI 1.27-8.81); Odds Ratio (OR) = 5.05 (p = 0.0018, CI 1.83-13.94); Odds Ratio (OR) = 7.27 (p = 7e-04, CI 2.32-22.78); Odds Ratio (OR) = 3.11 (p = 0.0246, CI 1.16-8.35); Odds Ratio (OR) = 5.22 (p = 0.0016, CI 1.87-14.6); Odds Ratio (OR) = 3.67 (p = 0.0131, CI 1.31-10.26); Odds Ratio (OR) = 9.34 (p = 0.0012, CI 2.41-36.19); Odds Ratio (OR) = 3.1 (p = 0.0359, CI 1.08-8.93); Odds Ratio (OR) = 5.86 (p = 0.0019, CI 1.91-17.92); Odds Ratio (OR) = 2.89 (p = 0.0465, CI 1.02-8.2); Odds Ratio (OR) = 3.56 (p = 0.0191, CI 1.23-10.28); Odds Ratio (OR) = 12.11 (p = 0.0019, CI 2.52-58.22); Odds Ratio (OR) = 4.95 (p = 0.0048, CI 1.63-15.04); Odds Ratio (OR) = 2.75 (p = 0.0494, CI 1-7.57); Odds Ratio (OR) = 14.37 (p = 0.0141, CI 1.71-120.6); Odds Ratio (OR) = 4.35 (p = 0.0283, CI 1.17-16.19); Odds Ratio (OR) = 13.53 (p = 0.0162, CI 1.62-113); Odds Ratio (OR) = 7.8 (p = 0.0061, CI 1.79-33.87); Odds Ratio (OR) = 5.4 (p = 0.0181, CI 1.33-21.85); Odds Ratio (OR) = 12.85 (p = 0.0195, CI 1.51-109.5); Odds Ratio (OR) = 7.72 (p = 0.0144, CI 1.5-39.66); Odds Ratio (OR) = 11.13 (p = 0.028, CI 1.3-95.49); Odds Ratio (OR) = 14.22 (p = 0.0145, CI 1.69-119.5); Odds Ratio (OR) = 13.08 (p = 0.018, CI 1.56-110); Odds Ratio (OR) = 18.53 (p = 0.008, CI 2.14-160.6); Odds Ratio (OR) = 5.07 (p = 0.0236, CI 1.24-20.65); Odds Ratio (OR) = 10.02 (p = 0.0343, CI 1.19-84.66); Odds Ratio (OR) = 9.45 (p = 0.0391, CI 1.12-79.82); Odds Ratio (OR) = 13.31 (p = 0.0187, CI 1.54-115.1); Odds Ratio (OR) = 7.11 (p = 0.0228, CI 1.31-38.49); Odds Ratio (OR) = 2.67 (p = 0.01798, CI 0.64-11.2). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 3.99 (p = 0.0093, CI 1.41-11.35); Odds Ratio (OR) = 4.66 (p = 0.0035, CI 1.66-13.09); Odds Ratio (OR) = 8.48 (p = 1e-04, CI 3.01-23.9); Odds Ratio (OR) = 7.57 (p = 2e-04, CI 2.65-21.59); Odds Ratio (OR) = 5.39 (p = 0.0012, CI 1.94-14.96); Odds Ratio (OR) = 9.85 (p = 1e-04, CI 3.49-27.86); Odds Ratio (OR) = 2.73 (p = 0.0334, CI 1.08-6.89); Odds Ratio (OR) = 4.12 (p = 0.0034, CI 1.6-10.62); Odds Ratio (OR) = 6.55 (p = 2e-04, CI 2.45-17.47); Odds Ratio (OR) = 4.9 (p = 0.0014, CI 1.85-12.98); Odds Ratio (OR) = 3.19 (p = 0.0131, CI 1.28-7.98); Odds Ratio (OR) = 2.6 (p = 0.0386, CI 1.05-6.43); Odds Ratio (OR) = 3.11 (p = 0.0191, CI 1.2-8.05); Odds Ratio (OR) = 2.84 (p = 0.0291, CI 1.11-7.26); Odds Ratio (OR) = 6.09 (p = 4e-04, CI 2.23-16.58); Odds Ratio (OR) = 7.24 (p = 3e-04, CI 2.49-21.02); Odds Ratio (OR) = 5.66 (p = 6e-04, CI 2.11-15.16); Odds Ratio (OR) = 3.74 (p = 0.006, CI 1.46-9.59); Odds Ratio (OR) = 3.55 (p = 0.0117, CI 1.32-9.5); Odds Ratio (OR) = 4.24 (p = 0.0067, CI 1.49-12.03); Odds Ratio (OR) = 3.09 (p = 0.0194, CI 1.2-7.96); Odds Ratio (OR) = 2.64 (p = 0.0423, CI 1.03-6.73); Odds Ratio (OR) = 4.11 (p = 0.0118, CI 1.37-12.34); Odds Ratio (OR) = 16.28 (p = 6e-04, CI 3.29-80.46); Odds Ratio (OR) = 4.58 (p = 0.0059, CI 1.55-13.53); Odds Ratio (OR) = 3.32 (p = 0.0241, CI 1.17-9.44); Odds Ratio (OR) = 3.73 (p = 0.0264, CI 1.17-11.95); Odds Ratio (OR) = 4.6 (p = 0.0188, CI 1.29-16.42); Odds Ratio (OR) = 4.91 (p = 0.0101, CI 1.46-16.53); Odds Ratio (OR) = 4.07 (p = 0.0231, CI 1.21-13.64); Odds Ratio (OR) = 4.54 (p = 0.0196, CI 1.27-16.15); Odds Ratio (OR) = 3.83 (p = 0.0222, CI 1.21-12.12); Odds Ratio (OR) = 4.43 (p = 0.0224, CI 1.23-15.91); Odds Ratio (OR) = 4.38 (p = 0.04, CI 1.07-17.91); Odds Ratio (OR) = 7.46 (p = 0.0152, CI 1.47-37.83); Odds Ratio (OR) = 3.69 (p = 0.0477, CI 1.01-13.46); Odds Ratio (OR) = 5.54 (p = 0.0173, CI 1.35-22.71); Odds Ratio (OR) = 4.95 (p = 0.0255, CI 1.22-20.12); Odds Ratio (OR) = 9.37 (p = 0.0071, CI 1.84-47.69); Odds Ratio (OR) = 3.8 (p = 0.0453, CI 1.03-14.01); Odds Ratio (OR) = 6.02 (p = 0.0129, CI 1.46-24.73); Odds Ratio (OR) = 4.12 (p = 0.0303, CI 1.14-14.83). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 4.3 (p = 0.0037, CI 1.6-11.54); Odds Ratio (OR) = 3.95 (p = 0.0057, CI 1.49-10.48); Odds Ratio (OR) = 6.03 (p = 3e-04, CI 2.26-16.13); Odds Ratio (OR) = 6.42 (p = 3e-04, CI 2.37-17.39); Odds Ratio (OR) = 5.85 (p = 4e-04, CI 2.2-15.55); Odds Ratio (OR) = 5.5 (p = 6e-04, CI 2.08-14.54); Odds Ratio (OR) = 4.09 (p = 0.0037, CI 1.58-10.57); Odds Ratio (OR) = 4.31 (p = 0.0026, CI 1.67-11.16); Odds Ratio (OR) = 6.26 (p = 2e-04, CI 2.63-16.6); Odds Ratio (OR) = 9.4 (p = 1e-04, CI 3.23-27.34); Odds Ratio (OR) = 2.64 (p = 0.0431, CI 1.03-6.76); Odds Ratio (OR) = 4.4 (p = 0.002, CI 1.72-11.29); Odds Ratio (OR) = 2.76 (p = 0.0291, CI 1.11-6.86); Odds Ratio (OR) = 3.96 (p = 0.0063, CI 1.48-10.61); Odds Ratio (OR) = 3.11 (p = 0.0202, CI 1.19-8.11); Odds Ratio (OR) = 4.1 (p = 0.0044, CI 1.55-10.84); Odds Ratio (OR) = 9.21 (p = 2e-04, CI 2.89-29.38); Odds Ratio (OR) = 8.2 (p = 1e-04, CI 2.79-24.08); Odds Ratio (OR) = 3.24 (p = 0.0146, CI 1.26-8.32); Odds Ratio (OR) = 4.93 (p = 0.0042, CI 1.65-14.73); Odds Ratio (OR) = 2.73 (p = 0.0488, CI 1.01-7.41); Odds Ratio (OR) = 3.85 (p = 0.0075, CI 1.43-10.36); Odds Ratio (OR) = 26.62 (p = 0.0025, CI 3.16-223.9); Odds Ratio (OR) = 5.66 (p = 0.0045, CI 1.71-18.74); Odds Ratio (OR) = 5.52 (p = 0.0157, CI 1.38-22.1); Odds Ratio (OR) = 5.31 (p = 0.0085, CI 1.53-18.43); Odds Ratio (OR) = 9.57 (p = 0.0063, CI 1.89-48.39); Odds Ratio (OR) = 3.57 (p = 0.0326, CI 1.11-11.47); Odds Ratio (OR) = 4.22 (p = 0.044, CI 1.04-17.14); Odds Ratio (OR) = 4.67 (p = 0.0222, CI 1.25-17.47); Odds Ratio (OR) = 14.62 (p = 0.0137, CI 1.73-123.3); Odds Ratio (OR) = 5.6 (p = 0.0186, CI 1.33-23.47); Odds Ratio (OR) = 5.22 (p = 0.0215, CI 1.28-21.39); Odds Ratio (OR) = 4.75 (p = 0.0306, CI 1.16-19.52); Odds Ratio (OR) = 10.1 (p = 0.0059, CI 1.92-52.29); Odds Ratio (OR) = 7.69 (p = 0.0129, CI 1.54-38.41); Odds Ratio (OR) = 7.12 (p = 0.0168, CI 1.42-35.61); Odds Ratio (OR) = 9.95 (p = 0.0058, CI 1.94-50.97); Odds Ratio (OR) = 8.02 (p = 0.0125, CI 1.57-41.08); Odds Ratio (OR) = 4.02 (p = 0.0305, CI 1.14-14.16). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 4.89 (p = 0.0103, CI 1.46-16.4); Odds Ratio (OR) = 7.19 (p = 0.0011, CI 2.2-23.48); Odds Ratio (OR) = 11.06 (p = 1e-04, CI 3.41-35.86); Odds Ratio (OR) = 10.48 (p = 1e-04, CI 3.18-34.55); Odds Ratio (OR) = 7.14 (p = 0.001, CI 2.21-23.04); Odds Ratio (OR) = 7.35 (p = 8e-04, CI 2.29-23.61); Odds Ratio (OR) = 2.78 (p = 0.0342, CI 1.08-7.18); Odds Ratio (OR) = 2.98 (p = 0.0231, CI 1.16-7.66); Odds Ratio (OR) = 4.12 (p = 0.0032, CI 1.6-10.55); Odds Ratio (OR) = 3.89 (p = 0.0059, CI 1.48-10.22); Odds Ratio (OR) = 2.66 (p = 0.0381, CI 1.05-6.7); Odds Ratio (OR) = 3.34 (p = 0.0113, CI 1.31-8.48); Odds Ratio (OR) = 2.56 (p = 0.0486, CI 1.01-6.52); Odds Ratio (OR) = 2.71 (p = 0.035, CI 1.07-6.87); Odds Ratio (OR) = 4.24 (p = 0.0027, CI 1.65-10.9); Odds Ratio (OR) = 4.68 (p = 0.002, CI 1.76-12.47); Odds Ratio (OR) = 4.02 (p = 0.0034, CI 1.58-10.21); Odds Ratio (OR) = 2.9 (p = 0.0222, CI 1.16-7.22); Odds Ratio (OR) = 2.72 (p = 0.0345, CI 1.08-6.88); Odds Ratio (OR) = 2.76 (p = 0.0319, CI 1.09-6.99); Odds Ratio (OR) = 5.27 (p = 0.0013, CI 1.92-14.47); Odds Ratio (OR) = 4.46 (p = 0.0019, CI 1.73-11.5); Odds Ratio (OR) = 2.79 (p = 0.0284, CI 1.11-6.97); Odds Ratio (OR) = 3.22 (p = 0.0219, CI 1.18-8.74); Odds Ratio (OR) = 5.46 (p = 0.0022, CI 1.84-16.16); Odds Ratio (OR) = 5.05 (p = 0.0018, CI 1.83-13.97); Odds Ratio (OR) = 3.17 (p = 0.0205, CI 1.19-8.42); Odds Ratio (OR) = 5.39 (p = 0.0031, CI 1.76-16.47); Odds Ratio (OR) = 4.15 (p = 0.0115, CI 1.38-12.5); Odds Ratio (OR) = 3.94 (p = 0.0099, CI 1.39-11.14); Odds Ratio (OR) = 3.19 (p = 0.0242, CI 1.16-8.74); Odds Ratio (OR) = 3.88 (p = 0.015, CI 1.3-11.55); Odds Ratio (OR) = 5.28 (p = 0.0046, CI 1.67-16.68); Odds Ratio (OR) = 2.82 (p = 0.0424, CI 1.04-7.7); Odds Ratio (OR) = 3.69 (p = 0.0139, CI 1.3-10.43); Odds Ratio (OR) = 3.32 (p = 0.0252, CI 1.16-9.5); Odds Ratio (OR) = 3.56 (p = 0.0235, CI 1.19-10.69); Odds Ratio (OR) = 4.58 (p = 0.0061, CI 1.54-13.62); Odds Ratio (OR) = 3.7 (p = 0.0149, CI 1.29-10.61); Odds Ratio (OR) = 3.89 (p = 0.029, CI 1.15-13.16); Odds Ratio (OR) = 3.17 (p = 0.0422, CI 1.04-9.63); Odds Ratio (OR) = 5.44 (p = 0.0061, CI 1.62-18.27); Odds Ratio (OR) = 5.91 (p = 0.0037, CI 1.78-19.66); Odds Ratio (OR) = 4.02 (p = 0.0139, CI 1.33-12.2); Odds Ratio (OR) = 3.21 (p = 0.0473, CI 1.01-10.14); Odds Ratio (OR) = 5.84 (p = 0.0066, CI 1.64-20.89); Odds Ratio (OR) = 3.06 (p = 0.0466, CI 1.02-9.18); Odds Ratio (OR) = 4 (p = 0.0233, CI 1.21-13.26). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 5.35 (p = 0.0044, CI 1.69-16.96); Odds Ratio (OR) = 8.65 (p = 2e-04, CI 2.79-26.83); Odds Ratio (OR) = 10.82 (p = 1e-04, CI 3.49-33.54); Odds Ratio (OR) = 10.01 (p = 1e-04, CI 3.2-31.29); Odds Ratio (OR) = 5.72 (p = 0.0024, CI 1.85-17.66); Odds Ratio (OR) = 7.93 (p = 3e-04, CI 2.59-24.26); Odds Ratio (OR) = 3.11 (p = 0.0217, CI 1.18-8.17); Odds Ratio (OR) = 4.63 (p = 0.0021, CI 1.75-12.25); Odds Ratio (OR) = 4.72 (p = 0.0016, CI 1.8-12.37); Odds Ratio (OR) = 4.8 (p = 0.0018, CI 1.79-12.86); Odds Ratio (OR) = 2.69 (p = 0.0467, CI 1.01-7.14); Odds Ratio (OR) = 4.7 (p = 0.0016, CI 1.8-12.28); Odds Ratio (OR) = 2.98 (p = 0.0234, CI 1.16-7.65); Odds Ratio (OR) = 2.88 (p = 0.0294, CI 1.11-7.46); Odds Ratio (OR) = 3.74 (p = 0.0068, CI 1.44-9.73); Odds Ratio (OR) = 4.35 (p = 0.0025, CI 1.68-11.29); Odds Ratio (OR) = 5.82 (p = 6e-04, CI 2.13-15.92); Odds Ratio (OR) = 6.03 (p = 3e-04, CI 2.28-15.97); Odds Ratio (OR) = 2.55 (p = 0.046, CI 1.02-6.38); Odds Ratio (OR) = 2.97 (p = 0.0234, CI 1.16-7.63); Odds Ratio (OR) = 2.82 (p = 0.0302, CI 1.1-7.22); Odds Ratio (OR) = 5.23 (p = 0.0016, CI 1.87-14.63); Odds Ratio (OR) = 4.17 (p = 0.0033, CI 1.61-10.81); Odds Ratio (OR) = 3.97 (p = 0.0119, CI 1.63-11.61); Odds Ratio (OR) = 5.08 (p = 0.0026, CI 1.76-14.67); Odds Ratio (OR) = 3.35 (p = 0.0258, CI 1.16-9.69); Odds Ratio (OR) = 4.77 (p = 0.0076, CI 1.51-15.04); Odds Ratio (OR) = 4.89 (p = 0.0045, CI 1.64-14.62); Odds Ratio (OR) = 2.74 (p = 0.0493, CI 1-7.5); Odds Ratio (OR) = 2.99 (p = 0.0376, CI 1.06-8.41); Odds Ratio (OR) = 3.11 (p = 0.0396, CI 1.06-9.17); Odds Ratio (OR) = 6.18 (p = 0.0031, CI 1.85-20.67); Odds Ratio (OR) = 5.47 (p = 0.0029, CI 1.78-16.75); Odds Ratio (OR) = 3.01 (p = 0.0364, CI 1.07-8.45); Odds Ratio (OR) = 3.75 (p = 0.0199, CI 1.23-11.39); Odds Ratio (OR) = 4.24 (p = 0.019, CI 1.27-14.19); Odds Ratio (OR) = 5.88 (p = 0.005, CI 1.71-20.25); Odds Ratio (OR) = 3.17 (p = 0.0407, CI 1.05-9.57); Odds Ratio (OR) = 5.47 (p = 0.0059, CI 1.63-18.3); Odds Ratio (OR) = 3.85 (p = 0.023, CI 1.2-12.3); Odds Ratio (OR) = 7.36 (p = 0.0015, CI 2.14-25.29); Odds Ratio (OR) = 3.45 (p = 0.0248, CI 1.17-10.16); Odds Ratio (OR) = 3.28 (p = 0.0432, CI 1.04-10.37); Odds Ratio (OR) = 3.77 (p = 0.0315, CI 1.13-12.6); Odds Ratio (OR) = 4.26 (p = 0.0147, CI 1.33-13.64); Odds Ratio (OR) = 3.18 (p = 0.0405, CI 1.05-9.59); Odds Ratio (OR) = 3.49 (p = 0.0443, CI 1.03-11.8); Odds Ratio (OR) = 5.15 (p = 0.0095, CI 1.49-17.13); Odds Ratio (OR) = 3.66 (p = 0.0402, CI 1.06-12.63); Odds Ratio (OR) = 7.19 (p = 0.0055, CI 1.79-28.95). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 9.07 (p = 0.0442, CI 1.06-77.71); Odds Ratio (OR) = 12.3 (p = 0.0204, CI 1.47-102.6); Odds Ratio (OR) = 11.1 (p = 0.027, CI 1.31-93.74); Odds Ratio (OR) = 10.97 (p = 0.0266, CI 1.32-91.15); Odds Ratio (OR) = 18.28 (p = 0.007, CI 2.21-151.2); Odds Ratio (OR) = 10.08 (p = 0.0338, CI 1.19-85.2); Odds Ratio (OR) = 5.42 (p = 0.0177, CI 1.34-21.93); Odds Ratio (OR) = 5.38 (p = 0.0178, CI 1.34-21.65); Odds Ratio (OR) = 19.9 (p = 0.0056, CI 2.4-165.1); Odds Ratio (OR) = 25.05 (p = 0.0027, CI 3.05-205.5); Odds Ratio (OR) = 17.02 (p = 0.0081, CI 2.09-138.7); Odds Ratio (OR) = 26.54 (p = 0.0023, CI 3.23-218.3); Odds Ratio (OR) = 19.09 (p = 0.0062, CI 2.31-157.9); Odds Ratio (OR) = 22.3 (p = 0.0036, CI 2.75-180.6); Odds Ratio (OR) = 15.46 (p = 7e-04, CI 3.18-75.14); Odds Ratio (OR) = 10.94 (p = 0.0032, CI 2.22-53.77); Odds Ratio (OR) = 11.04 (p = 0.0027, CI 2.3-53.06); Odds Ratio (OR) = 4.83 (p = 0.0248, CI 1.22-19.1); Odds Ratio (OR) = 7.14 (p = 0.0054, CI 1.79-28.53); Odds Ratio (OR) = 10.01 (p = 0.001, CI 2.55-39.36); Odds Ratio (OR) = 5.58 (p = 0.0138, CI 1.42-21.93); Odds Ratio (OR) = 3.92 (p = 0.0402, CI 1.06-14.45); Odds Ratio (OR) = 8.05 (p = 0.001, CI 2.32-27.95); Odds Ratio (OR) = 6.03 (p = 0.0043, CI 1.76-20.66); Odds Ratio (OR) = 10.49 (p = 0.001, CI 2.59-42.46); Odds Ratio (OR) = 13.01 (p = 2e-04, CI 3.31-51.14); Odds Ratio (OR) = 6.47 (p = 0.0072, CI 1.66-25.28); Odds Ratio (OR) = 3.07 (p = 0.0396, CI 1.05-8.92). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 8.83 (p = 0.0469, CI 1.03-75.68); Odds Ratio (OR) = 14.39 (p = 0.0134, CI 1.74-119.1); Odds Ratio (OR) = 11.98 (p = 0.0217, CI 1.44-99.74); Odds Ratio (OR) = 19.24 (p = 0.0058, CI 2.36-157.1); Odds Ratio (OR) = 15.95 (p = 0.0095, CI 1.97-129.4); Odds Ratio (OR) = 10.28 (p = 0.0321, CI 1.22-86.53); Odds Ratio (OR) = 14.48 (p = 0.0131, CI 1.75-119.7); Odds Ratio (OR) = 25.22 (p = 0.0025, CI 3.11-204.6); Odds Ratio (OR) = 10.33 (p = 0.032, CI 1.22-87.31); Odds Ratio (OR) = 11.24 (p = 0.0251, CI 1.35-93.33); Odds Ratio (OR) = 3.67 (p = 0.045, CI 1.03-13.07); Odds Ratio (OR) = 7.19 (p = 0.0017, CI 2.1-24.66); Odds Ratio (OR) = 11.41 (p = 0.0256, CI 1.35-96.77); Odds Ratio (OR) = 13.65 (p = 0.0153, CI 1.65-112.8); Odds Ratio (OR) = 21.76 (p = 0.0042, CI 2.64-179.2); Odds Ratio (OR) = 35.75 (p = 8e-04, CI 4.39-291.5); Odds Ratio (OR) = 23.63 (p = 0.003, CI 2.93-190.5); Odds Ratio (OR) = 9.72 (p = 0.0384, CI 1.13-83.68); Odds Ratio (OR) = 13.65 (p = 0.0153, CI 1.65-112.9); Odds Ratio (OR) = 30.55 (p = 0.0015, CI 3.72-250.6); Odds Ratio (OR) = 35.99 (p = 8e-04, CI 4.41-293.5); Odds Ratio (OR) = 12.67 (p = 0.0192, CI 1.51-106.1); Odds Ratio (OR) = 16.92 (p = 0.0089, CI 2.03-141); Odds Ratio (OR) = 24.96 (p = 0.0025, CI 3.09-201.6); Odds Ratio (OR) = 3.96 (p = 0.0296, CI 1.15-13.67); Odds Ratio (OR) = 8.23 (p = 9e-04, CI 2.38-28.44); Odds Ratio (OR) = 8.54 (p = 7e-04, CI 2.46-29.63); Odds Ratio (OR) = 5.83 (p = 0.0048, CI 1.71-19.84); Odds Ratio (OR) = 5.99 (p = 0.0028, CI 1.85-19.34); Odds Ratio (OR) = 7.84 (p = 5e-04, CI 2.45-25.13); Odds Ratio (OR) = 4.01 (p = 0.0215, CI 1.23-13.1); Odds Ratio (OR) = 4.42 (p = 0.0112, CI 1.4-13.94); Odds Ratio (OR) = 5.28 (p = 0.0029, CI 1.76-15.78); Odds Ratio (OR) = 5.95 (p = 0.0011, CI 2.03-17.4); Odds Ratio (OR) = 3.9 (p = 0.0111, CI 1.36-11.16); Odds Ratio (OR) = 7.57 (p = 9e-04, CI 2.29-25.04); Odds Ratio (OR) = 9.42 (p = 2e-04, CI 2.91-30.49); Odds Ratio (OR) = 4.63 (p = 0.0091, CI 1.46-14.64); Odds Ratio (OR) = 3.04 (p = 0.0394, CI 1.06-8.76); Odds Ratio (OR) = 3.36 (p = 0.0224, CI 1.19-9.53). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 10.92 (p = 1e-04, CI 3.53-33.74); Odds Ratio (OR) = 12.18 (p = 1e-04, CI 3.91-37.89); Odds Ratio (OR) = 8.58 (p = 2e-04, CI 2.77-26.53); Odds Ratio (OR) = 8.25 (p = 2e-04, CI 2.71-25.13); Odds Ratio (OR) = 3.04 (p = 0.0149, CI 1.24-7.45); Odds Ratio (OR) = 4.65 (p = 0.0011, CI 1.85-11.73); Odds Ratio (OR) = 6.36 (p = 1e-04, CI 2.46-16.45); Odds Ratio (OR) = 6.87 (p = 1e-04, CI 2.56-18.46); Odds Ratio (OR) = 3.46 (p = 0.007, CI 1.42-8.53); Odds Ratio (OR) = 3.75 (p = 0.0041, CI 1.52-9.23); Odds Ratio (OR) = 6.02 (p = 0.0018, CI 1.95-18.64); Odds Ratio (OR) = 8.28 (p = 2e-04, CI 2.7-25.42); Odds Ratio (OR) = 2.9 (p = 0.0214, CI 1.17-7.18); Odds Ratio (OR) = 3.67 (p = 0.0049, CI 1.48-9.09); Odds Ratio (OR) = 3.36 (p = 0.0078, CI 1.38-8.22); Odds Ratio (OR) = 2.77 (p = 0.0254, CI 1.13-6.78); Odds Ratio (OR) = 4 (p = 0.0032, CI 1.59-10.04); Odds Ratio (OR) = 6.25 (p = 2e-04, CI 2.37-16.51); Odds Ratio (OR) = 8.78 (p = 1e-04, CI 3-25.7); Odds Ratio (OR) = 2.94 (p = 0.0199, CI 1.19-7.29); Odds Ratio (OR) = 4.21 (p = 0.0034, CI 1.61-11.01); Odds Ratio (OR) = 2.92 (p = 0.0255, CI 1.14-7.47); Odds Ratio (OR) = 4.18 (p = 0.0066, CI 1.49-11.75); Odds Ratio (OR) = 4.46 (p = 0.0061, CI 1.53-13.01); Odds Ratio (OR) = 6.26 (p = 7e-04, CI 2.16-18.26); Odds Ratio (OR) = 3.58 (p = 0.007, CI 1.42-9.03); Odds Ratio (OR) = 3.41 (p = 0.0088, CI 1.36-8.54); Odds Ratio (OR) = 2.68 (p = 0.0389, CI 1.05-6.83); Odds Ratio (OR) = 2.62 (p = 0.0446, CI 1.02-6.73); Odds Ratio (OR) = 4.08 (p = 0.0114, CI 1.37-12.11); Odds Ratio (OR) = 3.51 (p = 0.0252, CI 1.17-10.53); Odds Ratio (OR) = 2.98 (p = 0.049, CI 1-8.87); Odds Ratio (OR) = 3.29 (p = 0.0307, CI 1.12-9.71); Odds Ratio (OR) = 3.31 (p = 0.0224, CI 1.18-9.25); Odds Ratio (OR) = 3.92 (p = 0.0215, CI 1.22-12.57); Odds Ratio (OR) = 7.21 (p = 0.004, CI 1.88-27.73); Odds Ratio (OR) = 4.6 (p = 0.029, CI 1.17-18.12); Odds Ratio (OR) = 5.96 (p = 0.0045, CI 1.74-20.4); Odds Ratio (OR) = 3.59 (p = 0.0207, CI 1.22-10.62); Odds Ratio (OR) = 4.59 (p = 0.0093, CI 1.46-14.5); Odds Ratio (OR) = 4.44 (p = 0.0103, CI 1.42-13.87); Odds Ratio (OR) = 7.03 (p = 0.0046, CI 1.82-27.1); Odds Ratio (OR) = 5.12 (p = 0.0098, CI 1.48-17.7); Odds Ratio (OR) = 7.08 (p = 0.0047, CI 1.82-27.5); Odds Ratio (OR) = 6.09 (p = 0.0042, CI 1.77-20.95); Odds Ratio (OR) = 6.09 (p = 0.0039, CI 1.78-20.74). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 5.75 (p = 0.0012, CI 1.99-16.62); Odds Ratio (OR) = 8.86 (p = 1e-04, CI 3.06-25.68); Odds Ratio (OR) = 11.55 (p = 1e-04, CI 3.94-33.85); Odds Ratio (OR) = 13.55 (p = 1e-04, CI 4.55-40.38); Odds Ratio (OR) = 7.98 (p = 1e-04, CI 2.75-23.18); Odds Ratio (OR) = 8.07 (p = 1e-04, CI 2.81-23.19); Odds Ratio (OR) = 4.55 (p = 0.0012, CI 1.82-11.39); Odds Ratio (OR) = 5.25 (p = 5e-04, CI 2.06-13.43); Odds Ratio (OR) = 5.62 (p = 3e-04, CI 2.2-14.39); Odds Ratio (OR) = 8.42 (p = 1e-04, CI 2.99-23.74); Odds Ratio (OR) = 2.74 (p = 0.0277, CI 1.12-6.7); Odds Ratio (OR) = 4.15 (p = 0.0022, CI 1.66-10.32); Odds Ratio (OR) = 3.06 (p = 0.0314, CI 1.26-7.41); Odds Ratio (OR) = 3.92 (p = 0.0041, CI 1.54-9.97); Odds Ratio (OR) = 4.19 (p = 0.0028, CI 1.64-10.74); Odds Ratio (OR) = 4.96 (p = 0.0011, CI 1.9-12.98); Odds Ratio (OR) = 8.79 (p = 1e-04, CI 2.86-26.99); Odds Ratio (OR) = 4.09 (p = 0.0036, CI 1.59-10.57); Odds Ratio (OR) = 4.52 (p = 0.0018, CI 1.75-11.67); Odds Ratio (OR) = 2.76 (p = 0.0243, CI 1.14-6.68); Odds Ratio (OR) = 2.61 (p = 0.0451, CI 1.02-6.69); Odds Ratio (OR) = 3.36 (p = 0.0165, CI 1.25-9.04); Odds Ratio (OR) = 5.28 (p = 0.0037, CI 1.72-16.23); Odds Ratio (OR) = 2.7 (p = 0.0404, CI 1.04-7); Odds Ratio (OR) = 4.3 (p = 0.0054, CI 1.54-11.99); Odds Ratio (OR) = 3.37 (p = 0.0186, CI 1.22-9.27); Odds Ratio (OR) = 6.58 (p = 0.0023, CI 1.96-22.14); Odds Ratio (OR) = 3.63 (p = 0.0118, CI 1.33-9.93); Odds Ratio (OR) = 5.57 (p = 0.002, CI 1.88-16.53); Odds Ratio (OR) = 2.71 (p = 0.043, CI 1.03-7.14); Odds Ratio (OR) = 3.69 (p = 0.0196, CI 1.23-11.05); Odds Ratio (OR) = 4.79 (p = 0.0121, CI 1.41-16.26); Odds Ratio (OR) = 4.94 (p = 0.0068, CI 1.55-15.68); Odds Ratio (OR) = 3.88 (p = 0.022, CI 1.22-12.39); Odds Ratio (OR) = 4.33 (p = 0.0196, CI 1.27-14.82); Odds Ratio (OR) = 3.09 (p = 0.0433, CI 1.03-9.24); Odds Ratio (OR) = 3.15 (p = 0.0355, CI 1.08-9.2); Odds Ratio (OR) = 3.88 (p = 0.0347, CI 1.1-13.64); Odds Ratio (OR) = 3.33 (p = 0.0284, CI 1.14-9.79); Odds Ratio (OR) = 4.81 (p = 0.0136, CI 1.38-16.77); Odds Ratio (OR) = 9.96 (p = 0.0043, CI 2.06-48.29); Odds Ratio (OR) = 5.75 (p = 0.0059, CI 1.65-20); Odds Ratio (OR) = 4.22 (p = 0.0143, CI 1.33-13.35); Odds Ratio (OR) = 4.59 (p = 0.0291, CI 1.17-18.07); Odds Ratio (OR) = 5.85 (p = 0.0107, CI 1.51-22.69); Odds Ratio (OR) = 9.68 (p = 0.0047, CI 2-46.77); Odds Ratio (OR) = 5.64 (p = 0.01255, CI 1.45-21.96); Odds Ratio (OR) = 4.97 (p = 0.0128, CI 1.41-17.54); Odds Ratio (OR) = 6.32 (p = 0.0079, CI 1.62-24.63). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 6.97 (p = 0.0162, CI 1.43-33.91); Odds Ratio (OR) = 14.37 (p = 8e-04, CI 3.04-67.96); Odds Ratio (OR) = 16.02 (p = 5e-04, CI 3.39-75.68); Odds Ratio (OR) = 11.44 (p = 0.0021, CI 2.43-53.94); Odds Ratio (OR) = 3.2 (p = 0.0181, CI 1.22-8.4); Odds Ratio (OR) = 6.43 (p = 2e-04, CI 2.43-17.05); Odds Ratio (OR) = 6.08 (p = 3e-04, CI 2.26-16.31); Odds Ratio (OR) = 3.53 (p = 0.0096, CI 1.36-9.18); Odds Ratio (OR) = 5.53 (p = 5e-04, CI 2.1-14.57); Odds Ratio (OR) = 14.54 (p = 1e-04, CI 4.85-43.58); Odds Ratio (OR) = 2.96 (p = 0.0262, CI 1.14-7.68); Odds Ratio (OR) = 5.07 (p = 9e-04, CI 1.95-13.19); Odds Ratio (OR) = 5.33 (p = 6e-04, CI 2.06-13.8); Odds Ratio (OR) = 5.01 (p = 0.0011, CI 1.9-13.21); Odds Ratio (OR) = 9.19 (p = 1e-04, CI 3.08-27.38); Odds Ratio (OR) = 3.22 (p = 0.0123, CI 1.29-8.03); Odds Ratio (OR) = 6.09 (p = 4e-04, CI 2.25-16.44); Odds Ratio (OR) = 9.13 (p = 1e-04, CI 3.04-27.4); Odds Ratio (OR) = 5.47 (p = 0.0023, CI 1.84-16.3); Odds Ratio (OR) = 2.64 (p = 0.0461, CI 1.02-6.83); Odds Ratio (OR) = 3.73 (p = 0.0096, CI 1.38-10.11); Odds Ratio (OR) = 2.91 (p = 0.00251, CI 1.14-7.39); Odds Ratio (OR) = 5.99 (p = 2e-04, CI 2.3-15.57); Odds Ratio (OR) = 7.29 (p = 1e-04, CI 2.7-19.71); Odds Ratio (OR) = 4.43 (p = 0.0017, CI 1.75-11.22); Odds Ratio (OR) = 3.99 (p = 0.0043, CI 1.54-10.3); Odds Ratio (OR) = 2.94 (p = 0.0226, CI 1.16-7.41); Odds Ratio (OR) = 3.55 (p = 0.0069, CI 1.42-8.91); Odds Ratio (OR) = 2.7 (p = 0.0317, CI 1.09-6.67); Odds Ratio (OR) = 5.28 (p = 0.0011, CI 1.94-14.39); Odds Ratio (OR) = 8.45 (p = 1e-04, CI 2.81-25.46); Odds Ratio (OR) = 2.91 (p = 0.025, CI 1.14-7.39); Odds Ratio (OR) = 3.08 (p = 0.0166, CI 1.23-7.75); Odds Ratio (OR) = 2.69 (p = 0.04, CI 1.05-6.91); Odds Ratio (OR) = 5.61 (p = 0.002, CI 1.88-16.72); Odds Ratio (OR) = 2.62 (p = 0.0426, CI 1.03-6.67); Odds Ratio (OR) = 4.27 (p = 0.005, CI 1.55-11.78); Odds Ratio (OR) = 8.48 (p = 3e-04, CI 2.69-26.76); Odds Ratio (OR) = 3.91 (p = 0.006, CI 1.48-10.35); Odds Ratio (OR) = 2.64 (p = 0.0414, CI 1.04-6.71); Odds Ratio (OR) = 5.12 (p = 0.0044, CI 1.66-15.78); Odds Ratio (OR) = 5.58 (p = 0.0038, CI 1.74-17.87); Odds Ratio (OR) = 3.32 (p = 0.0191, CI 1.22-9.07); Odds Ratio (OR) = 3.15 (p = 0.0244, CI 1.16-8.56); Odds Ratio (OR) = 0.18 (p = 0.0428, CI 0.03-0.94); Odds Ratio (OR) = 4.21 (p = 0.0087, CI 1.44-12.34); Odds Ratio (OR) = 6 (p = 0.0022, CI 1.9-18.94); Odds Ratio (OR) = 3.98 (p = 0.0074, CI 1.45-10.94); Odds Ratio (OR) = 3.26 (p = 0.0187, CI 1.22-8.75). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 6.78 (p = 0.0181, CI 1.39-33.1); Odds Ratio (OR) = 9.97 (p = 0.0039, CI 2.1-47.48); Odds Ratio (OR) = 6.84 (p = 1e-04, CI 2.53-18.46); Odds Ratio (OR) = 3.84 (p = 0.0065, CI 1.46-10.12); Odds Ratio (OR) = 3.9 (p = 0.0052, CI 1.5-10.14); Odds Ratio (OR) = 3.68 (p = 0.0064, CI 1.44-9.39); Odds Ratio (OR) = 5.86 (p = 3e-04, CI 2.26-15.21); Odds Ratio (OR) = 6.42 (p = 1e-04, CI 2.47-16.69); Odds Ratio (OR) = 8.21 (p = 1e-04, CI 3.01-22.42); Odds Ratio (OR) = 4.05 (p = 0.0031, CI 1.6-10.23); Odds Ratio (OR) = 9.82 (p = 1e-04, CI 3.41-28.28); Odds Ratio (OR) = 3.96 (p = 0.0036, CI 1.57-10.01); Odds Ratio (OR) = 4.79 (p = 9e-04, CI 1.89-12.11); Odds Ratio (OR) = 3.33 (p = 0.0091, CI 1.35-8.21); Odds Ratio (OR) = 4.7 (p = 0.0012, CI 1.84-12.01); Odds Ratio (OR) = 3.77 (p = 0.0058, CI 1.47-9.7); Odds Ratio (OR) = 8.07 (p = 2e-04, CI 2.73-23.83); Odds Ratio (OR) = 2.88 (p = 0.0221, CI 1.16-7.12); Odds Ratio (OR) = 4 (p = 0.0034, CI 1.58-10.13); Odds Ratio (OR) = 4.07 (p = 0.0045, CI 1.55-10.72); Odds Ratio (OR) = 3.66 (p = 0.0078, CI 1.41-9.51); Odds Ratio (OR) = 2.99 (p = 0.0253, CI 1.15-7.82); Odds Ratio (OR) = 6.23 (p = 0.0017, CI 1.99-19.55); Odds Ratio (OR) = 2.77 (p = 0.0352, CI 1.07-7.13); Odds Ratio (OR) = 3.33 (p = 0.0202, CI 1.21-9.18); Odds Ratio (OR) = 2.7 (p = 0.0383, CI 1.06-6.92); Odds Ratio (OR) = 3.46 (p = 0.0118, CI 1.32-9.1); Odds Ratio (OR) = 2.96 (p = 0.0314, CI 1.1-7.97); Odds Ratio (OR) = 6.8 (p = 0.001, CI 2.17-21.34); Odds Ratio (OR) = 4.8 (p = 0.0027, CI 1.72-13.4); Odds Ratio (OR) = 3.49 (p = 0.0159, CI 1.26-9.62); Odds Ratio (OR) = 3.27 (p = 0.0303, CI 1.12-9.53); Odds Ratio (OR) = 4.84 (p = 0.0071, CI 1.54-15.28); Odds Ratio (OR) = 4.2 (p = 0.0081, CI 1.45-12.15); Odds Ratio (OR) = 21.2 (p = 1e-04, CI 4.51-99.65); Odds Ratio (OR) = 23.97 (p = 1e-04, CI 5.09-112.9); Odds Ratio (OR) = 7.68 (p = 0.0116, CI 1.58-37.43); Odds Ratio (OR) = 12.74 (p = 0.0013, CI 2.71-59.81); Odds Ratio (OR) = 2.82 (p = 0.0359, CI 1.07-7.43); Odds Ratio (OR) = 5.8 (p = 4e-04, CI 2.2-15.33); Odds Ratio (OR) = 7.13 (p = 1e-04, CI 2.68-18.98); Odds Ratio (OR) = 3.12 (p = 0.0171, CI 1.22-7.97); Odds Ratio (OR) = 4.38 (p = 0.002, CI 1.71-11.18); Odds Ratio (OR) = 3.97 (p = 0.0034, CI 1.58-9.99); Odds Ratio (OR) = 2.63 (p = 0.0399, CI 1.05-6.59); Odds Ratio (OR) = 5.76 (p = 3e-04, CI 2.23-14.84); Odds Ratio (OR) = 3.22 (p = 0.0123, CI 1.29-8.04); Odds Ratio (OR) = 3.27 (p = 0.0118, CI 1.3-8.21); Odds Ratio (OR) = 3.93 (p = 0.0058, CI 1.49-10.4); Odds Ratio (OR) = 5.98 (p = 0.0012, CI 2.03-17.65); Odds Ratio (OR) = 5.01 (p = 0.0015, CI 1.85-13.54); Odds Ratio (OR) = 5.01 (p = 0.0013, CI 1.88-13.34); Odds Ratio (OR) = 3.66 (p = 0.0096, CI 1.37-9.75); Odds Ratio (OR) = 6.06 (p = 0.0012, CI 2.04-17.96); Odds Ratio (OR) = 2.75 (p = 0.0344, CI 1.08-7.02); Odds Ratio (OR) = 3.12 (p = 0.0276, CI 1.13-8.59); Odds Ratio (OR) = 4.99 (p = 0.006, CI 1.58-15.7); Odds Ratio (OR) = 3.27 (p = 0.0313, CI 1.11-9.64); Odds Ratio (OR) = 5.76 (p = 0.0056, CI 1.67-19.88); Odds Ratio (OR) = 3.51 (p = 0.0184, CI 1.24-10); Odds Ratio (OR) = 3.8 (p = 0.0299, CI 1.14-12.69); Odds Ratio (OR) = 4.48 (p = 0.0188, CI 1.28-15.65). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 11.92 (p = 0.0019, CI 2.5-56.87); Odds Ratio (OR) = 14.4 (p = 8e-04, CI 3.02-68.73); Odds Ratio (OR) = 7.69 (p = 0.011, CI 1.6-37.11); Odds Ratio (OR) = 8.97 (p = 4e-04, CI 2.68-30.07); Odds Ratio (OR) = 4.62 (p = 0.0049, CI 1.59-13.59); Odds Ratio (OR) = 3.92 (p = 0.006, CI 1.48-10.36); Odds Ratio (OR) = 3.67 (p = 0.019, CI 1.24-10.9); Odds Ratio (OR) = 9.9 (p = 1e-04, CI 3.2-30.68); Odds Ratio (OR) = 14.81 (p = 1e-04, CI 4.67-47.05); Odds Ratio (OR) = 3.39 (p = 0.0335, CI 1.1-10.47); Odds Ratio (OR) = 6.18 (p = 9e-04, CI 2.1-18.17); Odds Ratio (OR) = 3.71 (p = 0.0075, CI 1.42-9.69); Odds Ratio (OR) = 4.86 (p = 0.002, CI 1.78-13.26); Odds Ratio (OR) = 2.84 (p = 0.0281, CI 1.12-7.19); Odds Ratio (OR) = 5.68 (p = 0.0011, CI 2.01-16.06); Odds Ratio (OR) = 4.58 (p = 0.0041, CI 1.62-12.98); Odds Ratio (OR) = 7.11 (p = 0.0016, CI 2.1-24.09); Odds Ratio (OR) = 6.32 (p = 0.0027, CI 1.9-21.06); Odds Ratio (OR) = 6.21 (p = 9e-04, CI 2.11-18.27); Odds Ratio (OR) = 5.28 (p = 0.0027, CI 1.78-15.64); Odds Ratio (OR) = 7.04 (p = 5e-04, CI 2.34-21.22); Odds Ratio (OR) = 8.5 (p = 1e-04, CI 2.82-25.63); Odds Ratio (OR) = 5.17 (p = 0.0028, CI 1.76-15.14); Odds Ratio (OR) = 6 (p = 6e-04, CI 2.16-16.67); Odds Ratio (OR) = 7.63 (p = 1e-04, CI 2.69-21.65); Odds Ratio (OR) = 3.31 (p = 0.0149, CI 1.26-8.67); Odds Ratio (OR) = 5.64 (p = 9e-04, CI 2.03-15.65); Odds Ratio (OR) = 3.65 (p = 0.0104, CI 1.35-9.82); Odds Ratio (OR) = 6.66 (p = 4e-04, CI 2.34-18.94). Non-inferiority type: SUPERIORITY. Outcome: Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe Vasomotor Symptoms From Baseline to Each Study Week.Parameters: Odds Ratio (OR) = 14.16 (p = 0.014, CI 1.71-117.2); Odds Ratio (OR) = 17.5 (p = 0.0075, CI 2.15-142.7); Odds Ratio (OR) = 5.99 (p = 0.0093, CI 1.56-23.04); Odds Ratio (OR) = 10.13 (p = 6e-04, CI 2.69-38.22); Odds Ratio (OR) = 15.63 (p = 1e-04, CI 4.11-59.4); Odds Ratio (OR) = 6.31 (p = 0.007, CI 1.66-24.07); Odds Ratio (OR) = 3.39 (p = 0.0392, CI 1.06-10.85); Odds Ratio (OR) = 4.49 (p = 0.0096, CI 1.44-13.96); Odds Ratio (OR) = 10.11 (p = 1e-04, CI 3.28-31.16); Odds Ratio (OR) = 11.76 (p = 1e-04, CI 3.75-36.9); Odds Ratio (OR) = 4.26 (p = 0.0131, CI 1.36-13.38); Odds Ratio (OR) = 5.39 (p = 0.0031, CI 1.76-16.46); Odds Ratio (OR) = 3.54 (p = 0.0128, CI 1.31-9.56); Odds Ratio (OR) = 6.5 (p = 3e-04, CI 2.37-17.81); Odds Ratio (OR) = 6.42 (p = 3e-04, CI 2.32-17.77); Odds Ratio (OR) = 3.23 (p = 0.0201, CI 1.2-8.67); Odds Ratio (OR) = 3.57 (p = 0.0123, CI 1.32-9.66); Odds Ratio (OR) = 6.08 (p = 6e-04, CI 2.17-17.03); Odds Ratio (OR) = 9.82 (p = 1e-04, CI 3.4-28.36); Odds Ratio (OR) = 4.02 (p = 0.0063, CI 1.48-10.91); Odds Ratio (OR) = 3.55 (p = 0.0092, CI 1.37-9.21); Odds Ratio (OR) = 5.69 (p = 7e-04, CI 2.09-15.48); Odds Ratio (OR) = 8.85 (p = 1e-04, CI 3.08-25.43); Odds Ratio (OR) = 3.39 (p = 0.012, CI 1.31-8.77); Odds Ratio (OR) = 4.6 (p = 0.0022, CI 1.73-12.25); Odds Ratio (OR) = 6.6 (p = 4e-04, CI 2.35-18.58); Odds Ratio (OR) = 12.17 (p = 1e-04, CI 4.05-36.63); Odds Ratio (OR) = 3.65 (p = 0.0116, CI 1.34-10); Odds Ratio (OR) = 4.15 (p = 0.0045, CI 1.56-11.05); Odds Ratio (OR) = 3.19 (p = 0.0163, CI 1.24-8.2); Odds Ratio (OR) = 8.49 (p = 1e-04, CI 2.81-25.64); Odds Ratio (OR) = 2.53 (p = 0.0484, CI 1.01-6.34); Odds Ratio (OR) = 3.43 (p = 0.0126, CI 1.3-9.02); Odds Ratio (OR) = 5.56 (p = 0.0014, CI 1.94-15.98); Odds Ratio (OR) = 3.2 (p = 0.0199, CI 1.2-8.51); Odds Ratio (OR) = 8.45 (p = 2e-04, CI 2.8-25.54); Odds Ratio (OR) = 2.6 (p = 0.0449, CI 1.02-6.6); Odds Ratio (OR) = 3.47 (p = 0.0153, CI 1.27-9.51); Odds Ratio (OR) = 6.04 (p = 9e-04, CI 2.08-17.53); Odds Ratio (OR) = 2.62 (p = 0.046, CI 1.02-6.76); Odds Ratio (OR) = 5.67 (p = 0.0016, CI 1.93-16.69); Odds Ratio (OR) = 12.82 (p = 0.0214, CI 1.46-112.7). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_69'}, page_content='Study: A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms\\n\\nSummary: The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.\\n\\nResults: Outcome: Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12.Parameters: Difference in LS means = -2.95 (p = 0.0116, CI -5.22--0.67). Non-inferiority type: SUPERIORITY. Outcome: Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4.Parameters: Difference in LS means = -3.93 (p = 2e-04, CI -5.94--1.92); Difference in LS means = -2.63 (p = 0.0115, CI -4.66--0.6). Non-inferiority type: SUPERIORITY. Outcome: Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12.Parameters: Difference in LS means = -0.27 (p = 0.0479, CI -0.53-0). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_70'}, page_content='Study: A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women\\n\\nSummary: The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause. G-CSF will be administered three times at 28 day intervals to postmenopausal women, ages 40 to 65, suffering at least 49 moderate to severe hot flashes per week.\\n\\nResults: Outcome: Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28.Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56..Parameters: NA = NA (p = 0.001, CI NA-NA); NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12.Parameters: NA = NA (p = 0.014, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12.Parameters: NA = NA (p = 0.032, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Percent Change in M+S at 12 Weeks in Demographic Subgroups.Parameters: NA = NA (p = 0.047, CI NA-NA). Non-inferiority type: SUPERIORITY.'),\n",
       " Document(metadata={'source': 'study_71'}, page_content='Study: Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption\\n\\nSummary: The objective of this study is to measure the early effects of abaloparatide on tissue-based bone formation using samples obtained by transiliac crest bone biopsy after quadruple fluorochrome labeling.\\n\\nResults: Outcome: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3.Parameters: NA = NA (p = 1e-04, CI NA-NA). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_72'}, page_content='Study: Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause\"\\n\\nSummary: Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women with depression.\\n\\nResults: Outcome: Depressive Symptoms as Measured by the MASQ-AD.Parameters: GLM = -5.8 (p = 0.001, CI NA-NA). Non-inferiority type: NON_INFERIORITY.'),\n",
       " Document(metadata={'source': 'study_73'}, page_content='Study: The Effect of a Multivitamin in the Treatment of Memory Loss in Postmenopausal Women\\n\\nSummary: Complaints about memory loss are very common in women in the menopausal transition period. The effectiveness of estrogen replacement therapy in cognitive improvement is controversial. Partial positive results were obtained in some studies with regard to memory improvement, so far no standard treatment considered effective in these cases. Effective pharmacological approaches to the treatment of memory loss associated with menopause are an unmet medical need. CogmaxÂ® is a multivitamin and mineral supplement that contains numerous key elements for cognitive function, and may be a safe therapeutic option in these cases.\\n\\nThe multicenter, non-comparative (single-arm) phase IV clinical trial will be conducted with 80 female participants aged 45 to 60 years and menopausal memory loss complaint.\\n\\nAfter 3 months of using multivitamin and mineral supplement, memory and attention will be reevaluated through specific questionnaire and the Stroop Test Victoria version.\\n\\nResults: Outcome: Change From Baseline of the Score Number Relative to the Self-efficacy Factor, Consisting of Average Scores on the Domains Capacity, Control and Change of the Meta-memory in Adulthood Questionnaire - Portuguese Reduced Version.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_74'}, page_content='Study: Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods\\n\\nSummary: Recent studies have shown that C natriuretic peptide (CNP) is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.It has been suggested that the transport of cGMP to oocyte via gap junctions causes a continuous increase in cyclic adenosine monophosphate (cAMP) levels within the oocyte. An important role of increased cAMP levels in oocyte is shown to suppress meiotic progression. Deoxyribonucleic acid (DNA) studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after Luteinizing hormone(LH) / human chorionic(hCG) stimulation. Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG (9).\\n\\nResults: Outcome: Serum C Type Natriuretic Peptide Levels.Parameters: NA = NA (p = 0.017, CI NA-NA). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_75'}, page_content='Study: Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis\\n\\nSummary: Symptoms of periodontal disease are tissue destruction and destruction of the alveolar bone which supports the tooth. Wnt way (wingless-type MMTV integration site family) plays a role in the regulation of bone homeostasis in periodontal disease-induced bone resorption. The Wnt / Î²-catenin signal is controlled by physiological antagonists, including dickkopf released from osteocytes-associated protein 1 (DKK-1) and sclerostin (SOST). Thus, Wnt inhibitors SOST and DKK-1 affect bone mass changes. Bisphosphonates used in osteoporous treatment are selective inhibitors of bone resorption. In the serum of postmenopausal osteoporotic women treated with bisphosphonate, short-term and decreased DKK-1 level during the treatment, and increased SOST in the late period were reported. Increased bone formation after bisphosphonate treatment in postmenopausal osteoporotic patients has been associated with increased serum SOST level. The aim of our study is to investigate the effect of bisphosphonate in patients with post-menopausal osteoporosis on the bone demolition metabolism in periodontally healthy and periodontally diseased tooth regions and gingival health with the clinical data by investigating the SOST and DDK-1 molecules that play role in bone destruction mechanism.\\n\\nResults: Outcome: Sost Values for 6th Month.Parameters: Mean Difference (Final Values) = 0.01 (p = 0.01, CI NA-NA). Non-inferiority type: OTHER.'),\n",
       " Document(metadata={'source': 'study_76'}, page_content=\"Study: MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making\\n\\nSummary: As part of a National Institute on Aging -funded R01, the investigators developed an evidence-based, multi-media digital resource entitled MyMenoPlan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. MyMenoPlan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.\\n\\nResults: Outcome: Perceived Quality of Information.Parameters: NA = NA (p = 0.001, CI NA-NA). Non-inferiority type: SUPERIORITY. Outcome: Readability.Parameters: NA = NA (p = 0.02, CI NA-NA). Non-inferiority type: SUPERIORITY.\")]"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "daa0c677",
   "metadata": {},
   "source": [
    "## Build Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e575177c",
   "metadata": {},
   "outputs": [],
   "source": [
    "TRIPLE_PROMPT = \"\"\"\n",
    "You are an expert medical knowledge graph constructor specializing in menopause and women's health. \n",
    "Your primary task is to meticulously analyze the provided CLINICAL TRIAL SUMMARIES and extract ALL relevant concepts and relationships \n",
    "into a structured list of knowledge triples.\n",
    "---\n",
    "**GOAL**\n",
    "Identify and normalize key biomedical concepts and relationships relevant to menopause, including but not limited to Symptom, Condition, Biomarker, Treatment, Intervention, Medication, Lifestyle Factor, Outcome, Risk, Population, Supplement, Food.\n",
    "\n",
    "---\n",
    "TEXT BLOCK:\n",
    "{text}\n",
    "\n",
    "---\n",
    "**EXTRACTION STEPS (Follow This Sequence)**\n",
    "1.  **Terminology Recognition & Typing:** Scan the TEXT BLOCK and identify all concepts belonging to the required categories (Symptom, Treatment, Outcome, etc.).\n",
    "    - *Action:* Immediately map any synonyms found (e.g., \"HRT,\" \"Hormone Therapy\") to their single, authoritative concept name (e.g., **'Hormone Replacement Therapy (HRT)'**).\n",
    "    - *Action:* For terms with synonyms, use just one of the synonyms. Make it consistent.\n",
    "    - *Action:* Assign a clear type (e.g., 'Symptom', 'Intervention') to each concept.\n",
    "\n",
    "2.  **Relationship Identification:** Identify explicit connections between the recognized concepts (e.g., 'causes', 'treats', 'mitigates', 'increases_risk_of', 'is_a_type_of', 'affects', 'is_a_symptom_of', etc.). Pay close attention to negative and conditional language.\n",
    "    - Relationships MUST be concise. \n",
    "    - Use specific predicates for negative or conditional relationships (e.g., 'does_not_increase_risk', 'may_mitigate').\n",
    "\n",
    "3.  **Triple Construction:** Formulate the [Head, Relation, Tail] structure based *only* on the statements found in the text. Ensure both the Head and Tail use the **normalized name and consistent capitalization**.\n",
    "\n",
    "4.  **Internal Verification (Self-Correction):** Before generating the output, check every constructed triple: Does the relationship and connection exist *verbatim* or *explicitly implied* by the current text? **Discard any triple that cannot be directly supported by the TEXT BLOCK.**\n",
    "---\n",
    "**OUTPUT RULES & SCHEMA**\n",
    "\n",
    "1. REQUIRED CONCEPTS (Subjects/Objects) & TYPES:\n",
    "* You MUST classify each entity into a single type.\n",
    "\n",
    "2. REQUIRED RELATIONSHIPS:\n",
    "* Relationships MUST be concise verb phrases (e.g., 'causes', 'treats').\n",
    "* NEGATIVE/UNCERTAINTY RULE: Use specific predicates for negative or conditional relationships (e.g., 'does_not_increase_risk', 'may_mitigate').\n",
    "\n",
    "3. FOCUS ON CLINICAL TRIAL SUMMARIES:\n",
    "* Ignore metadata such as study names, research title, sample sizes, recruitment details, and funding information.\n",
    "* Do NOT include results stated as non-significant, negative, or uncertain findings.\n",
    "\n",
    "4. STRICT JSON OUTPUT:\n",
    "You MUST output ONLY a list of JSON objects. Do NOT include any introductory or explanatory prose, or quotes. \n",
    "If NO triples are found after verification, output an empty list: **[]**.\n",
    "\n",
    "**JSON SCHEMA:**\n",
    "[{\"head\": \"\",\"head_type\": \"\",\"relation\": \"\",\"tail\": \"\",\"tail_type\": \"\"}]\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "8aa4afdb",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_triples(text):\n",
    "    raw = client.chat.completions.create(\n",
    "        model=os.getenv(\"OPENAI_MODEL_NAME\", \"gpt-4o\"),\n",
    "        temperature=0,\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You output ONLY clean JSON, never code fences.\"},\n",
    "            {\"role\": \"user\", \"content\": TRIPLE_PROMPT.replace(\"{text}\", text)}\n",
    "        ]\n",
    "    ).choices[0].message.content\n",
    "\n",
    "    cleaned = raw.strip()\n",
    "\n",
    "    # Remove ```json ... ``` if present\n",
    "    if cleaned.startswith(\"```\"):\n",
    "        cleaned = re.sub(r\"```json|```\", \"\", cleaned).strip()\n",
    "\n",
    "    # Debug if JSON fails\n",
    "    try:\n",
    "        return json.loads(cleaned)\n",
    "    except Exception as e:\n",
    "        print(\"\\n JSON PARSE ERROR:\", e)\n",
    "        print(\" RAW OUTPUT START:\", raw[:200], \"...\\n\")\n",
    "        return []\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b3769134",
   "metadata": {},
   "outputs": [],
   "source": [
    "import time\n",
    "import json\n",
    "import re\n",
    "from openai import RateLimitError\n",
    "\n",
    "def extract_triples_with_retry(text, max_retries=5):\n",
    "    retries = 0\n",
    "    wait_time = 3\n",
    "\n",
    "    while True:\n",
    "        try:\n",
    "            raw = client.chat.completions.create(\n",
    "                model=os.getenv(\"OPENAI_MODEL_NAME\", \"gpt-4o\"),\n",
    "                temperature=0,\n",
    "                messages=[\n",
    "                    {\"role\": \"system\", \"content\": \"You output ONLY clean JSON, never code fences.\"},\n",
    "                    {\"role\": \"user\", \"content\": TRIPLE_PROMPT.replace(\"{text}\", text)}\n",
    "                ]\n",
    "            ).choices[0].message.content\n",
    "\n",
    "            cleaned = raw.strip()\n",
    "            if cleaned.startswith(\"```\"):\n",
    "                cleaned = re.sub(r\"```json|```\", \"\", cleaned).strip()\n",
    "\n",
    "            return json.loads(cleaned)\n",
    "\n",
    "        except RateLimitError as e:\n",
    "            retries += 1\n",
    "            if retries > max_retries:\n",
    "                print(\"Too many rate limit retries â€” skipping this study.\")\n",
    "                return []\n",
    "\n",
    "            print(f\"Rate limit hit, retrying in {wait_time} seconds...\")\n",
    "            time.sleep(wait_time)\n",
    "            wait_time *= 1.5  # exponential backoff\n",
    "\n",
    "        except Exception as e:\n",
    "            print(\"JSON parse error or unexpected error:\", e)\n",
    "            return []\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a412e1da",
   "metadata": {},
   "source": [
    "## Running in batches"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "bd19e3ee",
   "metadata": {},
   "outputs": [],
   "source": [
    "BATCH_SIZE = 10\n",
    "output = {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "9e992a01",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Part 1: 16 studies\n",
      "Part 2: 16 studies\n",
      "Part 3: 16 studies\n",
      "Part 4: 16 studies\n",
      "Part 5: 13 studies\n"
     ]
    }
   ],
   "source": [
    "import math\n",
    "\n",
    "def split_into_chunks(lst, k=5):\n",
    "    chunk_size = math.ceil(len(lst) / k)\n",
    "    return [lst[i:i+chunk_size] for i in range(0, len(lst), chunk_size)]\n",
    "\n",
    "# Split into 5 groups\n",
    "docs_parts = split_into_chunks(documents, k=5)\n",
    "\n",
    "for i, p in enumerate(docs_parts):\n",
    "    print(f\"Part {i+1}: {len(p)} studies\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "0cf23ce1",
   "metadata": {},
   "outputs": [],
   "source": [
    "import time\n",
    "\n",
    "def run_extraction_on_part(part_docs, label):\n",
    "    output_partial = {}\n",
    "\n",
    "    for idx, doc in enumerate(part_docs):\n",
    "        print(f\"[{label}] doc {idx+1}/{len(part_docs)}: {doc.metadata['source']}\")\n",
    "\n",
    "        triples = extract_triples_with_retry(doc.page_content)\n",
    "        output_partial[doc.metadata[\"source\"]] = triples\n",
    "\n",
    "    return output_partial\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "9124df84",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[PART 1] doc 1/16: study_0\n",
      "[PART 1] doc 2/16: study_1\n",
      "[PART 1] doc 3/16: study_2\n",
      "[PART 1] doc 4/16: study_3\n",
      "[PART 1] doc 5/16: study_4\n",
      "[PART 1] doc 6/16: study_5\n",
      "[PART 1] doc 7/16: study_6\n",
      "[PART 1] doc 8/16: study_7\n",
      "[PART 1] doc 9/16: study_8\n",
      "[PART 1] doc 10/16: study_9\n",
      "[PART 1] doc 11/16: study_10\n",
      "[PART 1] doc 12/16: study_11\n",
      "[PART 1] doc 13/16: study_12\n",
      "[PART 1] doc 14/16: study_13\n",
      "[PART 1] doc 15/16: study_14\n",
      "[PART 1] doc 16/16: study_15\n",
      "[PART 2] doc 1/16: study_16\n",
      "[PART 2] doc 2/16: study_17\n",
      "[PART 2] doc 3/16: study_18\n",
      "[PART 2] doc 4/16: study_19\n",
      "[PART 2] doc 5/16: study_20\n",
      "[PART 2] doc 6/16: study_21\n",
      "[PART 2] doc 7/16: study_22\n",
      "[PART 2] doc 8/16: study_23\n",
      "[PART 2] doc 9/16: study_24\n",
      "[PART 2] doc 10/16: study_25\n",
      "[PART 2] doc 11/16: study_26\n",
      "[PART 2] doc 12/16: study_27\n",
      "[PART 2] doc 13/16: study_28\n",
      "[PART 2] doc 14/16: study_29\n",
      "[PART 2] doc 15/16: study_30\n",
      "[PART 2] doc 16/16: study_31\n",
      "[PART 3] doc 1/16: study_32\n",
      "[PART 3] doc 2/16: study_33\n",
      "[PART 3] doc 3/16: study_34\n",
      "[PART 3] doc 4/16: study_35\n",
      "[PART 3] doc 5/16: study_36\n",
      "[PART 3] doc 6/16: study_37\n",
      "[PART 3] doc 7/16: study_38\n",
      "[PART 3] doc 8/16: study_39\n",
      "[PART 3] doc 9/16: study_40\n",
      "[PART 3] doc 10/16: study_41\n",
      "[PART 3] doc 11/16: study_42\n",
      "[PART 3] doc 12/16: study_43\n",
      "[PART 3] doc 13/16: study_44\n",
      "[PART 3] doc 14/16: study_45\n",
      "[PART 3] doc 15/16: study_46\n",
      "[PART 3] doc 16/16: study_47\n",
      "[PART 4] doc 1/16: study_48\n",
      "[PART 4] doc 2/16: study_49\n",
      "[PART 4] doc 3/16: study_50\n",
      "[PART 4] doc 4/16: study_51\n",
      "[PART 4] doc 5/16: study_52\n",
      "[PART 4] doc 6/16: study_53\n",
      "[PART 4] doc 7/16: study_54\n",
      "[PART 4] doc 8/16: study_55\n",
      "[PART 4] doc 9/16: study_56\n",
      "[PART 4] doc 10/16: study_57\n",
      "[PART 4] doc 11/16: study_58\n",
      "[PART 4] doc 12/16: study_59\n",
      "[PART 4] doc 13/16: study_60\n",
      "[PART 4] doc 14/16: study_61\n",
      "[PART 4] doc 15/16: study_62\n",
      "[PART 4] doc 16/16: study_63\n",
      "[PART 5] doc 1/13: study_64\n",
      "[PART 5] doc 2/13: study_65\n",
      "[PART 5] doc 3/13: study_66\n",
      "[PART 5] doc 4/13: study_67\n",
      "[PART 5] doc 5/13: study_68\n",
      "[PART 5] doc 6/13: study_69\n",
      "[PART 5] doc 7/13: study_70\n",
      "â³ Rate limit hit, retrying in 3 seconds...\n",
      "â³ Rate limit hit, retrying in 4.5 seconds...\n",
      "â³ Rate limit hit, retrying in 6.75 seconds...\n",
      "[PART 5] doc 8/13: study_71\n",
      "[PART 5] doc 9/13: study_72\n",
      "[PART 5] doc 10/13: study_73\n",
      "[PART 5] doc 11/13: study_74\n",
      "[PART 5] doc 12/13: study_75\n",
      "[PART 5] doc 13/13: study_76\n"
     ]
    }
   ],
   "source": [
    "outputs = []\n",
    "\n",
    "for i, part in enumerate(docs_parts, start=1):\n",
    "    partial = run_extraction_on_part(part, label=f\"PART {i}\")\n",
    "    outputs.append(partial)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "0af3eccb",
   "metadata": {},
   "outputs": [],
   "source": [
    "output_final = {}\n",
    "for o in outputs:\n",
    "    output_final.update(o)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "68f0d5d3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'study_0': [{'head': 'Bonviva (Ibandronate)',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Vitamin D',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'supplementation_with',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Calcium',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'supplementation_with',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bonviva (Ibandronate)',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Bone Mineral Density',\n",
       "   'tail_type': 'Biomarker'}],\n",
       " 'study_1': [{'head': 'Bonviva (Ibandronate)',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Intravenous Administration',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'compared_to',\n",
       "   'tail': 'Oral Daily Administration',\n",
       "   'tail_type': 'Intervention'},\n",
       "  {'head': 'Vitamin D',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'supplementation_with',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Calcium',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'supplementation_with',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bonviva (Ibandronate)',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density (BMD) of Lumbar Spine (L2-L4)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Bone Mineral Density (BMD) of Lumbar Spine (L2-L4)',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'outcome_of',\n",
       "   'tail': 'Bonviva (Ibandronate) Treatment',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_2': [{'head': 'AMG 162',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prevents',\n",
       "   'tail': 'Lumbar Spine Bone Loss',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'AMG 162',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Postmenopausal Women with Osteopenia',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'experiences',\n",
       "   'tail': 'Lumbar Spine Bone Loss',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Lumbar Spine Bone Mineral Density',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'measured_by',\n",
       "   'tail': 'Percent Change From Baseline at Month 24',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_3': [{'head': 'Bonviva',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteopenia',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bonviva',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_4': [{'head': 'Menatetrenone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Postmenopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Menatetrenone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Osteocalcin',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Menatetrenone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Undercarboxylated Osteocalcin',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Menatetrenone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Undercarboxylated Osteocalcin/Osteocalcin Ratio',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Alfacalcidol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'compared_with',\n",
       "   'tail': 'Menatetrenone',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_5': [{'head': 'Levonorgestrel Intrauterine System (LNG IUS)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'used for',\n",
       "   'tail': 'Contraception',\n",
       "   'tail_type': 'Intervention'},\n",
       "  {'head': 'Levonorgestrel Intrauterine System (LNG IUS)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'used for',\n",
       "   'tail': 'Endometrial Protection',\n",
       "   'tail_type': 'Intervention'},\n",
       "  {'head': 'Hormone Replacement Therapy (HRT)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Levonorgestrel Intrauterine System (LNG IUS)',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Menopausal Age',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'associated with',\n",
       "   'tail': 'Endometrial Protection',\n",
       "   'tail_type': 'Intervention'},\n",
       "  {'head': 'Menopausal Age',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'associated with',\n",
       "   'tail': 'Climacteric Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Climacteric Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Climacteric Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Sweating Episodes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Climacteric Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Vaginal Dryness',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Climacteric Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Sleep Problems',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Climacteric Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Irritability',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Progestogenic Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Headache',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Progestogenic Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Depressive Mood',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Progestogenic Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Acne or Greasy Skin',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Progestogenic Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Nausea',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Progestogenic Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Decreased Libido',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Progestogenic Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'includes',\n",
       "   'tail': 'Greasy Hair',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_6': [{'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'suppresses',\n",
       "   'tail': 'Serum C-terminal Telopeptide of Type 1 Collagen (sCTX)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Vitamin D',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'used_with',\n",
       "   'tail': 'Ibandronate',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Calcium',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'used_with',\n",
       "   'tail': 'Ibandronate',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Serum C-terminal Telopeptide of Type 1 Collagen (sCTX)',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'associated_with',\n",
       "   'tail': 'Bone Resorption',\n",
       "   'tail_type': 'Biological Process'}],\n",
       " 'study_7': [{'head': 'Post-Menopausal Osteoporosis',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'treated_with',\n",
       "   'tail': 'Ibandronate',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Post-Menopausal Osteoporosis',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'treated_with',\n",
       "   'tail': 'Risedronate',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'preferred_over',\n",
       "   'tail': 'Risedronate',\n",
       "   'tail_type': 'Medication'}],\n",
       " 'study_8': [{'head': 'Alendronate',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'transitioned_to',\n",
       "   'tail': 'Denosumab',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Serum C-Telopeptide-I (CTX-I)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_9': [{'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'is_preferred_over',\n",
       "   'tail': 'Risedronate',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'has_dosing_frequency',\n",
       "   'tail': 'Once-monthly',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Risedronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'has_dosing_frequency',\n",
       "   'tail': 'Once-weekly',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Korean women with postmenopausal osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'receives',\n",
       "   'tail': 'Ibandronate',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Korean women with postmenopausal osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'receives',\n",
       "   'tail': 'Risedronate',\n",
       "   'tail_type': 'Medication'}],\n",
       " 'study_10': [{'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Hypothalamus',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Pituitary',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Hypothalamus',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'secretes',\n",
       "   'tail': 'Gonadotropin-Releasing Hormone (GnRH)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Gonadotropin-Releasing Hormone (GnRH)',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'signals',\n",
       "   'tail': 'Pituitary',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Pituitary',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'secretes',\n",
       "   'tail': 'Luteinizing Hormone (LH)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Pituitary',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'secretes',\n",
       "   'tail': 'Follicle Stimulating Hormone (FSH)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Luteinizing Hormone (LH)',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'acts_on',\n",
       "   'tail': 'Ovaries',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Follicle Stimulating Hormone (FSH)',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'acts_on',\n",
       "   'tail': 'Ovaries',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Ovaries',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'produce',\n",
       "   'tail': 'Estrogen',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Ovaries',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'produce',\n",
       "   'tail': 'Progesterone',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'modulates',\n",
       "   'tail': 'Luteinizing Hormone (LH)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'modulates',\n",
       "   'tail': 'Follicle Stimulating Hormone (FSH)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Aging',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Estrogen feedback on Luteinizing Hormone (LH)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'influences',\n",
       "   'tail': '18 FDG Uptake at the Hypothalamus',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'influences',\n",
       "   'tail': '18 FDG Uptake at the Pituitary',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_11': [{'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces_risk_of',\n",
       "   'tail': 'Fracture',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density (BMD)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Bone-Specific Alkaline Phosphatase (BSAP)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'N-Terminal Propeptide of Type 1 Collagen (P1NP)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Serum C-Telopeptides of Type I Collagen (s-CTx)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Urinary N-Telopeptides of Type I Collagen/Creatinine (u-NTx/Cr) Ratio',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_12': [{'head': 'Esmirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Esmirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Hot Flushes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Esmirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Severity of Hot Flushes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vasomotor Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'associated_with',\n",
       "   'tail': 'Menopause',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_13': [],\n",
       " 'study_14': [{'head': 'Bonviva',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prevents',\n",
       "   'tail': 'Glucocorticoid-Induced Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bonviva',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Turnover Markers',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Bonviva',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density (BMD)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bonviva',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Bone Mineral Density (BMD)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vitamin D',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'used_with',\n",
       "   'tail': 'Bonviva',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Calcium',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'used_with',\n",
       "   'tail': 'Bonviva',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Post-menopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'target_of',\n",
       "   'tail': 'Bonviva',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_15': [{'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Structure',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Areal BMD at the Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Areal BMD at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Areal BMD at â…“ Distal Radius',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Serum Procollagen Type I N-Terminal Propeptide (PINP)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Volumetric Bone Mineral Density (BMD) of Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Volumetric Bone Mineral Density (BMD) of Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Estimate of Bone Strength of Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Estimate of Bone Strength of Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_16': [{'head': 'Esmirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Vasomotor Symptoms',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'associated_with',\n",
       "   'tail': 'Menopause',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': '5-HT2A Receptor Antagonist',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'may_treat',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Mirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'blocks',\n",
       "   'tail': '5-HT2A Receptors',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Mirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Selective Serotonin Reuptake Inhibitors (SSRIs)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'manage',\n",
       "   'tail': 'Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Esmirtazapine',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'shows_superior_efficacy_to',\n",
       "   'tail': 'Placebo',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_17': [{'head': 'GSK232802',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Vasomotor Symptoms',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'GSK232802',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Severity of Vasomotor Symptoms',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Hot Flashes',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'associated_with',\n",
       "   'tail': 'Menopause',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_18': [{'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Femoral Neck Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Trochanter Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum Bone Specific Alkaline Phosphatase Level',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum C-Telopeptides of Type 1 Collagen Level',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum N-Terminal Propeptides of Type 1 Collagen Level',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Urinary Deoxypyridinoline/Creatinine Ratio',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Odanacatib',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Urinary N-telopeptides/Creatinine Ratio',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Vitamin D3',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'used_with',\n",
       "   'tail': 'Odanacatib',\n",
       "   'tail_type': 'Medication'},\n",
       "  {'head': 'Calcium Carbonate',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'used_with',\n",
       "   'tail': 'Odanacatib',\n",
       "   'tail_type': 'Medication'}],\n",
       " 'study_19': [],\n",
       " 'study_20': [{'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Menopausal Symptoms',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'protects',\n",
       "   'tail': 'Endometrium',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prevents',\n",
       "   'tail': 'Postmenopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Menopause-Specific Quality of Life',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Turnover Markers',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'causes',\n",
       "   'tail': 'Breast Tenderness',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'causes',\n",
       "   'tail': 'Cumulative Amenorrhea',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Bazedoxifene/Conjugated Estrogens',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'causes',\n",
       "   'tail': 'Uterine Bleeding',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_21': [{'head': 'Estrogen',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Hormone Levels',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Uterine Lining',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'has_outcome',\n",
       "   'tail': 'Proliferative Effects',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_22': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cortical Thickness at the Distal Radius',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cortical BMD at the Distal Radius',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Total BMD at the Distal Tibia',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Trabecular BMD at the Distal Tibia',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Distal 1/3 Radius BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Total Radius BMD',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_23': [{'head': 'Escitalopram',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Menopausal Hot Flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Escitalopram',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Severity of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Escitalopram',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Bother of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Serotonin',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Estradiol',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estradiol',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'related_to',\n",
       "   'tail': 'Menopausal Hot Flashes',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_24': [{'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women with Low Bone Density',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_outcome',\n",
       "   'tail': 'Percent Change in Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_25': [],\n",
       " 'study_26': [{'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone in Postmenopausal Osteoporotic Women',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone in Postmenopausal Osteoporotic Women',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Activation Frequency in Cancellous Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Activation Frequency in Cancellous Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Activation Frequency in Endocortical Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Activation Frequency in Endocortical Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Formation Rate in Cancellous Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Formation Rate in Cancellous Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Formation Rate in Endocortical Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Formation Rate in Endocortical Compartment',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Change From Baseline in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Change From Baseline in Serum Osteocalcin',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Change From Baseline in Serum Osteocalcin',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Change From Baseline in Serum Procollagen Type I N-Terminal Propeptide',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_27': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Femoral Neck Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Serum Type-1 C-Telopeptide',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Femoral Neck Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Serum Type-1 C-Telopeptide',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'treated_with',\n",
       "   'tail': 'Denosumab',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'treated_with',\n",
       "   'tail': 'Ibandronate',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_28': [{'head': 'Calcitonin Nasal Spray',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Oral Calcitonin',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Osteoporosis',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'characterized_by',\n",
       "   'tail': 'Loss of Bone Density',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Salmon Calcitonin',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'contained_in',\n",
       "   'tail': 'Calcitonin Nasal Spray',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Salmon Calcitonin',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'contained_in',\n",
       "   'tail': 'Oral Calcitonin',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Change in Plasma C-terminal Telopeptide of Collagen 1 (CTx-1)',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measured_in',\n",
       "   'tail': 'Postmenopausal Women with Osteoporosis',\n",
       "   'tail_type': 'Population'},\n",
       "  {'head': 'Change in Bone Mineral Density (BMD) of Axial Lumbar Spine',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measured_in',\n",
       "   'tail': 'Postmenopausal Women with Osteoporosis',\n",
       "   'tail_type': 'Population'}],\n",
       " 'study_29': [{'head': 'S-equol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'S-equol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Night Sweats',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'S-equol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Dryness of Vagina',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'S-equol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Irritability',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'S-equol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Joint/Muscular Discomfort',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_30': [{'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Areal Bone Mineral Density (BMD)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Cortical Volumetric BMD of the Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Femoral Neck Areal BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Serum Bone-Specific Alkaline Phosphatase (s-BSAP)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Serum C-Terminal Propeptide of Type 1 Collagen (s-CTx)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Serum N-Terminal Propeptide (s-P1NP)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Body Areal BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Areal BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Trochanter Areal BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'MK-5442',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Urinary-N Telopeptides of Type 1 Collagen (u-NTx)',\n",
       "   'tail_type': 'Biomarker'}],\n",
       " 'study_31': [{'head': 'Oral Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Anxiety',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Oral Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Stress Responsivity',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Oral Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cognition',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Soy Phytoestrogens',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Anxiety',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Soy Phytoestrogens',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Stress Responsivity',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Soy Phytoestrogens',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cognition',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Perimenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'experiences',\n",
       "   'tail': 'Anxiety',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Perimenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'experiences',\n",
       "   'tail': 'Stress Responsivity',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Perimenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'experiences',\n",
       "   'tail': 'Cognition',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_32': [{'head': 'MK-6913',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'MK-6913',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'MK-6913',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Change From Baseline in Follicle-stimulating Hormone (FSH) Level',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measured_at',\n",
       "   'tail': 'Week 4',\n",
       "   'tail_type': 'Timepoint'}],\n",
       " 'study_33': [{'head': 'Hot Flashes',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Sleep Disruption',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Hot Flashes',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Mood Changes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Gonadotropin-Releasing Hormone Agonist (GnRHa)',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'induces',\n",
       "   'tail': 'Hot Flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Leuprolide',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'is_a_type_of',\n",
       "   'tail': 'Gonadotropin-Releasing Hormone Agonist (GnRHa)',\n",
       "   'tail_type': 'Intervention'},\n",
       "  {'head': 'Change in Montgomery-Asperg Depression Rating Scale (MADRS)',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'assesses',\n",
       "   'tail': 'Mood Changes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Percent Change in Wake After Sleep Onset (WASO)',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'assesses',\n",
       "   'tail': 'Sleep Disruption',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_34': [{'head': 'Patient Decision Aid',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Menopause Knowledge',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Menopause',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'manages',\n",
       "   'tail': 'Menopausal Symptoms',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_35': [{'head': 'Bonviva/Boniva (Ibandronate)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Post-Menopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bonviva/Boniva (Ibandronate)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Lumbar Spine T-score',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bonviva/Boniva (Ibandronate)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Mean Hip Bone BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bonviva/Boniva (Ibandronate)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Mean Lumbar Spine BMD',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bonviva/Boniva (Ibandronate)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Total Hip T-score',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_36': [{'head': 'BA058 (Abaloparatide)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prevents',\n",
       "   'tail': 'Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'BA058 (Abaloparatide)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density (BMD) of Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'BA058 (Abaloparatide)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density (BMD) of Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'BA058 (Abaloparatide)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density (BMD) of Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'at risk of',\n",
       "   'tail': 'Fractures',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Severe Osteoporosis',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'increases risk of',\n",
       "   'tail': 'Fractures',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_37': [{'head': 'Alendronate/Vitamin D3 Combination Tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Calcitriol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Alendronate/Vitamin D3 Combination Tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum C-Telopeptides of Type 1 Collagen',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Alendronate/Vitamin D3 Combination Tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum Procollagen Type 1 N-Terminal Propeptide',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Alendronate/Vitamin D3 Combination Tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum 25-Hydroxyvitamin D <20 ng/mL',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_38': [{'head': 'Brisdelle',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Brisdelle',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'associated_with',\n",
       "   'tail': 'Menopause',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Brisdelle',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Hot Flash Severity',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Brisdelle',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Moderate to Severe Vasomotor Symptoms',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_39': [{'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prescribed_for',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Raloxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prescribed_for',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bisphosphonate',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prescribed_for',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of All Malignancies',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Biliary Events',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Cardiac Disorders',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Clinical Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Hypertriglyceridemia',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Ischemic Stroke',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Renal Failure',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Selected Ocular Events',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Thyroid Disorders- Goitre',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Bazedoxifene',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cumulative Incidence of Venous Thromboembolism (VTE)',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_40': [{'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Venlafaxine XR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'compared_to',\n",
       "   'tail': 'Venlafaxine XR',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'compared_to',\n",
       "   'tail': 'Placebo',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Venlafaxine XR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'compared_to',\n",
       "   'tail': 'Placebo',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Bothersomeness of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Venlafaxine XR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Bothersomeness of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Venlafaxine XR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Perceived Hot Flash Interference',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Venlafaxine XR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Perceived Hot Flash Interference',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Low-Dose 17-ÃŸ-Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Severity of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Venlafaxine XR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Severity of Hot Flashes',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_41': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Korean Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_42': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Indian Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_43': [{'head': 'Lidocaine Liquid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Pain with Sexual Intercourse',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Lidocaine Liquid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Quality of Sexual Life',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Lidocaine Liquid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prevents',\n",
       "   'tail': 'Entry Dyspareunia',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Pain with Sexual Intercourse',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'is_a_symptom_of',\n",
       "   'tail': 'Postmenopausal Dyspareunia',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Menopausal Breast Cancer Survivors',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'experiences',\n",
       "   'tail': 'Pain with Sexual Intercourse',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_44': [{'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Postmenopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of the Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'New Vertebral Fracture',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Multiple New or Worsening Vertebral Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Clinical Fracture',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Major Osteoporotic Fracture',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_45': [{'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Postmenopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Vertebral Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Clinical Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hip Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Major Nonvertebral Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Nonvertebral Fractures',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_46': [{'head': 'Individualized Homeopathic Treatment',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Depression',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Fluoxetine',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Depression',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Depression',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Peri- and Postmenopausal Women',\n",
       "   'tail_type': 'Population'},\n",
       "  {'head': \"Change From Baseline in Greene's Scale\",\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measures',\n",
       "   'tail': 'Depression',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_47': [{'head': 'Abaloparatide Transdermal',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Abaloparatide Transdermal',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Abaloparatide Injection',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Abaloparatide Injection',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density of Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'receives',\n",
       "   'tail': 'Abaloparatide Transdermal',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'receives',\n",
       "   'tail': 'Abaloparatide Injection',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_48': [{'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'is_superior_to',\n",
       "   'tail': 'Risedronate',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces_risk_of',\n",
       "   'tail': 'New Vertebral Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces_risk_of',\n",
       "   'tail': 'New Moderate and/or Severe Vertebral Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces_risk_of',\n",
       "   'tail': 'New Multiple Vertebral Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces_risk_of',\n",
       "   'tail': 'Pooled Clinical Vertebral and Non-Vertebral Fragility Fractures',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces_risk_of',\n",
       "   'tail': 'Pooled New and Worsening Vertebral Fractures',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_49': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'compared_with',\n",
       "   'tail': 'Zoledronic Acid',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Zoledronic Acid',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_50': [{'head': 'Vaginal Estrogen Cream',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Elastic Fiber Assembly',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vaginal Estrogen Cream',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Vaginal Muscularis Thickness',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vaginal Estrogen Cream',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Elastic Fiber Number and Morphology',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vaginal Estrogen Cream',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Elastic Fiber Synthesis or Degradation',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Pelvic Organ Prolapse',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Pelvic Reconstructive Surgery',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'targets',\n",
       "   'tail': 'Pelvic Organ Prolapse',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Vaginal Wall Composition',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measured_by',\n",
       "   'tail': 'Epithelium',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Vaginal Wall Degradative Activity',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measured_by',\n",
       "   'tail': 'MMP-9',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'hCOL1A1',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'measured_in',\n",
       "   'tail': 'Vaginal Wall',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_51': [{'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Cortical Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Cortical Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Estimated Strength at the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Estimated Strength at the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Femoral Neck Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Femoral Neck Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Integral Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Integral Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Lumbar Spine Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Integral Bone Mineral Content',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Teriparatide',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Total Hip Integral Bone Mineral Content',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'treated_with',\n",
       "   'tail': 'Romosozumab',\n",
       "   'tail_type': 'Treatment'},\n",
       "  {'head': 'Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'treated_with',\n",
       "   'tail': 'Teriparatide',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_52': [{'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Menopause-specific Quality of Life',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Sleep Adequacy',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Sleep Disturbance',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Sleep Problems Index I',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Sleep Problems Index II',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Sleep Somnolence',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Snoring',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Total Sleep Score',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Vasomotor Domain Score',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Cumulative Amenorrhea',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Bleeding',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol and Progesterone',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Spotting',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_53': [{'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at the Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Japanese Women with Postmenopausal Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'receives',\n",
       "   'tail': 'Romosozumab',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_54': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'Bone Mineral Density at Trochanter',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'Serum Procollagen Type I N Propeptideserum',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_55': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density at Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'has_condition',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'}],\n",
       " 'study_56': [{'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vulvar and Vaginal Atrophy',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Dyspareunia',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Parabasal Cells',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Superficial Cells',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal pH',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Female Sexual Function Index (FSFI) - Total Score',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Female Sexual Function Index (FSFI) Domain Score - Arousal',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Female Sexual Function Index (FSFI) Domain Score - Lubrication',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Female Sexual Function Index (FSFI) Domain Score - Pain',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Female Sexual Function Index (FSFI) Domain Score - Satisfaction',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vulvar and/or Vaginal Itching or Irritation',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Dryness',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Mucosa Assessment (Vaginal Color)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol Vaginal Softgel Capsules',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Vaginal Secretions',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_57': [{'head': 'Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Mood',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Brain Function',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Putamen Signal Intensity',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Putamen Signal Intensity',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'in_response_to',\n",
       "   'tail': 'Reward',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Inventory of Depression and Anxiety Symptoms (IDAS) Dysphoria Scores',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_58': [{'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vaginal Atrophy',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Vaginal Mucosa',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Vaginal Secretions',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Maturation Index of Vaginal Cell Type (Intermediate Cells)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Maturation Index of Vaginal Cell Type (Parabasal Cells)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Maturation Index of Vaginal Cell Type (Superficial Cells)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'TX-12-004-HR',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Vaginal pH',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_59': [{'head': 'Vaginal hormone tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Bothersome vaginal symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Over-the-counter gel',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Bothersome vaginal symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Vaginal hormone tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Sexual function',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Over-the-counter gel',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Sexual function',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vaginal hormone tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Vaginal Maturation Index',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Over-the-counter gel',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Vaginal Maturation Index',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vaginal hormone tablet',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'pH',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Over-the-counter gel',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'pH',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_60': [{'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Postmenopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Ibandronate',\n",
       "   'head_type': 'Medication',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Turnover Markers',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Outcome',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measured_by',\n",
       "   'tail': 'Boniva Confidence Scale (BCS)',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_61': [{'head': 'Neuropeptide Treatment',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Outcome',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'measures',\n",
       "   'tail': 'Total Number of Hot Flushes',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_62': [{'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'prevents',\n",
       "   'tail': 'Bone Loss',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Bone Density of the Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Bone Density of the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'CTX',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Denosumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'P1NP',\n",
       "   'tail_type': 'Biomarker'}],\n",
       " 'study_63': [{'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density at the Lumbar Spine',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density at the Femoral Neck',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Romosozumab',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mineral Density at the Total Hip',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Postmenopausal Women with Osteoporosis',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'receives',\n",
       "   'tail': 'Romosozumab',\n",
       "   'tail_type': 'Treatment'}],\n",
       " 'study_64': [],\n",
       " 'study_65': [{'head': 'NT-814',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'investigated_in',\n",
       "   'tail': 'Post-Menopausal Women',\n",
       "   'tail_type': 'Population'},\n",
       "  {'head': 'NT-814',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Luteinizing Hormone',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'NT-814',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Average Daily Hot Flushes Severity Score',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'NT-814',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Average Daily Severity of Hot Flushes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'NT-814',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Night-time Awakenings Secondary to Hot Flushes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'NT-814',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Hot Flushes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Vasomotor Symptoms',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'is_a_symptom_of',\n",
       "   'tail': 'Post-Menopausal Women',\n",
       "   'tail_type': 'Population'}],\n",
       " 'study_66': [{'head': 'Brown Adipose Tissue Activity',\n",
       "   'head_type': 'Outcome',\n",
       "   'relation': 'is_modulated_by',\n",
       "   'tail': 'Estradiol (E2)',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Suppression of Ovarian Hormones',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'impairs',\n",
       "   'tail': 'Brown Adipose Tissue Activity',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estradiol (E2)',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'prevents_reduction_in',\n",
       "   'tail': 'Resting Energy Expenditure (REE)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Cold Exposure',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'assesses',\n",
       "   'tail': 'Thermogenic Response of Brown Adipose Tissue',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_67': [{'head': 'Menopause-related Sleep Fragmentation',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Metabolic Biomarkers of Body Fat Gain',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Experimental Sleep Fragmentation',\n",
       "   'head_type': 'Intervention',\n",
       "   'relation': 'results_in',\n",
       "   'tail': 'Adverse Leptin Response',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Adverse Leptin Response',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'is_a_biomarker_for',\n",
       "   'tail': 'Body Fat Gain',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_68': [{'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'frequency of hot flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'severity of hot flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Greene Climacteric Scale (GCS)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Hot Flash-Related Daily Interference Scale (HFRDIS)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Menopause-Specific Quality of Life (MENQoL)',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Hot Flash Score of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Mean Frequency of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Mean Severity of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Leeds Sleep Evaluation Questionnaire (LSEQ) Domain Scores',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Mean Frequency of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Mean Severity of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Mean Percent Reduction of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Mean Percent Reduction of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 2 in Mean Number of Mild, Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 2 in Mean Number of Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 3 in Mean Number of Mild, Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 3 in Mean Number of Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 4 in Mean Number of Mild, Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 4 in Mean Number of Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 5 in Mean Number of Mild, Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Absolute Reduction of 5 in Mean Number of Moderate and Severe VMS Per Day',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 100% in The Mean Frequency of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 50% in The Mean Frequency of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 70% in The Mean Frequency of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Mild, Moderate, and Severe VMS',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'ESN364',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Number of Participants With Mean Percent Reduction of 90% in The Mean Frequency of Moderate and Severe VMS',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_69': [{'head': 'BAY3427080 (NT-814)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Post-menopausal Vasomotor Symptoms',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'BAY3427080 (NT-814)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Frequency of Moderate and Severe Hot Flushes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'BAY3427080 (NT-814)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'reduces',\n",
       "   'tail': 'Severity of Moderate and Severe Hot Flushes',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_70': [{'head': 'G-CSF',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Hot Flashes',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'G-CSF',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'treats',\n",
       "   'tail': 'Vasomotor Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'G-CSF',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'White Blood Cell Counts',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'G-CSF',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Mean Composite Daily Severity of Hot Flashes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'G-CSF',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'improves',\n",
       "   'tail': 'Mean Daily Severity of Hot Flashes',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_71': [],\n",
       " 'study_72': [{'head': 'Tissue Selective Estrogen Complex (TSEC)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Depressive Symptoms',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Tissue Selective Estrogen Complex (TSEC)',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Neural Reward System',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Mood',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Estrogen',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Brain Function',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'Perimenopausal Women',\n",
       "   'head_type': 'Population',\n",
       "   'relation': 'experiences',\n",
       "   'tail': 'Depressive Symptoms',\n",
       "   'tail_type': 'Symptom'}],\n",
       " 'study_73': [{'head': 'Memory Loss',\n",
       "   'head_type': 'Symptom',\n",
       "   'relation': 'is_a_symptom_of',\n",
       "   'tail': 'Menopause',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Estrogen Replacement Therapy',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'may_improve',\n",
       "   'tail': 'Memory Loss',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Cogmax',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'may_mitigate',\n",
       "   'tail': 'Memory Loss',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Multivitamin and Mineral Supplement',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'may_mitigate',\n",
       "   'tail': 'Memory Loss',\n",
       "   'tail_type': 'Symptom'},\n",
       "  {'head': 'Multivitamin and Mineral Supplement',\n",
       "   'head_type': 'Supplement',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Cognitive Function',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_74': [],\n",
       " 'study_75': [{'head': 'Postmenopausal Osteoporosis',\n",
       "   'head_type': 'Condition',\n",
       "   'relation': 'associated_with',\n",
       "   'tail': 'Increased Serum SOST Level',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Bisphosphonates',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'used_for',\n",
       "   'tail': 'Postmenopausal Osteoporosis',\n",
       "   'tail_type': 'Condition'},\n",
       "  {'head': 'Bisphosphonates',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'decreases',\n",
       "   'tail': 'DKK-1 Level',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'Bisphosphonates',\n",
       "   'head_type': 'Treatment',\n",
       "   'relation': 'increases',\n",
       "   'tail': 'SOST Level',\n",
       "   'tail_type': 'Biomarker'},\n",
       "  {'head': 'SOST',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mass Changes',\n",
       "   'tail_type': 'Outcome'},\n",
       "  {'head': 'DKK-1',\n",
       "   'head_type': 'Biomarker',\n",
       "   'relation': 'affects',\n",
       "   'tail': 'Bone Mass Changes',\n",
       "   'tail_type': 'Outcome'}],\n",
       " 'study_76': []}"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_final"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "aed1648a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "âœ… Saved: /Users/cj2837/Documents/Courses/Project/extraction_outputs/structured_triples.json\n"
     ]
    }
   ],
   "source": [
    "# Save to disk\n",
    "import json\n",
    "OUT_PATH = \"/Users/cj2837/Documents/Courses/Project/extraction_outputs/structured_triples.json\"\n",
    "with open(OUT_PATH, \"w\") as f:\n",
    "    json.dump(output_final, f, indent=2)\n",
    "\n",
    "print(\"Saved:\", OUT_PATH)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2e01deca",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "kg-env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
